KRAS MODULATORS AND THEIR USES.

Abstract

Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS GD12 and / or other G12 mutants.

Description

KRAS MODULATORS AND THEIR USES CROSS-REFERENCE

[0001] This application claims the benefit of US Provisional Patent Applications in 63 / 490.475 filed on March 15, 2023, and 63 / 508.213 filed on June 14, 2023; the full contents of each of which are incorporated herein by reference. BACKGROUND

[0002] The GTPase protein of the mouse sarcoma viral oncogene homolog Kiras2 Kirsten (KRAS) small is a member of the Ras family of cell signaling switches, which regulate the growth and survival of normal and cancerous cells (e.g., see Cully, M. and J. Downward, SnapShot: Ras Signaling. Cell, 2008. 133(7): p. 1292-1292 e1). Mutations in KRAS are the cause of approximately 25% of human cancers by abnormal regulation of the mitogen-activated protein kinase (MAPK) signaling cascade and other effector pathways (e.g., see Stephen, AG, et al., Dragging ras back in the ring. Cancer Cell, 2014. 25(3): p. 272-81). Although Ras has been recognized as a cancer target for about 40 years, Ras-derived cancers remain among the most difficult to treat due to insensitivity to available therapies. Ras, encoded by three main genes KRAS, NRAS, and HRAS, has the highest mutation frequency of any oncogene.All oncogenic Ras mutations trigger the switch to the accumulation of the active GTP-bound state. The most common Ras mutation found in human tumor types is KRAS G12D (e.g., see The AACR Project GENIE Consortium. Cancer Discovery, 2017. 7(8): p. 818-831. Dataset Version 4). Activation of mutations at codon 12 impairs the ability of small GTPases to perform their role in GTP hydrolysis. This regulatory impediment is fundamental to the initiation and maintenance of tumor progression.

[0003] Despite extensive efforts, no inhibitors have been identified that block effector binding or restore sensitivity of the GTPase activating protein (GAP), although some have been found to block the interaction of Ras with the guanine nucleotide exchange factor (GEF), SOS, which activate Ras in the plasma membrane. KRAS G12C mutations, more common in lung adenocarcinoma, have been shown clinically to be susceptible to direct inhibition by covalent modification with small molecule inhibitors that trap the protein in the inactive GDP-bound state. The KRAS G12D mutation confers a higher intrinsic rate of inhibition. Petition 870250100147, dated 10 / 31 / 2025, page 7 / 437 2 / 431 slow hydrolysis of GTP than G12C, resulting in more constitutive activation. Thus, a pharmacological target of the inactive state is unlikely to achieve similar results against G12D, despite the existence of a similar binding pocket in the GDP state. Additionally, a cysteine ​​present at the activating mutation site yields to covalent chemistry, while aspartic acid does not provide medicinal chemistry approaches via selective covalent modification.

[0004] In order to potentially exploit the accumulation of KRAS G12D and other mutant variants in the GTP-bound state as a vulnerability to achieve selective inhibition of cancer cells while preserving normal Ras function, it is attractive for small molecule inhibitors to selectively bind the GTP state and stabilize a conformation that is incompetent for oncogenic signaling interactions with effector proteins. It has been shown that only constitutive activation of Raf, MEK, and ERK kinases in the MAPK cascade downstream of Ras can bypass the requirement for Ras proteins in proliferative signaling (e.g., see Drosten, M., et al., Genetic analysis of Ras signaling pathways in cell proliferation, migration, and survival. EMBO J, 2010. 29(6): p. 1091-104).Since all evidence indicates that MAPK signaling is essential for Ras growth effects in cancer, selective inhibition of the KRAS mutant in this pathway is considered the critical functional readout for potential clinical benefit of new therapeutic approaches. Therefore, there is a need to develop new inhibitors for KRAS-induced cancers that demonstrate inhibition of MAPK signals through a mechanism of action that is selective for binding in the active GTP-binding state versus the inactive GDP-binding state. SUMMARY OF THE INVENTION

[0005] In one aspect, the present disclosure provides a compound represented by Formula (I), Formula (I), or a pharmaceutically acceptable salt thereof where: Petition 870250100147, dated 10 / 31 / 2025, page 8 / 437 3 / 431 piB R1AR1CR1dS'' R100 is selected from —I— , and —L~ ; R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11e where optionally two R11e on the same atom of R1A join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; R1bé is selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, 4- to 6-membered heterocycle where the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle, where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(=NR20)N(R20)2, -C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where the carbocycle C3-C12 and 5- to 12-membered heterocycle are each optionally replaced independently with one or more R1*; each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3C12 carbocycle; R1C is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R12e where optionally two R12e on the same R1C atom join to form a C3-C6 carbocycle Petition 870250100147, dated 10 / 31 / 2025, p. 9 / 437 4 / 431 or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally replaced with one or more R12A; R1D is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R13e where optionally two R13 on the same atom of R1D join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R13A; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Cl-C6 haloalkyl, -LNR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), L-OC(O)N(R20)2 and -LC(=O)OCl-C6 alkyl, wherein the heterocycle, the heterocyclic part of L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -L-NR20C(O)-aryl, the aryl de-L-aryl and the heteroaryl de-L-heteroaryl are each optionally replaced with one or more R7; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more independently selected substituents of halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; Each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, =O, =S, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl; n is selected from 0, 1, 2, 3 and 4; m is selected from 1 and 2; Each R5 is independently selected from hydrogen and C1-C6 alkyl; Petition 870250100147, dated 10 / 31 / 2025, page 10 / 437 5 / 431 each R6é independently selected from halogen, hydroxy, C1-C3 hydroxyalkyl, Cl-C3 alkyl, oxo, Cl-C3 haloalkyl, C1-C3 alkoxy, cyano, =CH2, =NOG-C3 alkyl, Cl-C3 amino alkyl, -R(S5)(S5), -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, -NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, tert-butyldimethylsilyloxyCH2-, -N(R5)2, (C1-C3 alkoxy)Cl-C3 alkyl-, (C3-C3), o (C1-C3 haloalkyl)C(=O), -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, -CH2OC(O)NCF3(R5), -CH2O-G-C6 alkyl,CH2OC(O)N(R5)2, -CH2NHC(O)OC1-C6 alkyl, -CH -CH2NHC(O)C1C6 alkyl, -CH2(pyrazolyl), -CH2NHSO2C1-C6 alkyl, -CH2OC(O)heterocycle, OC(O)N(R5)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl), -(O alkyl)phenyl(C1-C3 alkyl)N(CH3)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl)phenyl, OC(O)heterocycle, -O-Cl-C3 alkyl, -O-Cl-C6 haloalkyl, -C1-C3 alkyl-Cl-Cl-C alkyl-N(R20)2, -SF5, -C1-C3 alkyl-N3, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20),-NR20S(O)2R20, -(CH2)0-1S-heterocycle, -(CH2)0-1-O-heterocycle, (CH2)0-1-O-phenyl and -CH2heterocycle, wherein the phenyl of -NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(Cl-C3 alkyl)phenyl is optionally substituted with one or more substituents selected from -C(O)H and OH, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with heterocycle, oxo and hydroxy substituents selected; where the alkyl group of -CH2O-Cl-C6 alkyl is optionally replaced with one or more substituents selected from halogen and C3-C6 carbocycle; where the -CH2 heterocycle is optionally replaced with oxo; and where the phenyl group of -(CH2)0-1-O-phenyl is optionally replaced with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, SF5, C1-6 alkyl-OR20, OR20; where the heterocycle of -(CH2)0-1-O-heterocycle and -(CH2)0-1-S-heterocycle is each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20; each Q is selected from a connection and O; Each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; Petition 870250100147, dated 10 / 31 / 2025, p. 11 / 437 6 / 431 Selected 5- to 12-membered heterocycle R8é, wherein the 5- to 12-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20), -SR20, -SR20, O -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -C(O)NR20-OR20, C1-6 alkyl-N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-61, Cxi-alkyl alcohol, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; R9 is selected from hydrogen, halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanone, Cyl-Cyl-Cyl-61-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ca-Ce carbocycle, wherein the Ca-Ce carbocycle is optionally substituted with one or more halogens, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkyl-N(R20) alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; Your R8 and R9 combine with the atoms to which they are attached to form B, where B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and the C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; Each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more independently selected substituents Petition 870250100147, dated 10 / 31 / 2025, p. 12 / 437 7 / 431 halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C110 haloalkyl, -O-C1-10 alkyl, oxo; each R11, R12and R13are independently selected halogen, -B(OR20)2, OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR2020), -R2020, -R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -ROC(O)20, -NR20(C=NH)N(R20)2, -NO2, =o, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6, halo alkyl, C1-6 alkenyl, C2-6 alkynyl, C3C12 carbocycle and heterocycle of 5 to 12 members, wherein the C3-C12 carbocycle and heterocycle of 5 to 12 members are each optionally substituted with one or more independently selected halogen substituents, -OH, -NO2, -CN -N(R21)2, -SR21, C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)2(R21) and oxo; each R11a, R12ae R13Aé independently selected halogen, -B(OR20)2, OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20, -NR20 -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -O =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -OC1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

[0006] In some embodiments, for a compound or salt of Formula (I), where R100piB R1Ar1C R1dé selected from «~J— , —e —; Petition 870250100147, dated 10 / 31 / 2025, p. 13 / 437 8 / 431 R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11a, where optionally two R11a on the same R1a atom join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11a; R1bé selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, where the C1-6 alkyl and C3-C6 carbocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle, where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, C(=NR20)N(R20)2, -C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, Ci-6alkyl-N(R20)2, Ci6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle 12 members are each optionally independently replaced with one or more R1*; each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, Ci-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-C12 carbocycle; R1c is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R12e where optionally two R12 on the same atom of R1c join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R12a; Petition 870250100147, dated 10 / 31 / 2025, p. 14 / 437 9 / 431 R1d is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R13e where optionally two R13 on the same atom of R1d join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R13a; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Ci-C6 haloalkyl, -L-NR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OCi-C6 alkyl, wherein the heterocycle, the heterocyclic part of -L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -LNR20C(O)-aryl, The aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally replaced with one or more R7s; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more independently selected substituents of halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; Each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), N(C1-6 alkyl)2, =O, =S, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl; n is selected from 0, 1, 2, 3 and 4; m is selected from 1 and 2; Each R5 is independently selected from hydrogen and C1-C1 alkyl; Petition 870250100147, dated 10 / 31 / 2025, page 15 / 437 10 / 431 each R6é independently selected from halogen, hydroxy, C1-C3 hydroxyalkyl, ClC3 alkyl, oxo, Cl-C3 haloalkyl, Cl-C3 alkyl-N3, C1-C3 alkoxy, cyano, =CH2, =NO-ClC3, alkyl Cl-C3, amino -N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, NHC(O)phenyl, - NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, tertbutyldimethylsilyloxyCH2-, -N(R5)2, (C1-C3) alcohol-Cl alkyl)C(=O), oxo, (C1-C3 haloalkyl)C(=O)-, -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, CH2OC(O)N(R5)2, -CH2NHC(O)OCi-C6 alkyl, -CH2NHC(O)N(R52), -CH2(pyrazolyl), -CH2NHSO2C1-C6 alkyl, CH2OC(O)heterocycle, -OC(O)N(R5)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl), OC(O)NH(C1-C3 alkyl)O(Cl-Cl-C3) alkyl)N(CH3)2, -OC(O)NH(C1C3 alkyl)O(Cl-C3 alkyl)phenyl, -OC(O)heterocycle, -O-Cl-C3 alkyl, -S(O)2(R20), S(O)2N(R20)2, -S(O)2N(R20)2, -S(O)N(R2020), -NR20S(O)2R20e -CH2heterocycle,where the phenyl group of -NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(Cl-C3 alkyl)phenyl are optionally substituted with one or more substituents selected from -C(O)H and OH, and where the alkyl group of -O-Cl-C3 alkyl is optionally substituted with heterocyclic, oxo, and hydroxyl substituents selected; and where the heterocycle group of -CH2heterocyclyl is optionally substituted with oxo; each Q is selected from a connection and O; Each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; Selected 5- to 12-membered heterocycle R8é, wherein the 5- to 12-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20), -SR20, -SR20, O -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -C(O)NR20-OR20, C1-6 alkyl-N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-61, Cxi-alkyl alcohol, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; R9 is selected from hydrogen, halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ca-G carbocycle, where the C3-C6 carbocycle is optionally replaced with one or more halogen, -CN, -NO2, Petition 870250100147, dated 10 / 31 / 2025, page 16 / 437 11 / 431 N(R20)2, -OR20, -SR20, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; or R8 and R9 combine with the atoms to which they are bonded to form B, where B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and the C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C16 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; Each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo; Each R11, R12, and R13 is independently selected from halogen, -B(OR20)2, -OR20, SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -N(R21)2, -SR21, C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl and oxo; Petition 870250100147, dated 10 / 31 / 2025, p. 17 / 437 12 / 431 each R11a, R12ae R13Aé independently selected halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)N(R20)2, -S(O)R2(=R20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, R20, -OC(O)N(R20)2, -NO2, =o, =NO(R20), -cn, NHCN, Ci-6 alkyl-N(R20)2, Ci-6 aminoalkyl, Ci-6 alkoxy, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, Ci-6haloalkyl, Ci-6alkyl, Cyl-Cyl-Cl-62, and Ci-62; each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

[0007] In certain embodiments, the disclosure provides a pharmaceutical composition comprising a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ) and a pharmaceutically acceptable excipient.

[0008] In certain embodiments, the disclosure provides a method for treating a disease or disorder by using a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ).

[0009] In certain embodiments, the disclosure provides a method for treating a disease or disorder by using a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ) and a pharmaceutically acceptable excipient.

[0010] In certain realizations, disclosure provides a method for the inhibition of KRas G12D and / or other G12 mutants, through the use of a compound or salt of Formula Petition 870250100147, dated 10 / 31 / 2025, p. 18 / 437 13 / 431 (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ).

[0011] In certain realizations, disclosure provides a method for the inhibition of KRas G12D and / or other G12 mutants, by use of a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ) and a pharmaceutically acceptable excipient. Incorporation by Reference

[0012] All publications, patents and patent applications mentioned in this descriptive report are incorporated herein by reference to the same extent as if each individual publication, patent or patent application were individually indicated as being incorporated by reference. DETAILED DESCRIPTION OF THE INVENTION

[0013] The following description presents numerous exemplary configurations, methods, parameters, and the like. It should be recognized, however, that such description is not intended to limit the scope of the present disclosure, but is instead provided as a description of exemplary embodiments.

[0014] In the following description, certain specific details are presented in order to provide a complete understanding of the various realizations of disclosure. However, a person skilled in the art will understand that disclosure can be practiced without these details. Definitions

[0015] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention pertains. All patents and publications referenced herein are incorporated by reference.

[0016] Alkyl refers to a straight or branched hydrocarbon chain radical consisting only of carbon and hydrogen atoms, containing no unsaturation and preferably containing from one to fifteen carbon atoms (i.e., C1-C15 alkyl). In certain embodiments, an alkyl comprises from one to thirteen carbon atoms (i.e., C1-C13 alkyl). In certain embodiments, an alkyl comprises from one to eight carbon atoms (i.e., C1-C8 alkyl). In other embodiments, an alkyl comprises from one to five carbon atoms (i.e., C1-C5 alkyl). In other embodiments, an alkyl comprises from one to four carbon atoms (i.e., C1-C4 alkyl). In other embodiments, an alkyl Petition 870250100147, dated 10 / 31 / 2025, p. 19 / 437 14 / 431 comprises one to three carbon atoms (i.e., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (i.e., C1-C2 alkyl). In other embodiments, an alkyl comprises one carbon atom (i.e., C1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (i.e., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (i.e., C5-C8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (i.e., C2-C5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (i.e., C3-C5 alkyl). In certain embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl is attached to the rest of the molecule by a single bond.

[0017] The term “Cx-y” or “Cx-Cy” when used in conjunction with a chemical radical, such as alkyl, alkenyl, or alkynyl, includes groups containing dexay carbons in the chain. For example, the term “C1-6 alkyl” or “C1-C6 alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl groups and branched-chain alkyl groups containing from 1 to 6 carbons. The term -Cx-y alkylene- refers to a substituted or unsubstituted alkylene chain with dexay carbons in the alkylene chain. For example, -C1-6 alkylene- can be selected from methylene, ethylene, propylene, butylene, pentylene, and hexylene, any of which is optionally substituted.

[0018] Alkoxy refers to a radical linked via an oxygen atom of formula -O-alkyl, where alkyl is an alkyl chain as defined above.

[0019] Alkenyl refers to a straight or branched chain radical group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon double bond and preferably containing from two to twelve carbon atoms (i.e., C2-C12 alkenyl). In certain embodiments, an alkenyl comprises from two to eight carbon atoms (i.e., C2-C8 alkenyl). In certain embodiments, an alkenyl comprises from two to six carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, an alkenyl comprises from two to four carbon atoms (i.e., C2-C4 alkenyl). The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl and the like. Petition 870250100147, dated 10 / 31 / 2025, p. 20 / 437 15 / 431

[0020] Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond and preferably containing from two to twelve carbon atoms (i.e., C2-C12 alkynyl). In certain embodiments, an alkynyl comprises from two to eight carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, an alkynyl comprises from two to six carbon atoms (i.e., C2-C6 alkynyl). In other embodiments, an alkynyl comprises from two to four carbon atoms (i.e., C2-C4 alkynyl). The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, penthynyl, hexynyl, and the like.

[0021] The terms “Cx-y alkenyl” and “Cx-y alkynyl” refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length to the alkyl groups described above, but containing at least one double or triple bond, respectively. The term -Cx-y alkenylene- refers to a substituted or unsubstituted alkylene chain with xay carbons in the alkenylene chain. For example, -C2-6 alkenylene- may be selected from ethenylene, propenylene, butenylene, pentenylene, and hexenylene, any of which is optionally substituted. An alkenylene chain may have one or more double bonds in the alkenylene chain. The term -Cx-y alkynylene- refers to a substituted or unsubstituted alkynylene chain with xay carbons in the alkenylene chain. For example, -C2-6 alkenylene- can be selected from ethynylene, propynylene, butynylene, pentynylene, and hexynylene, any of which can be optionally substituted.An alkynylene chain can have one or more triple bonds in the alkynylene chain.

[0022] Alkylene or alkylene chain refers to a straight or branched hydrocarbon chain that links the rest of the molecule to a radical group, consisting only of carbon and hydrogen, containing no unsaturation and preferably containing from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene and the like. The alkylene chain is attached to the rest of the molecule by a single bond and to the radical group by a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through any two carbons in the chain. In certain embodiments, an alkylene comprises from one to ten carbon atoms (i.e., C1-C8 alkylene). In certain embodiments, an alkylene comprises from one to eight carbon atoms (i.e., C1-C8 Petition 870250100147, dated 10 / 31 / 2025, page 21 / 437 16 / 431 alkylene). In other embodiments, an alkylene comprises from one to five carbon atoms (i.e., C1-C5 alkylene). In other embodiments, an alkylene comprises from one to four carbon atoms (i.e., C1-C4 alkylene). In other embodiments, an alkylene comprises from one to three carbon atoms (i.e., C1-C3 alkylene). In other embodiments, an alkylene comprises from one to two carbon atoms (i.e., C1-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (i.e., C1 alkylene). In other embodiments, an alkylene comprises from five to eight carbon atoms (i.e., C5-C8 alkylene). In other embodiments, an alkylene comprises from two to five carbon atoms (i.e., C2-C5 alkylene). In other embodiments, an alkylene comprises from three to five carbon atoms (i.e., C3-C5 alkylene).

[0023] Alkenylene or alkenylene chain refers to a straight or branched divalent hydrocarbon chain that links the rest of the molecule to a radical group, consisting only of carbon and hydrogen, containing at least one carbon-carbon double bond and preferably containing from two to twelve carbon atoms. The alkenylene chain is attached to the rest of the molecule by a single bond and to the radical group by a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through any two carbons in the chain. In certain embodiments, an alkenylene comprises from two to ten carbon atoms (i.e., C2-C10 alkenylene). In certain embodiments, an alkenylene comprises from two to eight carbon atoms (i.e., C2-C8 alkenylene). In other embodiments, an alkenylene comprises from two to five carbon atoms (i.e., C2-C5 alkenylene).In other embodiments, an alkenylene comprises two to four carbon atoms (i.e., C2-C4 alkenylene). In other embodiments, an alkenylene comprises two to three carbon atoms (i.e., C2-C3 alkenylene). In other embodiments, an alkenylene comprises two carbon atoms (i.e., C2 alkenylene). In other embodiments, an alkenylene comprises five to eight carbon atoms (i.e., C5-C8 alkenylene). In other embodiments, an alkenylene comprises three to five carbon atoms (i.e., C3-C5 alkenylene).

[0024] Alkynylene or alkynylene chain refers to a straight or branched hydrocarbon chain that links the rest of the molecule to a radical group, consisting only of carbon and hydrogen, containing at least one carbon-carbon triple bond and preferably containing from two to twelve carbon atoms. The alkynylene chain is attached to the rest of the molecule by means of a single bond and to the group Petition 870250100147, dated 10 / 31 / 2025, p. 22 / 437 17 / 431 radical by means of a single bond. The attachment points of the alkynylene chain to the rest of the molecule and to the radical group can be via any two carbons in the chain. In certain embodiments, an alkynylene comprises from two to ten carbon atoms (i.e., C2-C10 alkynylene). In certain embodiments, an alkynylene comprises from two to eight carbon atoms (i.e., C2-C8 alkynylene). In other embodiments, an alkynylene comprises from two to five carbon atoms (i.e., C2-C5 alkynylene). In other embodiments, an alkynylene comprises from two to four carbon atoms (i.e., C2-C4 alkynylene). In other embodiments, an alkynylene comprises from two to three carbon atoms (i.e., C2-C3 alkynylene). In other embodiments, an alkynylene comprises two carbon atoms (i.e., C2 alkynylene). In other embodiments, an alkynylene comprises five to eight carbon atoms (i.e., C5-C8 alkynylene).In other embodiments, an alkynylene comprises three to five carbon atoms (i.e., C3-C5 alkynylene).

[0025] Aryl refers to a radical derived from a monocyclic or multicyclic aromatic hydrocarbon ring system by the removal of a hydrogen atom from a carbon atom of the ring. The monocyclic or multicyclic aromatic hydrocarbon ring system contains only hydrogen and carbon and from five to eighteen carbon atoms, where at least one of the rings in the ring system is aromatic, that is, it contains a cyclic (4n+2) π-displaced electronic system according to Hückel's theory. The ring system from which aryl groups are derived includes, but is not limited to, groups such as benzene, fluorene, indane, indene, tetralin, and naphthalene.

[0026] Aralkyl refers to a radical of formula -Rc-aryl where Rc is an alkylene chain as defined above, for example, methylene, ethylene and the like.

[0027] Aralkenyl refers to a radical of formula -Rd-aryl where Rd is an alkenylene chain as defined above. Aralquinyl refers to a radical of formula -Re-aryl, where Re is an alkynylene chain as defined above.

[0028] “Carbocycle” refers to saturated, unsaturated, or aromatic rings in which every ring atom is carbon. Carbocycles can include monocyclic rings of 3 to 10 members, bicyclic rings of 6 to 12 members, and bridge rings of 6 to 12 members. Each ring of a bicyclic carbocycle can be selected from saturated, unsaturated, and aromatic rings. An aromatic ring, for example, phenyl, can be fused to a saturated or unsaturated ring, for example, cyclohexane, cyclopentane, or cyclohexene. Any Petition 870250100147, dated 10 / 31 / 2025, p. 23 / 437 18 / 431 combinations of saturated, unsaturated, and aromatic bicyclic rings, provided the valence allows, are included in the definition of a carbocycle. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. Bicyclic carbocycles can be fused, bridging, or spiro ring systems. In some cases, spiro ring carbocycles contain at least two molecular rings with only one atom in common.

[0029] The term “unsaturated carbocycle” refers to carbocycles with at least one degree of unsaturation and excluding aromatic carbocycles. Examples of unsaturated carbocycles include cyclohexadiene, cyclohexene, and cyclopentene.

[0030] Cycloalkyl refers to a fully saturated monocyclic or polycyclic hydrocarbon radical consisting only of carbon and hydrogen atoms, which includes fused or bridging ring systems and preferably containing three to twelve carbon atoms. In certain embodiments, a cycloalkyl comprises from three to ten carbon atoms. In other embodiments, a cycloalkyl comprises from five to seven carbon atoms. The cycloalkyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyl include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantil, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenil, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.

[0031] Cycloalkenyl refers to a non-aromatic unsaturated hydrocarbon radical, monocyclic or polycyclic, consisting only of carbon and hydrogen atoms, which includes fused or bridging ring systems, preferably containing from three to twelve carbon atoms and comprising at least one double bond. In certain embodiments, a cycloalkenyl comprises from three to ten carbon atoms. In other embodiments, a cycloalkenyl comprises from five to seven carbon atoms. The cycloalkenyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.

[0032] Cycloalkylalkyl refers to a radical of formula -Rc-cycloalkyl where Rc is an alkylene chain as described above.

[0033] Cycloalkylalkoxy refers to a radical linked via an oxygen atom of formula -O-Rc-cycloalkyl where Rc is an alkylene chain as described above. Petition 870250100147, dated 10 / 31 / 2025, page 24 / 437 19 / 431

[0034] Halo or halogen refers to halogen substituents such as bromine, chlorine, fluorine and iodine.

[0035] As used herein, the term haloalkyl or “haloalkane” refers to an alkyl radical, as defined above, which is replaced by one or more halogen radicals, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl and the like. In some embodiments, the alkyl part of the fluoroalkyl radical is optionally further substituted. Examples of halogen-substituted alkanes (“haloalkanes”) include halomethane (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), di- and trihalomethane (e.g., trichloromethane, tribromomethane, trifluoromethane, triiodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combinations of alkanes (or substituted alkanes) and halogens (e.g., Cl, Br, F, I, etc.).When an alkyl group is replaced with more than one halogen radical, each halogen can be independently selected, for example, from 1-chloro,2-fluoroethane.

[0036] Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluorine radicals, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl and the like.

[0037] Aminoalkyl refers to an alkyl radical, as defined above, that is substituted by one or more amino radicals, for example, propan-2-amine, butane-1,2-diamine, pentane-1,2,4-triamine and the like.

[0038] Hydroxyalkyl refers to an alkyl radical, as defined above, that is substituted by one or more hydroxy radicals, for example, propan-1-ol, butane-1,4-diol, pentane-1,2,4-triol and the like.

[0039] Alkoxyalkyl refers to an alkyl radical, as defined above, that is substituted by one or more alkoxy radicals, for example, methoxymethane, 1,3-dimethoxybutane, 1-methoxypropane, 2-ethoxypentane and the like.

[0040] Cyanoalkyl as used herein refers to an alkyl radical, as defined above, which is substituted by one or more cyano radicals, for example, acetonitrile, 2-ethyl-3-methylsuccinonitrile, butyronitrile and the like.

[0041] “Heterocycle” refers to a saturated or unsaturated or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include Petition 870250100147, dated 10 / 31 / 2025, p. 25 / 437 20 / 431 atoms of N, O, Si, P, B, Se, and S. Heterocycles include monocyclic rings with 3 to 10 members, bicyclic rings with 6 to 12 members, and bridging rings with 6 to 12 members. Each ring of a bicyclic heterocycle can be selected from saturated, unsaturated, and aromatic rings. Bicyclic heterocycles can be fused, bridging, or spiro ring systems. In some cases, heterocycles with spiro rings contain at least two molecular rings with only one atom in common. The heterocycle with spiro rings includes at least one heteroatom.

[0042] “Heterocyclone” refers to a divalent heterocycle that links the rest of the molecule to a radical group.

[0043] Heteroaryl or “aromatic heterocycle” refers to a radical derived from a heteroaromatic ring radical comprising from one to eleven carbon atoms and at least one heteroatom where each heteroatom can be selected from N, O, and S. As used herein, the heteroaryl ring can be selected from monocyclic or bicyclic and fused or bridging ring systems where at least one of the rings in the ring system is aromatic, i.e., contains a cyclic (4n+2) π-displaced electronic system according to Hückel theory. The heteroatom(s) in the heteroaryl radical may optionally be oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl can be attached to the rest of the molecule by means of any atom of the heteroaryl, provided the valence allows, such as a carbon or nitrogen atom of the heteroaryl.Examples of heteroaryl compounds include, but are not limited to, pyridine, pyrimidine, oxazole, furan, pyran, thiophene, isoxazole, benzimidazole, benzothiazole, and imidazopyridine.

[0044] An “X-membered heteroaryl” refers to the number of endocyclic atoms, i.e., X, in the ring. For example, a 5-membered heteroaryl ring or 5-membered aromatic heterocycle contains 5 endocyclic atoms, for example, triazole, oxazole, thiophene, etc.

[0045] The term “unsaturated heterocycle” refers to heterocycles with at least one degree of unsaturation and excluding aromatic heterocycles. Examples of unsaturated heterocycles include dihydropyrrole, dihydrofuran, oxazoline, pyrazoline, and dihydropyridine. Heterocycles may optionally be substituted by one or more substituents such as the substituents described herein.

[0046] The term “substituted” refers to radicals having substituents in place of a hydrogen on one or more carbons or replaceable heteroatoms, for example, NH, of the structure. It should be understood that “substitution” or “substituted with” includes the Petition 870250100147, dated 10 / 31 / 2025, p. 26 / 437 21 / 431 implicit condition that such substitution is in accordance with the permitted valence of the substituted atom and the substituent and that the substitution results in a stable compound, that is, a compound that is not subject to spontaneous transformation such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to radicals having substituents replacing two hydrogen atoms on the same carbon atom, such as replacing the two hydrogen atoms on a single carbon with an oxo, imino, or thioxo group.

[0047] As used herein, the term “substituted” includes all permissible substituents of organic compounds. In a broad sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. Permissible substituents may be one or more and the same or different appropriate for organic compounds. For the purpose of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of the organic compounds described herein that satisfy the valences of the heteroatoms. In some embodiments, the substituents may include any substituents described herein, for example: halogen, hydroxyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazino (=NNH2), -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra,-Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N( Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb-S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2 (where t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralquinyl, cycloalkyl, cycloalkylalkyl and heterocycle, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=NNH2), -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa (where t is 1 or 2), -Rb-S(O)tRa (where t is 1 or 2), -Rb-S(O)tORa (where t is 1 or 2) and -Rb-S(O)tN(Ra)2 (where t is 1 or 2); where each Ra is selected independently from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, where each Ra, provided the valence allows, may optionally be substituted with alkyl, Petition 870250100147, dated 10 / 31 / 2025, p. 27 / 437 22 / 431 alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=NNH2), -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C( O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N( Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa (where t is 1 or 2), -Rb-S(O)tORa (where t is 1 or 2) and -Rb-S(O)tN(Ra)2 (where t is 1 or 2); and where each Rb is independently selected from a direct linkage or a straight or branched alkylene, alkenylene or alkynylene chain and each Rc is a straight or branched alkylene, alkenylene or alkynylene chain.

[0048] As used herein, the term “optional” or “optionally” means that the subsequently described event of circumstances may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, “optionally substituted aril” means that the aril group may or may not be substituted and that the description includes both substituted aril groups and aril groups containing no substitution.

[0049] As used herein, the term “electrophile” or “electrophilic radical” is any radical capable of reacting with a nucleophile (e.g., a radical containing a single pair of electrons, a negative charge, a partial negative charge, and / or an excess of electrons, e.g., an -SH group). Electrophiles are typically electron-poor or comprise atoms which are electron-poor. In certain embodiments, an electrophile contains a positive charge or partial positive charge, exhibits a resonance structure containing a positive charge or partial positive charge, or is a radical in which electron displacement or polarization results in one or more atoms containing a positive charge or partial positive charge. In some embodiments, an electrophile comprises a conjugated double bond, e.g., an α,β-unsaturated carbonyl compound or α,β-unsaturated thiocarbonyl compound.

[0050] As used in the report and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly indicates otherwise.

[0051] The term “salt” or “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids from which salts can be derived include, for example, Petition 870250100147, dated 10 / 31 / 2025, page 28 / 437 23 / 431 For example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable basic addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion-exchange resins and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropropylamine, and ethanolamine. In some embodiments, the additionally pharmaceutically acceptable basic salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.

[0052] The phrases “parenteral administration” and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0053] The phrase “pharmaceutically acceptable” is used here to refer to compounds, materials, compositions and / or dosage forms that are, within the scope of good medical sense, suitable for use in contact with the tissues of humans and animals without toxicity, irritation, allergic response or other problems with excessive complications, consistent with a reasonable benefit / risk ratio.

[0054] The phrase “pharmaceutically acceptable excipient” or “pharmaceutically acceptable vehicle” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a pharmaceutically acceptable filler, diluent, excipient, solvent, or encapsulation material. Each vehicle must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that serve as vehicles Petition 870250100147, dated 10 / 31 / 2025, page 29 / 437 24 / 431 pharmaceutically acceptable substances include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository ceres; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline solution; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions;and (21) other compatible non-toxic substances used in pharmaceutical formulations.;

[0055] In certain embodiments, the term “prevent” or “preventing” as related to a disease or disorder may refer to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated sample or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.

[0056] The terms “treat”, “treating” or “treatment”, as used herein, may include relief, attenuation or improvement of the symptoms of a disease or condition, prevention of additional symptoms, improvement or prevention of the underlying causes of the symptoms, inhibition of the disease or condition, for example, interruption of the development of the disease or condition, relief of the disease or condition, causing regression of the disease or condition, relieving a condition caused BY the disease or condition, or interruption of the symptoms of the disease or condition prophylactically and / or therapeutically.

[0057] The term “G12 mutants”, as used herein, refers to other oncogenic KRAS alleles at amino acid position 12 (i.e., G12X). Dissemination Compounds

[0058] What follows is a discussion of the compounds and salts thereof that can be used in dissemination methods.

[0059] In aspects, the present disclosure provides a compound of Formula (I): Petition 870250100147, dated 10 / 31 / 2025, p. 30 / 437 25 / 431 Formula (I), or a pharmaceutically acceptable salt thereof where: piB R1AR1CR1dν' o'' s' R100 is selected from , -L- and -L- ; R1A is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11A, where optionally two R11A on the same R1A atom join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; R1bé selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, 4- to 6-membered heterocycle, wherein the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle, where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(=NR20)N(R20)2, -C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where the carbocycle C3-C12 and 5- to 12-membered heterocycle are each optionally replaced independently with one or more R1*; each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), Petition 870250100147, dated 10 / 31 / 2025, p. 31 / 437 26 / 431 =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl and C3C12 carbocycle; R1C is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R12e where optionally two R12 on the same atom of R1C join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R12A; R1D is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R13E where optionally two R13E on the same atom of R1D join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R13A; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Cl-C6 haloalkyl, -LNR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), L-OC(O)N(R20)2 and -LC(=O)OCl-C6 alkyl, wherein the heterocycle, the heterocyclic part of L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -L-NR20C(O)-aryl, the aryl de-L-aryl and the heteroaryl de-L-heteroaryl are each optionally replaced with one or more R7; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more independently selected substituents of halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; Petition 870250100147, dated 10 / 31 / 2025, page 32 / 437 27 / 431 each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, =O, =S, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl; n is selected from 0, 1, 2, 3 and 4; m is selected from 1 and 2; Each R5 is independently selected from hydrogen and C1-C6 alkyl; each R6 is independently selected from halogênio, hydroxi, Ci-C3 hidroxialquil, Ci-C3 alquil, oxo, Ci-C3 haloalquil, C1-C3 alkoxy, cyan, =CH2, =NOCi-C3 alquil, Ci-C3 aminoalquil, -N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, -NHC(O)phenylSO2F, C1-C3 alquil substituído pyrazolyl, tert-butyldimethylsilyloxyCH2-, N(R5)2, (C1-C3 alkoxy)Cl-C3 alquil-, (C1-C3 alquil)C(=O), oxo, (C1-C3 haloalquil)C(=O), -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, -CH2OC(O)NCF3(R5), -CH2O-Ci-C6 alkoxy,CH2OC(O)N(R5)2, -CH2NHC(O)OCi-C6 alkoxy, -CH2NHC(O)N(R5)2, -CH2NHC(O)CiC6 alkoxy, -CH2(pyrazolyl), -CH2NHSO2C1-C6 alkoxy, -CH2OC(O)heterocycle, OC(O)N(R5)2, -OC(O)NH(Ci-C3 alkoxy)O(Cl-C3 alkoxy), -OC(O)NH(Ci-C3 alkoxy)O(ClC3 alkoxy)phenyl(C1-C3 alkoxy)N(CH3)2, -OC(O)NH(Ci-C3 alkoxy)O(Cl-C3 alquil)phenyl, OC(O)heterocycle, -O-Ci-C3 alquil, -O-Ci-C6 haloalquil, -C1-C3 alquil-O-Cl-C6 haloalquil, C1-6 alquil-N(R20)2, -SF5, -C1-C3 alquil-N3, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20,-(CH2)0-1S-heterocycle, -(CH2)0-1-O-heterocycle, (CH2)0-1-O-phenyl and -CH2heterocycle, wherein the phenyl of -NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(C1-C3 alkyl)phenyl is optionally substituted with one or more substituents selected from -C(O)H and OH, wherein the alkyl of -O-C1-C3 alkyl is optionally substituted with heterocycle, oxo and hydroxy substituents selected; where the -CH2O-C1-C6 alkyl group is optionally replaced with one or more selected halogen and C3-C6 carbocycle substituents; where the -CH2heterocycle is optionally substituted with oxo; and where the phenyl group of -(CH2)0-1-O-phenyl is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, SF5, C1-6 alkyl-OR20, OR20; Petition 870250100147, dated 10 / 31 / 2025, p. 33 / 437 28 / 431 where the heterocycle of -(CH2)oiO-heterocycle and -(CH2)oiS-heterocycle are each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20; each Q is selected from a connection and O; Each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; Selected 5- to 12-membered heterocycle R8é, wherein the 5- to 12-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20), -SR20, -SR20, O -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -C(O)NR20-OR20, C1-6 alkyl-N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-61, Cxi-alkyl alcohol, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; R9 is selected from hydrogen, halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C16-alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C16 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ca-Co carbocycle, wherein the Ca-Co carbocycle is optionally substituted with one or more halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;ouR8 and R9 combine with the atoms to which they are attached to form B, where B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; Each R10 is independently selected from halogens: -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, Petition 870250100147, dated 10 / 31 / 2025, p. 34 / 437 29 / 431 C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, wherein the C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C110 haloalkyl, -O-C1-10 alkyl, oxo; each R11, R12and R13are independently selected halogen, -B(OR20)2, OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR2020), -R2020, -R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -ROC(O)20, -NR20(C=NH)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6, halo alkyl, C-26 alkenyl, C2-6 alkynyl, C3C12 carbocycle and heterocycle of 5 to 12 members, wherein the C3-C12 carbocycle and heterocycle of 5 to 12 members are each optionally substituted with one or more independently selected halogen substituents, -OH, -NO2, -CN -N(R21)2, -SR21, C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)2(R21) and oxo; each R11a, R12ae R13Aé independently selected halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR2020), -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, N(R20)2, -C(O)R20, -C(O)OR20, -O =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; Each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more independently selected substituents of halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C110 alkyl, C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more independently selected substituents Petition 870250100147, dated 10 / 31 / 2025, p. 35 / 437 30 / 431 selected halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

[0060] In some embodiments, for a compound or salt of Formula (I), where I^ib ^ia r1C n oxsx R100 is selected from —I— , and ; R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11e where optionally two R11e on the same atom of R1A join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; R1bé selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, where the C1-6 alkyl and C3-C6 carbocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle, where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, C(=NR20)N(R20)2, -C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6alkyl-N(R20)2, C16 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where the carbocycle C3-C12 and 5 to 12 membered heterocycle are each optionally replaced independently with one or more R1*; each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-C12 carbocycle; Petition 870250100147, dated 10 / 31 / 2025, p. 36 / 437 31 / 431 R1C is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R12e where optionally two R12 on the same atom of R1C join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R12A; R1D is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R13E where optionally two R13E on the same atom of R1D join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R13A; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Cl-C6 haloalkyl, -L-NR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OCl-C6 alkyl, wherein the heterocycle, the heterocyclic part of -L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -LNR20C(O)-aryl, the -L-aryl aril and -L-heteroaryl heteroaryl are each optionally replaced with one or more R7s; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more independently selected substituents of halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; Petition 870250100147, dated 10 / 31 / 2025, page 37 / 437 32 / 431 each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), N(C1-6 alkyl)2, =O, =S, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl; n is selected from 0, 1, 2, 3 and 4; m is selected from 1 and 2; Each R5 is independently selected from hydrogen and C1-C6 alkyl; each R6 is independently selected from halogênio, hydroxi, Ci-C3 hidroxialquil, CiC3 alquil, oxo, Ci-C3 haloalquil, C1-C3 alkoxy, cyano, =CH2, =NO-Ci-C3 alquil, Ci-C3 aminoalquil, -N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, NHC(O)phenylSO2F, C1-C3 alquil substituído pyrazolyl, tert-butyldimethylsililoxiCH2-, N(R5)2, (C1-C3 alkoxy)Cl-C3 alquil-, (C1-C3 alquil)C(=O), oxo, (C1-C3 haloalquil)C(=O)-, -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, -CH2OC(O)N(R5)2, CH2NHC(O)OCi-C6 alkoxy, -CH2NHC(O)N(R5)2, -CH2NHC(O)Ci-C6 alkoxy, CH2(pyrazolyl), -CH2NHSO2C1-C6 alkoxy, -CH2OC(O)heterocycle, -OC(O)N(R5)2, OC(O)NH(Ci-C3 alkoxy)O(Cl-C3 alkoxy), -OC(O)NH(Ci-C3 alkoxy)O(Cl-C3 alkoxy)phenyl(C1-C3 alkoxy)N(CH3)2, -OC(O)NH(Ci-C3 alkoxy)O(Cl-C3 alkoxy)phenyl, OC(O)heterocycle, -O-Ci-C3 alkoxy, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20e -CH2heterocycle,where the phenyl group of -NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(C1-C3 alkyl)phenyl is optionally substituted with one or more substituents selected from -C(O)H and OH, and where the alkyl group of -O-C1-C3 alkyl is optionally substituted with heterocyclic, oxo, and hydroxyl substituents; and where the heterocycle group of -CH2heterocyclyl is optionally substituted with oxo; each Q is selected from a connection and O; Each R7 is independently selected from halogen, hydroxy, HC(=O)-, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl and -N(R5)2; R8 is selected from a 5 to 12 membered heterocycle, whereby the 5 to 12 membered heterocycle is optionally substituted with one or more independently selected halogênium substitutions, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -C(O)NR20-OR20, Ci-6 alquil-N(R20)2, Ci-6 aminoalquil, Ci-6 alkoxy, Ci-6 alkoxyalquil, Ci-6 hidroxialquil, Ci-6 cyanoalquil, Ci-6 Petition 870250100147, 31 / 10 / 2025, pág. 38 / 437 33 / 431 haloalquil, C1-6 alquil, C2-6 alquenyl, C2-6 alquinyl, C3-C12 carbocycle and heterocycle of 5 to 12 members; R9 is selected from hydrogen, halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-C6 carbocycle, wherein the C3-C6 carbocycle is optionally substituted with one or more halogens, -CN, -NO2, N(R20)2, -OR20, -SR20, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; or R8 and R9 combine with the atoms to which they are attached to form B, where B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; Each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo; Each R11, R12, and R13 is independently selected from halogen, -B(OR20)2, -OR20, SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, Petition 870250100147, dated 10 / 31 / 2025, p. 39 / 437 34 / 431 NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -N(R21)2, C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl and oxo; each R11a, R12ae R13Aé independently selected halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20, -NR20 -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -O =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C110 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

[0061] In some embodiments, Formula (I) is represented by Formula (IA), or a pharmaceutically acceptable salt thereof. Petition 870250100147, dated 10 / 31 / 2025, p. 40 / 437 35 / 431

[0062] In some embodiments, Formula (I) is represented by Formula (IB), or a pharmaceutically acceptable salt thereof.

[0063] In some embodiments, Formula (I) is represented by Formula (IC), or a pharmaceutically acceptable salt thereof.

[0064] In some embodiments, Formula (I) is represented by Formula (IG), or a pharmaceutically acceptable salt thereof.

[0065] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (ID), Formula (IE), Formula (IG), Formula (IH), or Formula (IJ), R8 and R9 combine with the atoms to which they are attached to form B.

[0066] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from an optionally substituted 7- to 15-membered fused heterocycle and optionally substituted fused C7-C15 carbocycle. In some cases, optionally substituted fused C7-C15 carbocycle Petition 870250100147, dated 10 / 31 / 2025, p. 41 / 437 36 / 431 substituted. In some cases, B is an optionally substituted fused 7- to 15-membered heterocycle. In some cases, B is an optionally substituted fused unsaturated 7- to 15-membered heterocycle. In some cases, B is an optionally substituted fused 7- to 15-membered heteroaryl. In some cases, B is selected from an optionally substituted fused 7- to 15-membered heteroaryl and an optionally substituted fused C7-C15 aryl. In some cases, B is an optionally substituted fused C7-C15 carbocycle. In some cases, B is an optionally substituted fused 7- to 15-membered heterocycle where the fused heterocycle is partially unsaturated. In some cases, B is an optionally substituted fused 7- to 15-membered heterocycle where the fused heterocycle is partially saturated.

[0067] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from an optionally substituted fused 8- to 15-membered heterocycle and optionally substituted fused C8-C15 carbocycle. In some cases, optionally substituted fused C8-C15 carbocycle. In some cases, B is an optionally substituted fused 8- to 15-membered heterocycle. In some cases, B is an optionally substituted unsaturated fused 8- to 15-membered heterocycle. In some cases, B is an optionally substituted unsaturated fused C8-C15 carbocycle. In some cases, B is an optionally substituted fused 8- to 15-membered heterocycle, where the fused heterocycle is partially unsaturated. In some cases, B is an optionally substituted fused heterocycle with 8 to 15 members, where the fused heterocycle is partially saturated.

[0068] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from an optionally substituted fused 8- to 15-membered heterocycle, where the fused heterocycle is formed by the combination of three rings (e.g., tricyclic). In some cases, B is selected from an optionally substituted fused 8- to 15-membered heterocycle, where the fused heterocycle is formed by the combination of two rings (e.g., bicyclic). In some cases, for B the optionally substituted fused 8- to 15-membered heterocycle and the optionally substituted fused C8-C15 carbocycle are each independently bicyclic or tricyclic. In some cases, for B the heterocycle Petition 870250100147, dated 10 / 31 / 2025, p. 42 / 437 37 / 431 of 8 to 15 members optionally substituted fused is bicyclic. In some cases, for B the optionally substituted 8 to 15 membered fused heterocycle is tricyclic.

[0069] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), the heterocycle or carbocycle of B is bicyclic. In some cases, the heterocycle or carbocycle of B is tricyclic. In some cases, the tricyclic heterocycle contains three interconnected rings of atoms.

[0070] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), for B, the heterocycle and the carbocycle are each independently selected from bicyclic and tricyclic. In some cases, for B, the heterocycle and the carbocycle are each independently tricyclic. In some cases, for B, the heterocycle and the carbocycle are each independently bicyclic.

[0071] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), for B, the optionally substituted fused 8- to 15-membered heterocycle and the optionally substituted fused C8-C15 carbocycle are selected from, each of which is optionally substituted with one or more substituents. In some cases, for B, the optionally substituted fused 8- to 15-membered heterocycle and the optionally substituted fused C8-C15 carbocycle are selected from, each of which is optionally substituted with one or more substituents. In some cases, B is selected from Petition 870250100147, dated 10 / 31 / 2025, pp. 43 / 437 38 / 431 , , , , each of which is optionally replaced with one or more substituents. In some cases, B is selected from hn Fy, each of which is optionally replaced with one or more substituents. / p / hn py In some cases, B is selected from e — , each of which is optionally replaced with one or more substituents.

[0072] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula n (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from ^, each of which is optionally replaced with one or more substitutes. In some cases, B is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 44 / 437 39 / 431 HN ry Odd ·' , and , each of which is optionally replaced with one or more substituents. In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), ), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is an optionally substituted fused 8- to 15-membered heterocycle, where B contains a heteroatom selected from nitrogen, sulfur, and selenium. In some cases, B is an optionally substituted fused 8- to 15-membered heterocycle, where B contains at least one heteroatom selected from nitrogen and selenium. In some cases, B is an optionally substituted fused 8- to 15-membered heterocycle, where B contains at least one heteroatom selected from selenium. In some cases, B is an optionally substituted fused 8- to 15-membered heterocycle, where B contains at least one heteroatom selected from sulfur and selenium.In some cases, B is an optionally substituted fused 8- to 10-membered heterocycle, where B contains at least one heteroatom selected from nitrogen, sulfur, and selenium. In some cases, B is an optionally substituted fused 8-membered heterocycle, where B contains at least one heteroatom selected from nitrogen, sulfur, and selenium.

[0073] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), for B, the optional substituents of the heterocycle and carbocycle are each independently selected from halogen, CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle.In some cases, the optional substituents of the heterocycle and carbocycle are each independently selected from halogen, -CN, -NO2, =O, -N(R2O)2, -B(OR2O)2, -OH, -SR2O, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl. In some cases, for B, one or more. Petition 870250100147, dated 10 / 31 / 2025, p. 45 / 437 Optional substituents of the heterocycle and carbocycle are selected independently in each occurrence from halogen, oxo, -NH2, C1-C3 alkyl, -B(OH)2, -OH, -O-C1-C3 haloalkyl, -C(O)NH2, -NH2, =O, -CN, C1-6 alkoxy, C1-6 hydroxyalkyl, and C2-6 alkynyl. In some cases, the optional substituents of the heterocycle and carbocycle are each independently selected from halogen, -CN, =O, -NH2, -N(C1-6 alkyl)H, -N(C1-6 alkyl)2, -OH, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl. In some cases, one or more optional substituents of the heterocycle and carbocycle are each independently selected from oxo, -NH2, halogen, or C1-C3 alkyl. In some cases, for B, the optionally substituted 8- to 15-membered fused heterocycle is C8-C15. Optionally substituted molten carbocycles are selected from Hθ = N, and NH2 nh2nh2nh2 In some. In these cases, B is selected from, Cl, nh2 =N In some cases, B is selected from =N. CN HN'nnh2=N Cl, Petition 870250100147, dated 10 / 31 / 2025, page 46 / 437 41 / 431 Petition 870250100147, dated 10 / 31 / 2025, page 47 / 437 42 / 431 In some In these cases, B is selected from HO

[0074] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from an optionally substituted 7- to 12-membered fused heterocycle and optionally substituted fused C9-10 carbocycle. In some cases, the heterocycle of B contains at least one sulfur atom. In some cases, the heterocycle of B contains one or more sulfur atoms. In some cases, the heterocycle of B contains at least one nitrogen atom. In some cases, B is selected from , each of which is optionally substituted. In some cases, one or more optional substitutes for B. Petition 870250100147, dated 10 / 31 / 2025, pp. 48 / 437 43 / 431 are independently selected from each occurrence of halogen, C1-C3 alkyl, B(OR20)2, -OR20, -C(O)N(R20)2, -N(R20)2, =O, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl. In some cases, one or more optional substituents of B are independently selected from each occurrence of halogen, C1-C3 alkyl, -OH, -NH2, =O, and -CN. In some cases, B is selected from HO NH2

[0075] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is selected from an optionally substituted fused 8- to 10-membered heterocycle containing at least one sulfur atom. In some cases, B is selected from ~~, S—^, S—Ã, S, each of which is optionally substituted. In some cases, one or more optional substituents of B are independently selected at each occurrence of halogen, C1-C3 alkyl, -OR20, -C(O)N(R20)2, -N(R20)2, =O, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl. In some cases, one or more optional substituents of B are independently selected at each occurrence of halogen, C1-C3 alkyl, -NH2 and Petition 870250100147, dated 10 / 31 / 2025, page 49 / 437 44 / 431 CN. In some cases, B is replaced. In some cases, B is replaced with at least one -NH2. In some cases, B is selected from NH2, NH2 nh2, NH2, and NH2. In some cases, B is replaced with at least one -NH2 and at least one -CN. In some cases, B is selected from

[0076] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), B is an optionally substituted 7- to 11-membered fused heterocycle. In some cases, B is an optionally substituted 8- to 10-membered fused heterocycle. In some cases, the heterocycle of B is an unsaturated heterocycle. In some cases, the heterocycle of B is a non-aromatic heterocycle. In some cases, B contains at least one sulfur atom. In some cases, B contains at least two sulfur atoms. In some cases, B contains at least one sulfur atom and at least one nitrogen atom. In some cases, B contains at least one sulfur atom and at least one oxygen atom. In some cases, B contains only 1 heteroatom. In some cases, B contains at least 2 heteroatoms. In some cases, B is selected from each of which is Petition 870250100147, dated 10 / 31 / 2025, p. 50 / 437 45 / 431 optionally replaced. In some cases, B is selected from , each of which is optionally replaced. In some cases, B is selected from , each of which is optionally replaced. In some cases, one or more optional substituents of B are independently selected in each occurrence of halogen, oxo, -NH2, C1-C3 alkyl, -B(OH)2, -OH, O-Cl-C3 haloalkyl, -C(O)NH2, -NH2, =O, -CN, C1-6 alkoxy, C1-6 hydroxyalkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of B are independently selected in each occurrence of halogen, C1-C3 alkyl, -NH2, and CN. In some cases, B is substituted with at least one substituent selected from halogen, C1-C3 alkyl, -NH2, and -CN. In some cases, B is substituted with at least one substituent selected from halogen. In some cases, B is substituted with at least one substituent selected from -NH2. In some cases, B is substituted with at least one substituent selected from CN. In some cases, B is replaced with at least one substituent. In some cases, B is selected from NH2. Petition 870250100147, dated 10 / 31 / 2025, page 51 / 437 46 / 431 NH2

[0077] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (ID), Formula (IE), Formula (IH), or Formula (IJ), each R9 is selected from hydrogen, halogen, -CN, -N(R20)2, -OR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C3-C6 cycloalkyl, where the C3-C6 cycloalkyl is optionally replaced with one or more of halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl. In some cases, each R9 is selected from hydrogen, -CN, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C3-C6 cycloalkyl, where the C3-C6 cycloalkyl is optionally replaced with one or more halogens, -CN, -NO2, -N(R20)2, -OR20, SR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.In some cases, each R9 is selected from halogen, hydrogen, C1-6 alkyl, and C3-C6 cycloalkyl. In some cases, each R9 is selected from hydrogen, C1-6 alkyl, and C3-C6 cycloalkyl. In some cases, each R9 is selected from hydrogen, fluorine, methyl, and cyclopropyl. In some cases, each R9 is selected from hydrogen, methyl, and cyclopropyl.

[0078] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (ID), Formula (IE), Formula (IH), or Formula (IJ), R8 is selected from optionally substituted 5- to 6-membered heteroaryl. In some cases, R8 is selected from optionally substituted 5-membered heteroaryl. In some cases, the heteroaryl of R8 contains at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some cases, the heteroaryl of R8 contains only one sulfur atom. In some cases, the heteroaryl of R8 contains at least one sulfur atom. In some cases, the heteroaryl of R8 contains at most one sulfur atom. In some cases, the heteroaryl of R8 contains at least one oxygen atom. In some cases, the heteroaryl of R8 contains at least one nitrogen atom. In some cases, the heteroaryl of R8 is Petition 870250100147, dated 10 / 31 / 2025, p. 52 / 437 47 / 431s, which is optionally replaced. In some cases, the heteroaryl of R8 is , which is optionally substituted. In some cases, the heteroaryl of R8 is , which is substituted. In some cases, one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN. In some cases, one or more optional substituents of R8 are independently selected from halogen, -N(R20)2 and -CN. In some cases, one or more optional substituents of R8 are independently selected from halogen, -NH2 and -CN. In some cases, one or more substituents of R8 are independently selected from halogen, -NH2 and -CN. In some cases, one or more optional substituents of R8 are independently selected from chlorine, -NH2 and -CN. In some cases, R8 is selected from H2N, H2N, H2N, H2N eh2n. In some cases, R8 is selected from H2Ne. h2n. In some cases, R8 is H2N. In some cases, R8 is H2N.

[0079] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (ID), Formula (IE), Formula (IH), or Formula (IJ), R8 is selected from an optionally substituted 6- to 9-membered heteroaryl. In some cases, R8 is selected from , each of which is Petition 870250100147, dated 10 / 31 / 2025, p. 53 / 437 48 / 431 optionally replaced. In some cases, R8 is selected from Each of which is optionally substituted. In some cases, one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2, and -CN. In some cases, one or more optional substituents of R8 are independently selected from halogen, C2-6 alkyl, C1-6 haloalkyl, -N(R20)2, and -CN. In some cases, one or more optional substituents of R8 are independently selected from halogen, C1-6 haloalkyl, -N(R20)2, and -CN. In some cases, R8 is selected from In some cases, the heteroaryl group of R8 contains at least one sulfur atom. In some cases, the heteroaryl group of R8 is bicyclic. In some cases, the heteroaryl group of R8 is monocyclic. In some cases, R8 is , which is optionally replaced. In some cases, R8 is , which is optionally substituted. In some cases, one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN.

[0080] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (ID), Formula (IE), Formula (IH), or Formula (IJ), R8 is Petition 870250100147, dated 10 / 31 / 2025, p. 54 / 437 49 / 431 selected from an optionally substituted 5- to 12-membered unsaturated heterocycle. In some cases, R8 is selected from an optionally substituted 8- to 12-membered bicyclic unsaturated heterocycle. In some cases, R8 is selected from an optionally substituted 9-membered unsaturated heterocycle. In some cases, the heterocycle of R8 is a bicyclic heterocycle. In some cases, the bicyclic heterocycle has two rings. In some cases, one ring of the bicyclic heterocycle is an unsaturated carbocycle and the second ring is a heteroaryl. In some cases, the heterocycle of R8 contains at least one sulfur atom. In some cases, the heterocycle of R8 is optionally substituted. In some cases, one or more optional substituents of R8 are independently selected from halogens, -N(R2O)2, and -CN. In

[0081] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), n is selected from 0 and 1. In some cases, n is 1. In some cases, n is 0. In some cases, n is 3. In some cases, n is 2.

[0082] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, =O, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C1-6 haloalkyl. In some cases, each R4 is independently selected from =O.

[0083] In some embodiments, for a compound or salt of Formula (I), m is 1. In some cases, m is 2. In some cases, when R8 and R9 combine with the atoms to which they are bonded to form B, m is 1. In some cases, when R8 and R9 combine with the atoms to which they are bonded to form B, m is 2.

[0084] In some embodiments, for a compound or salt of Formula (I), R100 is R1. Petition 870250100147, dated 10 / 31 / 2025, p. 55 / 437 50 / 431

[0085] In some embodiments, for a compound or salt of Formula (I), R100 is R1AR1bR1CR1aR1bXNX' θ''N' selected from —J— and . In some cases, R100 is —J—.

[0086] In some embodiments, for a compound or salt of Formula (I), R100 is R1A / r1B / r1CNO selected from —1— and , where R1A is selected from C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more R11 and where optionally two R11 on the same atom of R1A join to form a C3-C6 carbocycle, where C3-C6 carbocycle is optionally substituted with one or more R11A; or R1A and R1B join with the atom to which they are attached to form R1, where R1 is an optionally substituted 6- to 10-membered heterocycle; R1B is selected from hydrogen and C1-6 alkyl; and R1C is selected from C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more R12 and where optionally two R12 on the same atom of R1C join to form a C3C6 carbocycle, where C3-C6 carbocycle is optionally substituted with one or more R12A.

[0087] In some embodiments, for a compound or salt of Formula (I), R100é ria / N selected from: , where R1A is selected from C1-6 alkyl, where C1-6 alkyl is optionally replaced with one or more R11e, and where optionally two R11e are used in the same R1C and R1A atoms join to form an unsubstituted C3 carbocycle; where R1C is selected from C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more R12s, and where optionally two R12s on the same R1C atom join to form a R1A^r16 N C3 unsubstituted carbocycle; and —L— , where R1A and R1B combine with the atom to which they are attached to form R1, where R1 is selected from each of which is optionally replaced.

[0088] In some embodiments, for a compound or salt of Formula (I), each R11 is selected from -CN and where optionally two R11s on the same R1A atom join to form an unsubstituted C3 carbocycle; each R12 is selected from -CN and where optionally two R12s on the same R1C atom join to form a C3 carbocycle Petition 870250100147, dated 10 / 31 / 2025, p. 56 / 437 51 / 431 unsubstituted; and one or more substituents of R1 are independently selected from halogen, -OR20, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(R20)2.

[0089] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), each R11 is selected from -CN and where optionally two R11s on the same R1A atom join to form an unsubstituted C3 carbocycle.

[0090] In some embodiments, for a compound or salt of Formula (I), one or more substituents of R1 are independently selected from halogen, -OR20, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(R20)2. In some cases, one or more substituents of R1 are independently selected from halogen, -OH, -CN, oxo, C16 alkyl, C1-6 hydroxyalkyl and -C(O)N(CH3)2.

[0091] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), each R12 is selected from -CN and where optionally two R12s on the same R1C atom join to form an unsubstituted C3 carbocycle.

[0092] In some embodiments, for a compound or salt of Formula (I), R1A is A / Cn ^cn AAnselected from x ; R1Cé selected from V ex ; and one or more substituents of R1 are independently selected from halogen, -OH, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(CH3)2.

[0093] In some embodiments, for a compound or salt of Formula (I), R1A is A^cn \^cn AAnselected from χ ; R1Cé selected from χ ex ; and one or more substituents of R1 are independently selected from halogen, -OH, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(CH3)2.

[0094] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from

[0095] In some embodiments, for a compound or salt of Formula (I), Formula (I\,cn D), Formula (IE), or Formula (IF), R1Cé selected from χ and

[0096] In some embodiments, for a compound or salt of Formula (I), R100 is R1AR1bR1CrID n O' S' selected from , and . In some cases R100 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 57 / 437 52 / 431

[0097] In some embodiments, for a compound or salt of Formula (I), R100 is selected from NC. OH OH CN, some realizations, for a compound ,, , ,

[0098] In . or salt of Formula (I), R100 is selected from to form R1.

[0099] In ^R1B N, where R1A and R1B join with some realizations, for a compound the atom to which they are attached or salt of Formula (I), R100 is R1Co

[00100] In some embodiments, for a compound or salt of Formula (I), R100 is R1^ / R7 N NH selected from: and . In some cases, R1A is selected from C1-6 alkyl, C3C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11e where optionally two R11e on the same R1A atom join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A.

[00101] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1B is hydrogen. In some cases, R1B is selected from an optionally substituted C1-6 alkyl. In some cases, R1B is selected from an optionally substituted C3-C6 carbocycle. Petition 870250100147, dated 10 / 31 / 2025, p. 58 / 437 53 / 431

[00102] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from an optionally substituted C1-6 alkyl. In some cases, R11 is -N(R20)2. In some cases, R1A is selected from H O e

[00103] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is a C4-C6 carbocycle, where the C4C6 carbocycle is optionally replaced with one or more R11s. In some cases, each R11 is selected from -N(R20)2, where each R20 is selected from hydrogen and optionally replaced C1-6 alkyl / ^^NH2. In some cases, R1A is selected from ' ,

[00104] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from a 4- to 12-membered heterocycle, where the 4- to 12-membered heterocycle is optionally replaced with one or more R11s. In some cases, each R11 is selected from halogen, -N(R2O)2, C(O)R2O, -C(O)N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, / ^NH C1-6 haloalkyl and C1-6 alkyl. In some cases, R1A is selected from ', Petition 870250100147, dated 10 / 31 / 2025, p. 59 / 437 54 / 431 In some cases, R1A is selected from a 5- to 6-membered heterocycle and where the 5- to 6-membered heterocycle is optionally with one or more R11s. In some cases, the heterocycle contains at least one oxygen atom. In some cases, the heterocycle contains one oxygen atom. In some cases, R1A is selected from , which is optionally substituted. In some cases, each R11 is selected from -OH and C1-6 hydroxyalkyl. In some cases, each R11 is -OH. In some cases, R1A is selected from and

[00105] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), each R11A is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl.

[00106] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), each R11 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, Petition 870250100147, 10 / 31 / 2025, p. 60 / 437 55 / 431 N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -NO2, =O, =NO(R20), -N(R20), -NHCN, -NHC6 alkyl-N(R20)2, Ci-6aminoalkyl, Ci-6 alkoxy, C1-6hydroxyalkyl, C1-6cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl, C3-C12 carbocycle and 12-membered heterocycle. In some cases, each independently selected halide R11, -OR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20(=NR20), -NR20S(O)2R20, -C(O)2, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, -NO, =NO, =NO, -NHCN, C1-6alkyl-N(R20)2, C1-6aminoalkyl, C1-6 alkoxy, C1-6hydroxyalkyl, C1-6cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl, C3-C12 and heterocyclic heterocyclic members.In some cases, each R11 is independently selected from halogen, -OR20, -N(R20)2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle. In some cases, each R11 is independently selected from halogen, -OR20, -N(R20)2, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C16 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 haloalkyl.

[00107] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1B is selected from hydrogen, optionally substituted C16 alkyl, and optionally substituted C3-C6 carbocycle. In some cases, R1B is hydrogen, C1-6 alkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C3-C6 carbocycle. In some cases, R1B is hydrogen, methyl, ethyl, C2 hydroxyalkyl, and cyclopropyl. In some cases, R1B is hydrogen. In some cases, R1B is selected from an optionally substituted C1-6 alkyl. In some cases, R1B is selected from methyl and ethyl. In some cases, R1B is methyl. In some cases, R1B is selected from an optionally substituted C3-C6 carbocycle. In some cases, R1B is selected from C1-6 cyanoalkyl. In some cases, R1B is selected from C1-6 hydroxyalkyl.

[00108] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from an optionally substituted C1-3 alkyl and where optionally two R11s on the same R1A atom join to form a C3 carbocycle. In some cases, R11 is selected from a halogen, N(R20)2, C3 carbocycle and 5- to 6-membered heterocycle, where the 5- to 6-membered heterocycle is optionally substituted with one or more substituents independently. Petition 870250100147, dated 10 / 31 / 2025, p. 61 / 437 56 / 431 selected from halogen, -OH, -CN, -N(R21)2, C1-10 alkyl and -C1-10 haloalkyl. In some cases, each R21 is independently selected from hydrogen; and C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more independently selected substituents from halogen, oxo, C3-6 carbocycle and 3- to 6-membered heterocycle.

[00109] In some embodiments, for a compound or salt of Formula (I), Formula (I- A), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 62 / 437 57 / 431 H O e

[00110] In some embodiments, for a compound or salt of Formula (I), R100 is ,, Cl nh2 HN NH2nh2,,, R , Petition 870250100147, dated 10 / 31 / 2025, p. 63 / 437 58 / 431

[00111] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A is selected from an optionally substituted C1-6 alkyl. In some cases, R1A is selected from an optionally substituted C1-3 alkyl and where optionally two R11s on the same R1A atom join to form a C3 carbocycle. In some cases, R1A is selected from an optionally substituted C1-2 alkyl. In some cases, R1A is selected from R11 Petition 870250100147, dated 10 / 31 / 2025, p. 64 / 437 59 / 431 R11 Faith In some cases, R1A is R11 is selected from . In some cases, R1A is selected from . In some cases, R11 is selected from an optionally substituted 5- to 12-membered heterocycle. In some cases, R11 is selected from an optionally substituted 5- to 8-membered heterocycle. In some cases, R11 is selected from an optionally substituted 5- to 6-membered heterocycle. In some cases, R11 is selected from an optionally substituted 5- to 6-membered heteroaryl. In some cases, the heterocycle contains at least one nitrogen atom. In some cases, the heterocycle contains at least two nitrogen atoms. In some cases, the heteroaryl contains at least one nitrogen atom. In some cases, the heteroaryl contains at least two nitrogen atoms. In some cases, the heterocycle contains only 1 nitrogen atom and no other heteroatoms. In some cases, the heterocycle contains only 2 nitrogen atoms and no other heteroatoms. In some cases, R11 is selected from CN INH, each of which is optionally replaced. In some cases, R11 is selected from , which is optionally replaced. In some cases, R11 is selected from , each of which is optionally replaced. In some cases, R11 is selected from each of which is optionally substituted. In some cases, one or more optional substituents are independently selected from halogen, -OH, -CN, N(R21)2, -C(O)N(R21)2, C1-10 alkyl and -C1-10 haloalkyl. In some cases, R21 is independently selected from hydrogen; and C1-6 alkyl, where C1-6 alkyl is Petition 870250100147, dated 10 / 31 / 2025, p. 65 / 437 60 / 431 optionally substituted with one or more independently selected substituents from halogen, oxo, C3-6 carbocycle and 3- to 6-membered heterocycle. In some cases, one or more optional substituents of R11 are selected from halogen, C1-6 haloalkyl, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl. In some cases, one or more optional substituents of R11 are selected from -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2 and C1-10 alkyl. In some cases, one or more optional substituents of R11 are selected from -NH2 and C1-10 alkyl. In some cases, one or more optional substituents of R11 are selected from -NH2. In some cases, R11 is selected from In some cases, R1A is selected from N= NH2 and NH2,nh2 NH2 In '2 In some cases, R1A is Petition 870250100147, dated 10 / 31 / 2025, page 66 / 437 61 / 431

[00112] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R100 is selected from and Petition 870250100147, dated 10 / 31 / 2025, page 67 / 437 62 / 431

[00113] In some embodiments, for a compound or salt of Formula (I), R100 is selected from In some cases, R100 is selected from HN and —L. In In some cases, R100 is selected from In some cases, R100 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 68 / 437 63 / 431

[00114] In some embodiments, for a compound or salt of Formula (I), R100 is selected from In some cases, R1B is selected from hydrogen, C1-6 alkyl, C1-6 hydroxyalkyl, and C1-6 cyanoalkyl. In some cases, R1B is selected from hydrogen and C1-6 alkyl. In some cases, R1B is selected from C1-6 alkyl. In some cases, R1B is cyclopropyl. In some cases, R1B is methyl. In some cases, Petition 870250100147, dated 10 / 31 / 2025, page 69 / 437 64 / 431 In some cases, R100 is selected from R1bé etil. e —1— . In some cases, R100 is selected from —I— , , and —. In some cases, R100 is NH2 In some cases, R100 is selected from

[00115] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB) and Formula (IC), R1a is selected from a C1-3 alkyl, which is Petition 870250100147, dated 10 / 31 / 2025, p. 70 / 437 65 / 431 optionally substituted with one or more R11s, where each R11 is selected from a C3-C6 carbocycle, and a 5- to 6-membered heterocycle, where the 5- to 6-membered heterocycle and C3-C6 carbocycle are each optionally substituted. In some cases, R1A is selected from a C1-3 alkyl, which is substituted with one or more R11s, where each R11 is selected from a phenyl and a 5- to 6-membered heterocycle, where the 5- to 6-membered heterocycle and phenyl are each optionally substituted. In some cases, R11 is phenyl, which is optionally substituted. In some cases, R11 is selected from a 5- to 6-membered heterocycle, which is optionally substituted. In some cases, R11 is pyridine, which is optionally substituted. In some cases, R1A is selected from, In some cases, R1A is In some cases, the heterocycle is a heteroaryl. In some cases, one or more substituents are independently selected from halogen, -P(O)(R21)2, OH, -CN, -N(R21)2, -C(O)N(R21)2, C1-10 alkyl, and -C1-10 haloalkyl. In some cases, one or more substituents are independently selected from -P(O)(R21)2, -N(R21)2, and C110 alkyl. In some cases, one or more substituents are independently selected from -P(O)(R21)2 and -N(R21)2. In some cases, one or more substituents are independently selected from -P(O)(R21)2. In some cases, each R21 is independently selected from hydrogen and C1-6 alkyl. In some cases, each R21 is a r;bria N selected independently of C1-3 alkyl. In some cases, R100 or —L- is selected from In some cases, R100 is Petition 870250100147, dated 10 / 31 / 2025, p. 71 / 437 66 / 431 In some cases, R100 or is selected from

[00116] In some embodiments, for a compound or salt of Formula (I), R100 is In some cases, selected from In some cases, R1B is selected from hydrogen and C1-6 alkyl. In some cases, R100 is selected from. In some cases, R100 is In some cases, R100 is In some cases, R100 is In some cases, R100 is selected from In some cases, B is selected from an 8- to 10-membered heterocycle, where the 8- to 10-membered heterocycle Petition 870250100147, dated 10 / 31 / 2025, page 72 / 437 67 / 431 members are optionally replaced with one or more independently selected halogen, -CN, -NH2, and C1-6 alkyl substituents. In some cases, B is selected from an 8-membered heterocycle, where the 8-membered heterocycle is replaced with one or more independently selected halogen, -CN, -NH2, and C1-6 alkyl substituents. In some cases, the heterocycle of B contains a sulfur atom and no other heteroatoms. In some cases, the heterocycle of B is an unsaturated heterocycle. In some cases, B is selected from , each of which is optionally replaced. In some cases, B is selected from , each of which is replaced with at least a substitute. In some cases, B is selected from NH2 nh2. In some cases, B is . In some cases, Y is O. In some cases, L is selected from C1-C4 alkylene. In some cases, L is selected from an unsubstituted C1C4 alkylene. In some cases, L is selected from an unsubstituted C1 alkylene. In some cases, two substituents on the same carbon atom of L combine to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl. In some cases, two substituents on the same carbon atom of L combine to form a C3-C6 Petition 870250100147, dated 10 / 31 / 2025, p. 73 / 437 68 / 431 carbocycle or heterocycle of 3 to 8 members. In some cases, two substituents on the same carbon atom of L combine to form a C3-C6 carbocycle. In some cases, each L is selected from In some cases, R2 is selected from an optionally substituted -L-heterocycle. In some cases, R2 is selected from an optionally substituted -L-heterocycle, where the heterocycle is a saturated heterocycle. In some cases, the heterocycle is selected from Each of which is optionally substituted with one or more R6s. In some cases, each R6 is independently selected from halogen, hydroxyl, Cl-C3 alkyl, Cl-C3 haloalkyl, N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-C1-C3 alkyl, -CH2OC(O)heterocycle, CH2heterocycle, -CH2OC(O)N(R5)2 and -O-Cl-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl. In some cases, each R6 is independently selected from halogen, Cl-C3 alkyl and Cl-C3 haloalkyl. In some cases, each R6 is independently selected from halogen. In some cases, Y-R2 is selected from In some cases, Y-R2 is In some cases, Y-R2 is

[00117] In some embodiments, for a compound or salt of Formula (I), Formula (Ir;bR1a N A), Formula (IB), Formula (IC), or Formula (IG), for —L- , R1a is selected from C1-6 alkyl, which is replaced with an R11, where the R11 is selected from an optionally replaced 5- to 6-membered heteroaryl, where the 5- to 6-membered heteroaryl is optionally replaced; Petition 870250100147, dated 10 / 31 / 2025, p. 74 / 437 69 / 431 R1bé is selected from hydrogen, optionally replaced by C1-6 alkyl and C3-C6 carbocycle. or R1ae R1bse combine with the atom to which they are attached to form R1, where R1 is selected from an optionally substituted 5- to 10-membered heterocycle r;bR1a N optionally replaced. In some cases, for —J— , R1a is selected from C1-6 alkyl, which is substituted with an R11, wherein the R11 is selected from an optionally substituted 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with one or more independently selected halogen substituents, -OH, -CN, -N(R21)2, C1-10 alkyl and -C1-10 haloalkyl; R1bé is selected from hydrogen, C1-6 alkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C3-C6 carbocycle. or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is selected from an optionally substituted 5- to 9-membered heterocycle, where the 5- to 9-membered heterocycle is optionally substituted with one or more substituents independently selected from -OH, -CN, oxo, -NHCN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, R1 is selected from, , each of which is optionally substituted; and where R1a is selected from a C1-3 alkyl substituted with an optionally substituted heteroaryl member (e.g., pyridine, pyrimidine). In some cases, R1 is selected from each of which is optionally replaced. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 75 / 437 70 / 431 H , which is optionally replaced. In some cases, R1 is selected from “L”, which is optionally replaced. In some cases, R1 is selected from —I— , which is optionally replaced. In some cases, R1 is selected from —I— , the which is optionally replaced. In some cases, R1 is selected from —I—, which H It is optionally replaced. In some cases, R1 is selected from —I— , ™L, and JL, each of which is optionally substituted. In some cases, one or more optional substitutes for R1 are independently selected from -OH, oxo, -CN, -NHCN, C1-6hydroxyalkyl, C1-6 cyanoalkyl, C1-6haloalkyl and C1-6 alkyl.

[00118] In some embodiments, for a compound or salt of Formula (I), R100 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 76 / 437 71 / 431

[00119] In some embodiments, for a compound or salt of Formula (I), R100 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 77 / 437 72 / 431 In some cases, R100 is selected.

[00120] In some embodiments, for a compound or salt of Formula (I), R100 is

[00121] In some embodiments, Formula (I) is represented by Petition 870250100147, dated 10 / 31 / 2025, p. 78 / 437 73 / 431 Formula (ID), or a pharmaceutically acceptable salt thereof.

[00122] In some embodiments, Formula (I) is represented by Formula (IE), or a pharmaceutically acceptable salt thereof.

[00123] In some embodiments, Formula (I) is represented by Formula (IF), or a pharmaceutically acceptable salt thereof.

[00124] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), R1C is selected from an optionally substituted C1-6 alkyl. In some cases, R1C is selected from an optionally substituted C1-6 alkyl and where optionally two R12s on the same R1C atom join to form an optionally substituted C3-C6 carbocycle.

[00125] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), each R12 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, Petition 870250100147, dated 10 / 31 / 2025, p. 79 / 437 74 / 431 =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkyl, C1-6, alkyne C3C12 carbocycle and heterocycle of 5 to 12 members. In some cases, each independently selected halide R12, -OR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20(=NR20), -NR20S(O)2R20, -C(O)2, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, -NO, =NO, =NO, -NHCN, C1-6 alkyl-N(R20)2, C1-6aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl, C3-C12 and heterocyclic heterocyclic members.In some cases, each R12 is independently selected from halogen, -OR20, -N(R20)2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle. In some cases, each R12 is independently selected from halogen, -OR20, -N(R20)2, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C16 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 haloalkyl. In some cases, R12 is selected from OH and -CN, and where two R12s on the same R1C atom join to form a C3 carbocycle. ZV0H not replaced. In some cases, R1C is selected from ' , ' and

[00126] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), R1C is selected from an optionally substituted 5- to 6-membered heterocycle. In some cases, R1C is selected from an optionally substituted 5-membered heterocycle. In some cases, R1C is selected from an optionally substituted 5-membered heterocycle containing at least one oxygen atom. In some cases, R1C is selected from N^, which is optionally substituted. In some cases, each R12 is selected from halogen, -OR20, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R12 is selected from -OH. In some cases, R1C is HO. Petition 870250100147, dated 10 / 31 / 2025, page 80 / 437 75 / 431

[00127] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), each R12A is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl.

[00128] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), R12 is -CN and where two R12s on the same R1C atom join to form an unsubstituted C3 carbocycle.

[00129] In some embodiments, for a compound or salt of Formula (I), Formula (ID), Formula (IE), or Formula (IF), R1C is selected from hydrogen and optionally substituted C1-6 alkyl. In some cases, R1C is selected from optionally substituted C1-6 alkyl. In some cases, R1C is selected from hydrogen and C1-6 alkyl. In some cases, R1C is selected from hydrogen. In some cases, R12 is selected from -OH and -CN and where two R12s on the same R1C atom join to form an unsubstituted C3 carbocycle.

[00130] In some embodiments, for a compound or salt of Formula (I), Formula (I\ / =n D), Formula (IE), or Formula (IF), R1Cé selected from ' and ' .

[00131] In some embodiments, for a compound or salt of Formula (I), R100 is selected from -~L~ and —I-- .

[00132] In some embodiments, for a compound or salt of Formula (I), R100 is ^R1Ds .

[00133] In some embodiments, Formula (I) is represented by Petition 870250100147, dated 10 / 31 / 2025, p. 81 / 437 76 / 431 Formula (IJ), or a pharmaceutically acceptable salt thereof.

[00134] In some embodiments, Formula (I) is represented by Formula (IH), or a pharmaceutically acceptable salt thereof.

[00135] In some embodiments, Formula (I) is represented by Formula (II), or a pharmaceutically acceptable salt thereof.

[00136] In some embodiments, for a compound or salt of Formula (I), Formula (IH), Formula (II), or Formula (IJ), where R1D is selected from an optionally substituted C1-6 alkyl. In some cases, R1D is selected from an optionally substituted C1-6 alkyl and where optionally two R13s on the same atom of R1D join to form an optionally substituted C3-C6 carbocycle. In some cases, R13 is selected from -OH and -CN and where two R13s on the same atom of R1D join to form Petition 870250100147, dated 10 / 31 / 2025, p. 82 / 437 77 / 431 an unreplaced C3 carbide cycle. In some cases, R1D is selected from

[00137] In some embodiments, for a compound or salt of Formula (I), Formula (IH), Formula (II), or Formula (IJ), each R13 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3C12 carbocycle and heterocycle from 5 to 12 members.In some cases, each R13 is independently selected halogen, -OR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20(=NR20), -NR20S(O)2R20, -C(O)2, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, OC(O)N(R20)2, -OC(O)R20, -NO, =NO, =NO, -NHCN, C1-6 alkyl-N(R20)2, C1-6aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl, C3-C12 and heterocyclic heterocyclic members. In some cases, each R13 is independently selected halogen, -OR20, -N(R20)2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyl alkyl, C1-6, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle.In some cases, each R13 is independently selected from halogen, -OR20, -N(R20)2, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C16 hydroxyalkyl, C1-6 cyanoalkyl, and C1-6 haloalkyl.

[00138] In some embodiments, for a compound or salt of Formula (I), Formula (IH), Formula (II), or Formula (IJ), each R13A is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. Petition 870250100147, dated 10 / 31 / 2025, p. 83 / 437 78 / 431

[00139] In some embodiments, for a compound or salt of Formula (I), R100 is selected from -J— and -J·— .

[00140] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1A and R1B combine with the atoms to which they are attached to form R1.

[00141] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1Be R1Ase combine with the atoms to which they are attached to form R1.

[00142] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a 5- to 12-membered heterocycle, where the 5- to 12-membered heterocycle is optionally substituted. In some cases, R1B and R1Ase combine with the atoms to which they are attached to form an optionally substituted 5- to 12-membered heterocycle, where the 5- to 12-membered heterocycle is optionally substituted. In some cases, R1B and R1Ase combine with the atoms to which they are attached to form a bridging heterocycle. In some cases, R1B and R1Ase combine with the atoms to which they are attached to form a spiral heterocycle. In some cases, R1B and R1Ase combine with the atoms to which they are attached to form a fused heterocycle. In some cases, R1B and R1Ase combine with the atoms to which they are attached to form the non-aromatic heterocycle. In some cases, R1Be and R1Ase combine with the atoms to which they are attached to form a saturated heterocycle.Each heterocycle can be replaced as described here.

[00143] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the heterocycle of R1 is a 5- to 12-membered heterocycle, a 6- to 12-membered heterocycle, a 7- to 12-membered heterocycle, or an 8- to 12-membered heterocycle. In some cases, the heterocycle of R1 is a 5- to 11-membered heterocycle, a 5- to 10-membered heterocycle, a 5- to 9-membered heterocycle, or a 5- to 8-membered heterocycle. In some cases, the heterocycle of R1 is a 6- to 11-membered heterocycle, a 6- to 10-membered heterocycle, a 6- to 9-membered heterocycle, or a 6- to 8-membered heterocycle. In some cases, the heterocycle of R1 is an 11-membered heterocycle, a 7-10-membered heterocycle, a 7-9-membered heterocycle, or a 7-8-membered heterocycle. In some cases, the heterocycle of R1 is a heterocycle of Petition 870250100147, dated 10 / 31 / 2025, page 84 / 437 79 / 431 to 6 members or a 5 to 9 member heterocycle. In some cases, the R1 heterocycle is an 8 to 9 member heterocycle. In some cases, the R1 heterocycle is saturated. The heterocycle is optionally substituted as described herein.

[00144] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a 5- to 12-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is a 5- to 12-membered monocyclic heterocycle, a 6- to 12-membered monocyclic heterocycle, a 7- to 12-membered monocyclic heterocycle, or an 8- to 12-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is a 5- to 11-membered monocyclic heterocycle, a 5- to 10-membered monocyclic heterocycle, a 5- to 9-membered monocyclic heterocycle, or a 5- to 8-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is a 6- to 11-membered monocyclic heterocycle, a 6- to 10-membered monocyclic heterocycle, a 6- to 9-membered monocyclic heterocycle, or a 6- to 8-membered monocyclic heterocycle.In some cases, the heterocycle of R1 is a 7- to 11-membered monocyclic heterocycle, a 7- to 10-membered monocyclic heterocycle, a 7- to 9-membered monocyclic heterocycle, or a 7- to 8-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is a 5- to 6-membered monocyclic heterocycle or a 5- to 9-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is an 8- to 9-membered monocyclic heterocycle. In some cases, the heterocycle of R1 is saturated. The monocyclic heterocycle is optionally substituted as described herein.

[00145] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a bridging heterocycle. In some cases, the heterocycle of R1 is a 5- to 12-membered bridging heterocycle, a 6- to 12-membered bridging heterocycle, a 7- to 12-membered bridging heterocycle, or an 8- to 12-membered bridging heterocycle. In some cases, the heterocycle of R1 is a 5- to 11-membered bridging heterocycle, a 5- to 10-membered bridging heterocycle, a 5- to 9-membered bridging heterocycle, or a 5- to 8-membered bridging heterocycle. In some cases, the heterocycle of R1 is a 6- to 11-membered bridging heterocycle, a 6- to 10-membered bridging heterocycle, a 6- to 9-membered bridging heterocycle, or a 6- to 8-membered bridging heterocycle. In some cases, the heterocycle of R1 is a 7- to 11-membered bridging heterocycle, a 7- to 10-membered bridging heterocycle, a 7- to 9-membered bridging heterocycle, or a 7- to 8-membered bridging heterocycle.In some cases, the R1 heterocycle is a 5- to 6-membered bridging heterocycle. Petition 870250100147, dated 10 / 31 / 2025, p. 85 / 437 80 / 431 heterocycle with 5 to 9 members in a bridging configuration. In some cases, the R1 heterocycle is an 8 to 9 member bridging heterocycle. In some cases, the R1 heterocycle is saturated. In some cases, the bridge heterocycle is selected from In some cases, the bridge heterocycle is selected from Each bridged heterocycle is optionally replaced as described here.

[00146] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a spiro heterocycle. The spiro heterocycle of R1 is a 7- to 12-membered spiro heterocycle, a 7- to 12-membered spiro heterocycle, or an 8- to 12-membered spiro heterocycle. In some cases, the spiro heterocycle of R1 is a 7- to 11-membered spiro heterocycle, a 7- to 10-membered spiro heterocycle, a 7- to 9-membered spiro heterocycle, or a 7- to 8-membered spiro heterocycle. In some cases, the spiro heterocycle of R1 is a 7- to 11-membered spiro heterocycle, a 7- to 10-membered spiro heterocycle, a 7- to 9-membered spiro heterocycle, or a 7- to 8-membered spiro heterocycle. In some cases, the spiral heterocycle of R1 is a 7- to 11-membered spiral heterocycle. In some cases, the spiral heterocycle of R1 is a 7-membered spiral heterocycle. In some cases, the spiral heterocycle of R1 is an 8-membered spiral heterocycle. In some cases, the spiral heterocycle of R1 is a 9-membered spiral heterocycle. In some cases, the spiral heterocycle of R1 is a 10-membered spiral heterocycle. In some cases, the spiral heterocycle of R1 contains at most 1 nitrogen atom. In some cases, the spiral heterocycle of R1 contains only 1 nitrogen atom. In some cases, the spiral heterocycle of R1 contains at most 2 heteroatoms. In some cases, the spiral heterocycle of R1 contains at least 2 heteroatoms. In some cases, the spiral heterocycle of R1 contains at least 3 heteroatoms. In some cases, the heteroatom is selected from nitrogen, oxygen, and sulfur. In some cases, the spiral heterocycle of R1 is linked to the formula through the nitrogen atom. In some embodiments, the spiral heterocycle of R1 is selected Petition 870250100147, dated 10 / 31 / 2025, page 86 / 437 81 / 431 of — . In some cases, the spiral heterocycle of R1 is selected from eH. Each spiro heterocycle is optionally replaced as described here.

[00147] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a fused heterocycle. In some cases, the fused heterocycle of R1 is a fused 6-12 membered heterocycle, fused 6-12 membered heterocycle, fused 7-12 membered heterocycle, or fused 8-12 membered heterocycle. In some cases, the fused heterocycle of R1 is a fused 6-11 membered heterocycle, fused 6-10 membered heterocycle, fused 6-9 membered heterocycle, or fused 6-8 membered heterocycle. In some cases, the fused heterocycle of R1 is a fused 7-11 membered heterocycle, fused 7-10 membered heterocycle, fused 7-9 membered heterocycle, or fused 7-8 membered heterocycle. In some cases, the fused heterocycle of R1 is a fused 8- to 11-membered heterocycle. In some cases, the fused heterocycle of R1 is a fused 6-membered heterocycle. In some cases, the fused heterocycle of R1 is a 7-membered fused heterocycle. In some cases, the fused heterocycle of R1 is a fused 10-membered heterocycle. In some cases, the fused heterocycle is Petition 870250100147, dated 10 / 31 / 2025, p. 87 / 437 82 / 431 selected from -~L~ , and . Each fused heterocycle is optionally replaced as described here.

[00148] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted fused 8- to 10-membered heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a bicyclic heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a saturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is an unsaturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a non-aromatic heterocycle. In some cases, R1 is selected from an optionally substituted fused 9-membered heterocycle. In some cases, R1 is selected from an optionally substituted fused 10-membered heterocycle. In some cases, the fused 10-membered heterocycle is a bicyclic heterocycle. In some cases, the fused 10-membered heterocycle is a saturated heterocycle. In some cases, the 9-membered heterocycle is a non-aromatic heterocycle.In some cases, the 10-membered heterocycle is a non-aromatic heterocycle. In some cases, the fused heterocycle contains one saturated ring and one aromatic ring. In some cases, the fused heterocycle contains one saturated ring and one unsaturated ring. In some cases, the fused heterocycle contains two saturated rings. In some cases, the 10-membered heterocycle contains at least one nitrogen atom. In some cases, the 10-membered heterocycle contains at least two nitrogen atoms. In some cases, the 10-membered heterocycle contains at least three nitrogen atoms. In some cases, the 9-membered heterocycle contains at least one nitrogen atom. In some cases, the 9-membered heterocycle contains at least two nitrogen atoms. In some cases, the 9-membered heterocycle contains at least three nitrogen atoms. In some cases, R1 is selected from... , each of which is optionally replaced with Petition 870250100147, dated 10 / 31 / 2025, p. 88 / 437 83 / 431 one or more substitutes. In some cases, R1 is —।— , which is optionally replaced with one or more substituents. In some cases, R1 is --1--, which is optionally replaced with one or more substituents. In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), C(=NR20)N(R20)2, -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C16 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl and 5- to 12-membered heterocycles, wherein the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*.In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C16 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents are independently selected from halogen, =O, -OH, -CN, -NHCN, S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, -S(O)R2O(=NR2O), -C(O)R2O, -C(O)N(R2O)2, C(O)NR2OOR2O, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, one or more optional substituents are independently selected from halogen, =O, C1-6 alkyl-N(R20)2, -S(O)2(R20), -S(O)N(R20)2, S(O)R20(=NR20), -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20.In some cases, one or more optional substituents are independently selected from halogen, =O, S(O)2(R20), -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20). In some cases, one or more optional substituents are independently selected from -S(O)N(R20)2. In some. Petition 870250100147, dated 10 / 31 / 2025, page 89 / 437 In 84 / 431 cases, one or more optional substituents are independently selected from S(O)2(R20). In some cases, one or more optional substituents are independently selected from S(O)R20(=NR20). In some cases, one or more optional substituents are independently selected from -C(O)R20. In some cases, one or more optional substituents are independently selected from -C(O)N(R20)2. In some cases, one or more optional substituents are independently selected from -C(O)NR20OR20. In some cases, R1 is selected. , each of which is additionally optionally substituted. In some cases, one or more additional optional substituents are selected from halogen, OH, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more additional optional substituents are selected from halogen, -CN, C2 alkenyl, and C1-6 alkyl. In some cases, one or more additional optional substituents are selected from halogen and C1-6 alkyl. In some cases, one or more additional optional substituents are selected from halogen. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl and 3- to 12-membered heterocycle.In some cases, each R20 is selected independently of hydrogen; and C1-6 alkyl and saturated 3- to 12-membered heterocycles. In some cases, each R20 is selected independently of 5- to 6-membered heterocycles. Petition 870250100147, dated 10 / 31 / 2025, p. 90 / 437 85 / 431 saturated. In some cases, the R20 heterocycle contains at least one nitrogen atom. In some cases, the R20 heterocycle contains at least one sulfur atom. In some cases, the R20 heterocycle contains at least one oxygen atom. In some cases, the R20 heterocycle contains only 1 heteroatom. In some cases, the R20 heterocycle contains at least two heteroatoms. In some cases, the R20 heterocycle contains only 2 heteroatoms. In some cases, one or more optional substituents of R1 are independently selected from halogen, -CN, C2 alkenyl, In some cases, one or more substituents R1 options are independently selected from halogen. THE In some cases, one or more optional substitutes for R1 are independently selected from NX / and I. In some cases, one or more optional substitutes for R1 are independently selected from Petition 870250100147, dated 10 / 31 / 2025, page 91 / 437 86 / 431 halogen, / ^N'N XχNH nA, nA 'nA, nA- ...... ' , / ,, ' and ' . In some cases, R1e is selected from In some cases, R1e is selected from Petition 870250100147, dated 10 / 31 / 2025, page 92 / 437 87 / 431 In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 93 / 437 88 / 431 In some cases, one or more optional substituents of R1 are independently selected from halogen and C1-6 alkyl-N(R20)2. In some cases, one or more optional substituents of R1 are independently selected from halogens. In some cases, R1 is selected from ---------- . In some cases, each R20 is independently selected from hydrogen, C1-6 alkyl, and C3-6 carbocycle. In some cases, R1 is selected of —J— , —J— and —I— . In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 94 / 437 89 / 431 , which is In some cases, R1 is selected from optionally substituted with one or more independently selected halogen substituents, -OH, -S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, S(O)R2O(=NR2O), -C(O)N(R2O)2, -C(=NR2O)N(R2O)2, -C(O)OR2O, -C(O)NHOR2O, N(R2O)2, -C(O)R2O, -NO2, =O, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl, 5- to 12-membered heterocycle, where the 5- to 12-membered heterocycle is optionally replaced with one or more selected halogen, -OR20e C1-6 alkyl substituents. In some cases, R1 is selected from — , which is optionally replaced with one or more independently selected halogen and C1-6 alkyl substituents. In some cases, R1 is selected from

[00149] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a Petition 870250100147, dated 10 / 31 / 2025, page 95 / 437 90 / 431 is selected from a 5- to 12-membered heterocycle, where the 5- to 12-membered heterocycle is optionally independently replaced with one or more R1*; and RB is selected from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkynyl, and -CN. In some cases, RB is selected from hydrogen and halogen. In some cases, RB is chlorine. In some cases, RB is hydrogen. In some cases, contains at least 1, 2, 3, or 4 heteroatoms. In some cases, contains at least 1, 2, 3 or 4 nitrogen atoms. In some cases, contains at least 1 oxygen atom. In some cases, It is a monocyclic heterocycle. In some cases, It is a bicyclic heterocycle. In some cases, It is selected from an optionally substituted 5-member heterocycle. In some cases, selected from a 9-membered heterocycle optionally replaced. In some is selected from cases, eN, each of which is optionally replaced with one or more is selected from R1*. In some cases, each of which is optionally replaced with one or more R1*. In some cases, each R1* is Petition 870250100147, dated 10 / 31 / 2025, page 96 / 437 91 / 431 independently selected halogen, -OR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl. In some cases, each R1* is independently selected from halogen, C16 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C16 alkyl. In some cases, each R1* is independently selected from halogen and C1-6 alkyl. is selected from In some cases,

[00150] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), when R1 is substituted with C(O)R20, R20 is selected from a 5- to 12-membered heterocycle, which is optionally substituted. In some cases, R1 is substituted with -C(O)R20. In some cases, R20 is selected from an unsubstituted 5- to 12-membered heterocycle. In some cases, R20 is selected from a 5- to 6-membered heterocycle, which is optionally substituted. In some cases, the heterocycle contains at least one nitrogen atom. In some cases, the heterocycle contains at least one sulfur atom. In some cases, the heterocycle contains at least one oxygen atom. In some cases, the heterocycle contains two heteroatoms. In some cases, the heterocycle of R20 is selected from , each of which is optionally replaced. In some cases, R20 is selected from In some cases, the optional substituents are selected from C1-10 alkyl, oxo, and =NH. Petition 870250100147, dated 10 / 31 / 2025, p. 97 / 437 92 / 431

[00151] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), each R20 is independently selected from hydrogen; and C1-6 alkyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more independently selected substituents from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo and =NH. In some cases, each R20 is independently selected from hydrogen; and unsubstituted C1-6 alkyl and 3- to 12-membered heterocycle which is optionally substituted with one or more independently selected substituents of halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo and =NH.

[00152] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 5- to 12-membered heterocycle, where the 5- to 12-membered heterocycle is optionally replaced with one or more substituents. In some cases, one or more optional substituents are independently selected from halogen, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, OC(O)N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. In some cases, one or more optional substituents are independently selected from halogen, -OH, -N(R2O)2, -NO2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl.In some cases, one or more optional substituents are independently selected from halogen, -OH, -N(R2O)2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, and C1-6 haloalkyl. In some cases, R2O is selected from hydrogen and C1-3 alkyl.

[00153] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a saturated 5- to 12-membered heterocycle, which is optionally substituted with one or more substituents. In some cases, the 5- to 12-membered heterocycle of R1 is bridged. In some cases, the 5- to 12-membered heterocycle of R1 is unbridged. In some cases, the 5- to 12-membered heterocycle is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 98 / 437 93 / 431 each of which is optionally replaced with one or more substitutes.

[00154] In some embodiments, for a compound or salt of Formula (I), Formula (I- A), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 99 / 437 94 / 431 ~~l~~ , each of which is optionally replaced with one or more substituents. In some cases, one or more of the optional substituents are independently selected from halogen, -OH, -N(R2O)2, -B(OH)2, -C(O)N(R2O)2, -NHCN, -NO2, C1-6 alkoxy, =O, -CN, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 100 / 437 95 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 101 / 437 96 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 102 / 437 97 / 431

[00155] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 5- to 12-membered unsaturated heterocycle, where the heterocycle contains at most one nitrogen atom. In some cases, the 5- to 12-membered unsaturated heterocycle contains at least one nitrogen atom. In some cases, the 5- to 12-membered unsaturated heterocycle contains at most one nitrogen atom.

[00156] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the R1 heterocycle contains only 1 nitrogen atom and optionally one or more heteroatoms selected from oxygen and sulfur. In some cases, the heterocycle is a fused heterocycle or a bridging heterocycle. In some cases, the heterocycle is a monocyclic heterocycle or a bridging heterocycle. In some cases, the heterocycle is a monocyclic heterocycle. In some cases, Petition 870250100147, dated 10 / 31 / 2025, p. 103 / 437 98 / 431 the heterocycle is a bridge heterocycle. In some cases, the heterocycle is selected from 'X-·^ and 0H. The heterocycle is optionally replaced as described here.

[00157] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the R1 heterocycle contains at most 1 nitrogen atom. In some cases, the R1 heterocycle contains only 1 nitrogen atom and optionally one or more other heteroatoms selected from oxygen and sulfur. In some cases, the R1 heterocycle contains only 1 nitrogen atom and no other heteroatoms.

[00158] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted saturated 5- to 12-membered heterocycle, where the heterocycle contains at most one nitrogen atom. In some cases, the unsaturated 5- to 12-membered heterocycle contains at least one nitrogen atom. In some cases, the unsaturated 5- to 12-membered heterocycle contains only one nitrogen atom and 0-2 other heteroatoms selected from nitrogen, oxygen, and sulfur. In some cases, the unsaturated 5- to 12-membered heterocycle contains only one nitrogen atom and no additional heteroatoms. In some cases, the unsaturated 5- to 12-membered heterocycle contains three nitrogen atoms and no additional heteroatoms.

[00159] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 5- to 12-membered unsaturated heterocycle, where the heterocycle contains at most one nitrogen atom. In some cases, the 5- to 12-membered unsaturated heterocycle contains at least one nitrogen atom. In some cases, the 5- to 12-membered unsaturated heterocycle contains only one nitrogen atom and no additional heteroatoms.

[00160] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 6- to 9-membered heterocycle. In some cases, R1 is selected from a 6- to 7-membered heterocycle. In some cases, R1 is selected from a 7-membered heterocycle. In some cases, R1 is selected from a 6-membered heterocycle. In some cases, the 6- to 7-membered heterocycle contains only 1 nitrogen atom and optionally one or more additional heteroatoms selected from oxygen and sulfur. In some cases, the optionally one or Petition 870250100147, dated 10 / 31 / 2025, p. 104 / 437 99 / 431 plus additional heteroatoms are selected from sulfur. In some cases, optionally one or more additional heteroatoms are selected from oxygen. In some cases, the 6-7 membered heterocycle contains only 1 nitrogen atom and no additional heteroatoms. In some cases, the 6-7 membered heterocycle is a non-aromatic 6-7 membered heterocycle. In some cases, R1 is selected from —l— , each of which is optionally replaced. In some cases, R1 is selected from and — , each of which is replaced. In some cases, the substituents of R1 are each selected from one or more halogens: -OR20, -SR20, N(R20)2, -NHCN, -NO2, =O, -CN, C1-6 haloalkyl, -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl. In some cases, the substituents of R1 are each selected from one or more halogens: -OR20, N(R20)2, -NHCN, =O, -CN, -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, the substituents of R1 are each selected from one or more halogens, -OH, -NHCN, =O, -CN, C2-6 alkynyl and C1-6 alkyl. In some cases, R1 is selected from —l— , e. In some cases, R1 is selected from --1-- , —I— , —I— , —1— , —I— , and —I— , each of Petition 870250100147, dated 10 / 31 / 2025, p. 105 / 437 100 / 431 which is optionally replaced. In some cases, R1 is selected from and —L, each of which is optionally replaced. In some cases, R1 is selected from , , —L , — , — each of which is optionally substituted. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -C(O)NH2, -NH-C(O)-(C1-6 alkoxy), -NHC(O)-(C1-6 hydroxyalkyl), -NH2, -NH(CN), =O, -CN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from halogen, -OH, -CN, C1-6 cyanoalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from halogen, -OH and -CN. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -CN, C1-6 cyanoalkyl, C1-6 alkyl, oxo, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -CN, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl.In some cases, R1 is... selected from Petition 870250100147, dated 10 / 31 / 2025, page 106 / 437 101 / 431 In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 107 / 437 102 / 431 HO F —I— , and In some cases, R1 is selected from —I— , -1- , —I— , OH and —1— In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 108 / 437 103 / 431 In some cases, R1 is selected from

[00161] In some embodiments, for a compound or salt of Formula (I), Formula (I- A), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from —I— , —I— , Petition 870250100147, dated 10 / 31 / 2025, p. 109 / 437 104 / 431 n=n each of which is optionally replaced with one or more substituents. In some cases, one or more of the optional substituents are independently selected from halogen, -OH, -N(R2O)2, -B(OH)2, -C(O)N(R2O)2, NHCN, -NO2, C1-6 alkoxy, -O, -CN, C1-6 alkyl, C2-6 alkenyl, C1-6 aminoalkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 110 / 437 105 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 111 / 437 106 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 112 / 437 107 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 113 / 437 108 / 431

[00162] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 6- to 8-membered unsaturated heterocycle. In some cases, R1 is selected from an optionally substituted 6-membered unsaturated heterocycle. In some cases, R1 is selected from an optionally substituted 7-membered unsaturated heterocycle. In some cases, the heterocycle contains 1 or 2 double bonds. In some cases, the heterocycle contains only 1 double bond. In some cases, the heterocycle In some cases, R1 is selected from It contains only 2 double bonds. where each is optionally replaced with one or more independently selected substituents from halogen, -OH, -NH2, NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, R1 is selected from one is optionally replaced with one or more independently selected substituents from halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 114 / 437 109 / 431 , , , where each is optionally replaced with one or more independently selected substituents from halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl. In In some cases, R1 is selected from and In some cases, R1 is selected from and —L. . In some cases, R1 is selected from —. In some cases, R1 is In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 115 / 437 110 / 431 , where each is replaced with one or more independently selected halogen substituents.

[00163] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an unsaturated 6- to 7-membered heterocycle, where the unsaturated 6- to 7-membered heterocycle is substituted with one or more substituents selected from halogens. In some cases, the unsaturated 6- to 7-membered heterocycle is substituted with at least one halogen. In some cases, the unsaturated 6- to 7-membered heterocycle is substituted with only one halogen. In some cases, the unsaturated 7-membered heterocycle is substituted with a fluorine. In some cases, R1 is selected from an unsaturated 6-membered heterocycle, substituted with at least one halogen. In some cases, R1 is selected from an unsaturated 7-membered heterocycle, substituted with at least one halogen. In some cases, R1 is selected from F , F In . In some cases, R1 is selected from . In some cases, In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 116 / 437 111 / 431 cases, R1 is R1 is selected from In some cases, R1 is In some

[00164] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 6- to 8-membered unsaturated heterocycle. In some cases, R1 is selected from an optionally substituted 7-membered unsaturated heterocycle. In In some cases, R1 is selected from -L, where each is optionally substituted with one or more independently selected substituents of halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 In some cases, R1 is selected from ,,alkyl.

[00165] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 6-membered heterocycle. In some cases, the 6-membered heterocycle contains only 1 nitrogen atom. In some cases, the 6-membered heterocycle of R1 is linked to the respective Formula by means of only 1 nitrogen atom. In some Petition 870250100147, dated 10 / 31 / 2025, p. 117 / 437 112 / 431 In some cases, R1 is selected from and , any of which is optionally substituted. In some cases, one or more optional substituents of R1 are each independently selected from halogen, -OR20, -N(R20)2, =O, -CN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -NH2, -NH(CN), =O, -CN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -NH2, -NH(CN), =O, -CN, C1-6 hydroxyalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, the 6-membered heterocycle is a partially unsaturated 6-membered heterocycle or a saturated 6-membered heterocycle. In some cases, the 6-membered heterocycle is partially unsaturated. In some cases, the 6-membered heterocycle is a saturated 6-membered heterocycle.In some cases, the 6-membered heterocycle is a monocyclic 6-membered heterocycle. In some cases, the 6-membered heterocycle is not a bridging heterocycle. In some... In these cases, R1 is selected from

[00166] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted unsaturated 6-membered heterocycle and a saturated 6-membered heterocycle. In some cases, R1 is selected from , where each is optionally replaced with one or more independently selected halogen substituents, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 cyanoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 Petition 870250100147, dated 10 / 31 / 2025, p. 118 / 437 113 / 431 haloalkyl and C1-6 alkyl. In some cases, R1 is selected from and — , where each is optionally replaced with one or more independently selected halogen and C1-6 haloalkyl substituents. In some cases, R1 is selected from F and —1— . In some cases, R1 is selected from —J— , which is optionally replaced with one or more independently selected halogen, C1-6 cyanoalkyl, and C1-6 haloalkyl substituents. In some cases, R1 is

[00167] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from , where each is optionally replaced with two independently selected halogen substituents, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 Hydroxyalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, R1 is selected from —।— where each is optionally replaced with two independently selected halogen and C1-6 haloalkyl substituents. In some cases, R1 is Petition 870250100147, dated 10 / 31 / 2025, page 119 / 437 114 / 431

[00168] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 6- to 10-membered heterocycle. In some cases, the 6- to 10-membered heterocycle contains 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulfur. In some cases, the 6- to 10-membered heterocycle contains at least 1 atom of nitrogen. In some cases, R1 is selected from , each of which is optionally substituted with one or more independently selected halogen substituents, =O, -OH, -CN, -NHCN, -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more independently selected halogen substituents, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 120 / 437 115 / 431

[00169] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 6- to 7-membered heterocycle. In some cases, R1 is selected from a 7-membered heterocycle. In some cases, R1 is selected from a 6-membered heterocycle. In some cases, the 6- to 7-membered heterocycle contains only 1 nitrogen atom and optionally one or more additional heteroatoms selected from oxygen and sulfur. In some cases, the one or more optional additional heteroatoms are selected from sulfur. In some cases, the one or more optional additional heteroatoms are selected from oxygen. In some cases, the 6- to 7-membered heterocycle contains only 1 nitrogen atom and no additional heteroatoms. In some cases, the 6- to 7-membered heterocycle is a non-aromatic 6- to 7-membered heterocycle.In some cases, the 6- to 7-membered heterocycle of R1 is linked to the respective formula by only one nitrogen atom. In some cases, R1 is selected from —1— , —I— , — , —I— , —I— , —I— and —1— , each of which is substituted. In some cases, R1 is selected from and —I— , each of which is substituted. In some cases, the substituents of R1 are each selected from one or more halogens, -OR20, -SR20, N(R20)2, -NHCN, -NO2, =O, -CN, C1-6 fluoroalkyl and C2-6 alkynyl; and optionally further substituted with one or more substituents independently selected from -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl and C2-6 alkenyl. In some cases, the substituents of R1 are each selected from one or more halogens, -OR20, -N(R20)2, -NHCN, =O, -CN and C2-6 alkynyl; and optionally further substituted with one or more independently selected substituents of -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, the substituents of R1 are each selected from one or more halogens, -OH, -NHCN, =O, -CN and C2-6 alkynyl; and optionally further substituted with one or more independently selected C1-6 alkyl substituents.In some cases, R1 is selected from. Petition 870250100147, dated 10 / 31 / 2025, p. 121 / 437 116 / 431 In some cases, R1 is selected from , each of which is optionally replaced. In some In some cases, R1 is selected from —L, ---, ™L and -d— optionally replaced. In some cases, R1 is selected from , each of which is , ™L , .X each of which is optionally substituted. In some cases, one or more optional substitutes for R1 are each independently selected from fluoride, -OH, -C(O)NH2, -NH-C(O)-(C1-6 alkoxy), -NH-C(O)-(C1-6 hydroxyalkyl), -NH2, NH(CN), =O, -CN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from halogen, -OH, -CN, C1-6 cyanoalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from halogen, -OH, and -CN. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -CN, C1-6 cyanoalkyl, C1-6 alkyl, oxo, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are each independently selected from fluorine, -OH, -CN, or Cl-6. OH cyanoalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 122 / 437 117 / 431 Petition 870250100147, dated 10 / 31 / 2025, page 123 / 437 118 / 431 In some In these cases, R1 is selected from, In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 124 / 437 119 / 431 of In some cases, R1 is selected. In some cases, R1 is selected from OH F

[00170] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the 5- to 12-membered heterocycle of R1 is unsaturated and a bridging heterocycle. In some cases, R1 is selected from an optionally substituted 7- to 8-membered unsaturated heterocycle and bridging heterocycle. In some cases, R1 is selected from .

[00171] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 5-membered heterocycle. Petition 870250100147, dated 10 / 31 / 2025, p. 125 / 437 120 / 431 to 10 members, 7, 8, 10, 11 member spiro heterocycles and 6, 9, 10, 11 and 12 member fused heterocycles, wherein each is optionally substituted with one or more substituents independently selected from halogen, -N(R20)2, C1-6 alkyl, -OR20, -N(R20)C(O)N(R20)2, -B(OR20)2, C1-6 cyanoalkyl, -N(R20)C(O)N(R20)2, =O, C1-6 hydroxyalkyl, halogen, -N(R20)C(O)R20, -N(R20)S(O)2(R20) and C1-6 aminoalkyl. In some cases, R1 is selected from where each is optionally replaced with one or more independently selected substituents of halogen, -N(R20)2, C1-6 alkyl, -OR20, -N(R20)C(O)N(R20)2, -B(OR20)2, C1-6 cyanoalkyl, -N(R20)C(O)N(R20)2, =O, C1-6 hydroxyalkyl, halogen, -N(R20)C(O)R20, -N(R20)S(O)2(R20) and C1-6 aminoalkyl. In some cases, R1 is selected from --- , Petition 870250100147, dated 10 / 31 / 2025, pp. 126 / 437 121 / 431

[00172] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 10-membered heterocycle. In some cases, the 10-membered heterocycle is a bicyclic heterocycle. In some cases, the 10-membered heterocycle is a spiro heterocycle. In some cases, the 10-membered heterocycle is a fused heterocycle. In some cases, the 10-membered heterocycle is a saturated heterocycle. In some cases, the 10-membered heterocycle is a non-aromatic heterocycle. In some cases, the 10-membered heterocycle contains at least 1 nitrogen atom. In some cases, the 10-membered heterocycle contains at least 2 nitrogen atoms. In Petition 870250100147, dated 10 / 31 / 2025, pp. 127 / 437 122 / 431 In some cases, the 10-membered heterocycle contains at least 3 nitrogen atoms. In some cases, the 10-membered heterocycle contains at least one sulfur atom. In some cases, R1 is selected from S. NH each of which is optionally replaced with one or more independently selected halogen substituents, =O, -OH, -CN, -NHCN, -C(O)N(R2O)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, R1 is selected from In some cases, R1 is selected with one or more independently selected halogen substituents, -OR20, -SR20, -N(R20)2, -NO2, =O, -CN, C1-6aminoalkyl, C1-6 alkoxy, C1-6hydroxyalkyl, C1-6cyanoalkyl, C1-6haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl.

[00173] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 9- to 11-membered unsaturated heterocycle. In some cases, R1 is selected from an optionally substituted 10-membered unsaturated heterocycle. In some cases, R1 is selected from a fused 10-membered unsaturated heterocycle. Petition 870250100147, dated 10 / 31 / 2025, pp. 128 / 437 123 / 431 N optionally substituted. In some cases, R1 is —Ί—, which is optionally substituted. In some cases, one or more optional substituents are selected from halogen, -OH, -C(O)N(R2O)2, -N(R2O)2, -C(O)R2O, -NO2, =O, -CN, C1-6 aminoalkyl, C16 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In In some cases, R1 is —I— , optionally substituted with one or more substituents selected from -N(R20)2, -C(O)R20, -NO2, -O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl and C312 carbocycle and each of which is optionally substituted with one or more independently selected substituents from halogen, -OH, -CN, -NO2, -NH2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle.

[00174] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 7- to 11-membered spiro heterocycle. In some cases, R1 is selected from a 10-membered spiro heterocycle. In some cases, the spiro heterocycle contains at least 3 nitrogen atoms. In some cases, the spiro heterocycle contains at least 1 sulfur atom. In some cases, R1 is selected from and —— , each of which is optionally substituted. In some cases, one or more optional substituents are independently selected from halogen, -OH, -N(R2O)2, -NO2, =O, CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, pp. 129 / 437 124 / 431 -L- and . In some cases, R1 is . In some cases, R1é

[00175] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted fused 8- to 10-membered heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a bicyclic heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a saturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is an unsaturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a non-aromatic heterocycle. In some cases, R1 is selected from an optionally substituted fused-membered heterocycle. In some cases, a fused-membered heterocycle is a bicyclic heterocycle. In some cases, a fused-membered heterocycle is a saturated heterocycle. In some cases, a member heterocycle is a non-aromatic heterocycle. In some cases, the fused heterocycle contains one saturated ring and one aromatic ring. In some cases, the fused heterocycle contains one saturated ring and one unsaturated ring. In some cases, the fused heterocycle contains two saturated rings. In some cases, the 10-membered heterocycle contains at least one nitrogen atom. In some cases, the 10-membered heterocycle contains at least two nitrogen atoms. In some cases, the 10-membered heterocycle contains at least three nitrogen atoms. In some cases, R1 is selected from and —1— , each of which is optionally replaced with one or more substituents. In some cases, R1 is , which is optionally replaced with one or more substituents. In some cases, the one or more substituents Petition 870250100147, dated 10 / 31 / 2025, pp. 130 / 437 125 / 431 optional R1 are independently selected from halogen, -OH, -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, C(O)R20, -NO2, =O, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents are independently selected from halogen, =O, -OH, -CN, -NHCN, -S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, -S(O)R2O(=NR2O), C(O)R2O, -C(O)N(R2O)2, -C(O)NR2OOR2O, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, one or more optional substituents are independently selected from halogen, =O, C1-6 alkyl-N(R20)2, S(O)2(R20), -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20.In some cases, one or more optional substituents are independently selected from halogen, =O, -S(O)2(R20), -S(O)N(R20)2, -S(O)R20(=NR20), C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, R1 is selected from. , and —1— , each of which is optionally substituted. In some cases, one or more optional substituents are independently selected from -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20). In some cases, one or more optional substituents are independently selected from -S(O)N(R20)2. In some cases, one or more optional substituents are independently selected from S(O)2(R20). In some cases, one or more optional substituents are independently selected from S(O)R20(=NR20). In some cases, one or more optional substituents are independently selected from -C(O)R20. In some cases, one or more optional substituents are independently selected from -C(O)N(R20)2. In some cases, one or more optional substituents are Petition 870250100147, dated 10 / 31 / 2025, pp. 131 / 437 126 / 431 selected independently of -C(O)NR20OR20. In some cases, each R20 is selected independently of hydrogen; and C1-6 alkyl, C3-12 carbocycle and 3- to 12-membered heterocycle. In some cases, each R20 is selected independently of hydrogen; and C1-6 alkyl and 3- to 12-membered heterocycle. In some cases, each R20 is selected independently of hydrogen; and C1-6 alkyl and 3- to 12-membered saturated heterocycle. In some cases, one or more optional substituents of R1 are selected independently of halogen, II 0 II Á iz । z Ϊ OH 1 , , , In some cases, R1 is selected from 0 XN OH ζ / Ν^\ 1 , O 0 __n—k \ / In—\ , 0 o^o In OH J1 o^J ^ / N—\ XNX , , O 0 L n—\ । L n—\ Cl VJVJNN , , A- A- । c'n 'H , , , In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, pp. 132 / 437 127 / 431 In some cases, one or more optional substituents of R1 are independently selected from halogen and C1-6 alkyl-N(R20)2. In some cases, one or more optional substituents of R1 are independently selected from halogen, In some cases, R1 is selected. of -L-. In some cases, each R20 is independently selected from Petition 870250100147, dated 10 / 31 / 2025, page 133 / 437 128 / 431 hydrogen, C1-6 alkyl and C3-6 carbocycle. In some cases, R1 is selected from

[00176] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted fused 8- to 10-membered heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a bicyclic heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a saturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is an unsaturated heterocycle. In some cases, the fused 8- to 10-membered heterocycle is a non-aromatic heterocycle. In some cases, R1 is selected from an optionally substituted fused 10-membered heterocycle. In some cases, the fused 10-membered heterocycle is a bicyclic heterocycle. In some cases, the fused 10-membered heterocycle is a saturated heterocycle. In some cases, the fused 10-membered heterocycle is a non-aromatic heterocycle. In some cases, the fused heterocycle contains both a saturated ring and an aromatic ring.In some cases, the fused heterocycle contains one saturated ring and one unsaturated ring. In some cases, the fused heterocycle contains two saturated rings. In some cases, the 10-membered heterocycle contains at least one nitrogen atom. In some cases, the 10-membered heterocycle contains at least two nitrogen atoms. In some cases, the 10-membered heterocycle contains at least three nitrogen atoms. In some cases, R1 is selected from... , each of which is optionally replaced with one or more substituents. In some cases, R1 is Petition 870250100147, dated 10 / 31 / 2025, pp. 134 / 437 129 / 431 Η Ν Η Τ) selected from —I— and -4- , each of which is optionally replaced with r--N In some cases, R1 is —L-, which is optionally substituted with one or more substituents. In some cases, the one or more optional substituents of R1 are independently selected from halogen, -OH, -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, C(O)R20, -NO2, =O, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents are independently selected from halogen, =O, -OH, -CN, -NHCN, -S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, -S(O)R2O(=NR2O), C(O)R2O, -C(O)N(R2O)2, -C(O)NR2OOR2O, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl.In some cases, one or more optional substituents are independently selected from halogen, =O, C1-6 alkyl-N(R20)2, S(O)2(R20), -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from halogen, =O, -S(O)2(R20), -S(O)N(R20)2, -S(O)R20(=NR20), C(O)R20, -C(O)N(R20)2 and -C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from -C(O)R20, -C(O)N(R20)2, and C(O)NR20OR20. In some cases, one or more optional substituents are independently selected from -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20). In some cases, one or more optional substituents are independently selected from -S(O)N(R20)2. In some cases, one or more optional substituents are independently selected from S(O)2(R20). In some cases, one or more optional substituents are independently selected from S(O)R20(=NR20).In some cases, one or more optional substituents are independently selected from -C(O)R20. In some cases, one or more optional substituents are independently selected from -C(O)N(R20)2. In some cases, one or more optional substituents are independently selected from Petition 870250100147, dated 10 / 31 / 2025, p. 135 / 437. 130 / 431 C(O)NR20OR20. In some cases, R1 is selected from and ™L·., each of which is optionally further substituted. In some cases, one or more additional optional substituents are selected from halogen, -OH, =O, -CN, C1-6 aminoalkyl, C16 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more additional optional substituents are selected from halogen and C1-6 alkyl. In some cases, one or more additional optional substituents are selected from halogen. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl and 3- to 12-membered heterocycle. In some cases, each R20 is independently selected from hydrogen; and C1-6 alkyl and saturated 3- to 12-membered heterocycles. In some cases, each R20 is independently selected from saturated 5- to 6-membered heterocycles.In some cases, the R20 heterocycle contains at least one nitrogen atom. In some cases, the R20 heterocycle contains at least one sulfur atom. In some cases, the R20 heterocycle contains at least one oxygen atom. In some cases, the R20 heterocycle contains only one heteroatom. In some cases, the R20 heterocycle contains at least two heteroatoms. In some cases, the R20 heterocycle contains only two heteroatoms. In some cases, one or more optional substituents of R1 are independently selected from halogens. Petition 870250100147, dated 10 / 31 / 2025, pp. 136 / 437 131 / 431 O In some cases, one or more optional substitutes for R1 are independently selected from In these cases, R1 is selected from THE Petition 870250100147, dated 10 / 31 / 2025, pp. 137 / 437 132 / 431 NH / / s. —I— . In some cases, R1 is selected from ,and In some cases, one or more optional substitutes for R1. NH , are independently selected from halogen and C1-6 alkyl-N(R20)2. In some cases, one or more optional substituents of R1 are independently selected from halogen, In some cases, R1 is selected. Petition 870250100147, dated 10 / 31 / 2025, pp. 138 / 437 133 / 431 of --I— . In some cases, each R20 is independently selected from hydrogen, C1-6 alkyl and C3-6 carbocycle. H 1 N—\ 1 1 N—\ cr \ 1 cr \ , 0 HN'V^t cases, R1 is selected from OO x N , 0 0 XnX / N XX> / -N^XN—\ \ ci7^ ) cr ^X , 0 XnX / NX^X^N xx Jxx ' JXx hn cr In some cases, R1 is selected from HN—\ ) '^0 N and —1— . In some 0 O XN'xrísN X''JXíSN N^\ / 1 N—\ / 1 N—\ 0 / .NX^N-Xv^N Ur XX Jxx XJ 0 Cl t JNN , , Petition 870250100147, dated 10 / 31 / 2025, pp. 139 / 437 134 / 431

[00177] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), when R1 is replaced with C(O)R20, R20 is selected from a 5- to 12-membered heterocycle.

[00178] In some embodiments, for a compound or salt of Formula (I), Formula (I'X N A), Formula (IB), Formula (IC), or Formula (IG), R1 is —I— , and one or more optional substituents of R1 are independently selected from halogen, -OH, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, C(=NR20)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl and heterocycle of 5 to 12 optionally substituted members. In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(=NR20)N(R20)2, -C(O)NHOR20, N(R20)2, -C(O)R20, -NO2, =O, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl and optionally substituted 5- to 12-membered heterocycles.In some cases, one or more optional substituents of R1 are independently selected from halogen, -CN, C26 alkynyl, -C(=NR20)N(R20)2 and optionally substituted 5- to 12-membered heterocycles. In some cases, one or more optional substituents of R1 are independently selected from halogen, -C(=NR20)N(R20)2 and optionally substituted 5- to 12-membered heterocycles. In some cases, one or more optional substituents of R1 are independently selected from -C(=NR20)N(R20)2 and optionally substituted 5- to 12-membered heterocycles. In some cases, one or more optional substituents of R1 are independently selected from optionally substituted 5- to 12-membered heterocycles. In some cases, one or more optional substituents of R1 are independently selected from a 5-membered heterocycle and a 9-membered heterocycle, each of which is optionally replaced independently with one or more R1*.In some cases, R1 is substituted with at least one halogen atom and optionally substituted with one or more independently selected substituents from -CN, C2-6 alkynyl, -C(=NR20)N(R20)2 and 5- to 12-membered heterocycles, where the 5- to 12-membered heterocycle is optionally independently substituted with one. Petition 870250100147, dated 10 / 31 / 2025, p. 140 / 437 135 / 431 or more R1*. In some cases, the heterocycle contains at least one nitrogen atom. In some cases, the heterocycle contains at least one oxygen atom. In some cases, the heterocycle contains at least one nitrogen atom and at least one oxygen atom. In some cases, the heterocycle contains at least two heteroatoms. In some cases, the heterocycle contains at least three heteroatoms. In some cases, the heterocycle contains at least four heteroatoms. In some cases, the heterocycle of one or more optional substituents of R1 is selected from , each of which is optionally replaced with one or more R1* substituents. In some cases, the heterocycle of one or more optional R1 substituents is selected from , which is optionally replaced with one or more R1*. In some cases, each R1* is independently selected from halogen, -OR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20(=NR20), -NR20S(O)2R20, -C(O)2(R20)2 -C(O)NR20OR20, N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -O =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkylN(R20)2, C1-6aminoalkyl, C1-6alkoxy, C1-6hydroxyalkyl, C1-6 cyanoalkyl, C1-6haloalkyl and C1-6 alkyl. In some cases, each R1* is independently selected from halogen, OR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2 -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -O =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl.In some cases, each R1* is independently selected from halogen, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R1* is independently selected from halogen, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R1* is independently selected from halogen and C1-6 alkyl. In some cases, each R1* is independently selected from halogen. In some cases, each R1* is independently selected from C1-6 alkyl. In some cases, each R1* is... Petition 870250100147, dated 10 / 31 / 2025, page 141 / 437 136 / 431 independently selected from -OR20. In some cases, each R1* is independently selected from -OH. In some cases, each R1* is independently selected from -OMe. In some cases, the heterocycle of one or more optional substituents of R1 is selected from

[00179] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), one or more optional substituents of R1 are independently selected from -C(=NR20)N(R20)2 and optionally substituted 5- to 12-membered heterocycles. In some cases, one or more optional substituents of R1 are independently selected from optionally substituted 5- to 12-membered heterocycles. In some cases, the heterocycle is selected from , each of which is optionally replaced with one or more R1*. In some cases, one or more optional substitutes for R1 are selected from Petition 870250100147, dated 10 / 31 / 2025, p. 142 / 437 137 / 431 F

[00180] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), each R1* is independently selected from halogen, -OR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.In some cases, each R1* is independently selected from halogen, -OR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R1* is independently selected from halogen, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R1* is independently selected from halogen, C1-6 haloalkyl, and C1-6 alkyl. In some cases, each R1* is independently selected from halogen and C1-6 alkyl. In some cases, each R1* is independently selected from halogen. In some cases, each R1* is independently selected from C1-6 alkyl.

[00181] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 5- to 15-membered heterocycle (preferably an 8- to 10-membered heterocycle or preferably a 10-membered heterocycle), each of which is optionally substituted with one or more substituents independently selected from halogen, oxo, -C(O)N(R20)2, C(O)NR20OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -SO2R20, -NHCN, C1-6-cyanoalkyl, C1-6-alkyl, C1-6-alkyl-N(R20)2, C2-6-alkynyl and a 5- to 12-membered heterocycle (preferably a 5- to 9-membered heterocycle), wherein the 5- to 12-membered heterocycle is optionally Petition 870250100147, dated 10 / 31 / 2025, pp. 143 / 437 138 / 431 independently substituted with one or more R1*; each R1* is independently selected from halogen, C1-6 haloalkyl and C1-6 alkyl. In some cases, the 10-membered heterocycle is bicyclic. In some cases, the 10-membered heterocycle is substituted. In some cases, R1 is selected from and JL, each of which is optionally replaced. In some cases, R1 is selected from -L, which It is optionally replaced. In some cases, R1 is selected from F A- and -J~ . In some cases, R1 is selected from , ~1~ and ~L . In some cases, R1 is Petition 870250100147, dated 10 / 31 / 2025, p. 144 / 437 139 / 431

[00182] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from a 5- to 15-membered heterocycle (preferably an 8- to 10-membered heterocycle or preferably a 10-membered heterocycle or preferably an 8-membered heterocycle), each of which is optionally substituted with one or more independently selected halogen substituents, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)2, -C(O)R20, C(O)OR20, -NHCN, C1-6 cyanoalkyl, C1-6 alkyl, C2-6 alkynyl and a 5- to 12-membered heterocycle (preferably a 5- to 6-membered heterocycle), wherein the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*; Each R1* is independently selected from halogen, C1-6 haloalkyl, and C1-6 alkyl. In some cases, the 8- to 10-membered heterocycle is bicyclic. In some cases, the 10-membered heterocycle is bicyclic. The « $ members are replaced. In some cases, R1 is selected from -1-, -t-, and -t-, each of which is optionally replaced. In some cases, R1 is selected from -1, which is optionally replaced. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 145 / 437 140 / 431 -I— . In some cases, R1 is selected from J- and ~L .

[00183] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted spiro-7 to 10-membered heterocycle and an optionally substituted fused 7 to 10-membered heterocycle. In some cases, the heterocycle of R1 contains at least one nitrogen atom. In some cases, at least one nitrogen in the heterocycle of R1 is attached to Formula (I). In some cases, R1 is selected from an optionally substituted spiro-10-membered heterocycle and an optionally substituted fused 10-membered heterocycle.In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, C(=NR20)N(R20)2, -C(O)OR20, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl, 5- to 12-membered heterocycle, where the 5-membered heterocycle The 12-membered group is optionally replaced with one or more selected halogen and C1-6 alkyl substituents. In some cases, R1 is selected. of — , which is substituted with one or more independently selected halogen substituents, -OH, -S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, S(O)R2O(=NR2O), -C(O)N(R2O)2, -C(=NR2O)N(R2O)2, -C(O)OR2O, -C(O)NHOR2O, -N(R2O)2, -C(O)R2O, -NO2, =O, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkynyl, 5- to 12-membered heterocycle, wherein the 5-membered heterocycle The 12-membered group is optionally replaced with one or more substituents selected from halogen and C1-6 alkyl groups. Petition 870250100147, dated 10 / 31 / 2025, p. 146 / 437 141 / 431 in some cases, R1 is selected from In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 147 / 437 142 / 431 pn ΊC1AGClV J NJN ~L , ™L· e —I—

[00184] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 6- to 11-membered heterocycle, wherein the 6- to 11-membered heterocycle contains at least one nitrogen atom. In some cases, one or more optional substituents of R1 are selected from halogen, -OR20, -C(O)N(R20)2, -C(O)R20, -S(O)2R20, =O, -C1-6 alkyl(=NR20OR20), =NO(R20), -CN, -NHCN, C1-6 alkyl and 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*; and where each R1* is independently selected from halogen and C1-6 alkyl. In some embodiments, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, pp. 148 / 437 143 / 431 In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 149 / 437 144 / 431 hydrogen, Petition 870250100147, dated 10 / 31 / 2025, p. 150 / 437 145 / 431 hydrogen, In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 151 / 437 146 / 431

[00185] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from hydrogen and optionally substituted 5- to 15-membered heterocycle. In some cases, R1 is ,0. n=n nh2 IN——1' ΙΝΓΊ2 d is selected from -d— , ~~d— , —A- , —1— , —1— , —1— , -1— , , each of which is optionally substituted. In some cases, one or more optional substituents of R1 is selected from -OH, =NO(R2O), -NHCN and C1-6 alkyl. In some cases, R1 is selected from hydrogen. Petition 870250100147, dated 10 / 31 / 2025, p. 152 / 437 147 / 431

[00186] In some embodiments, for a compound or salt of Formula (I), Formula (I- A), Formula (IB), Formula (IC), or Formula (IG), R1é —L™

[00187] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from hydrogen and optionally substituted 7- to 10-membered heterocycle. In some cases, R1 is selected from hydrogen , each of which is optionally substituted. In some cases, one or more optional substituents of R1 are independently selected from halogen, NH2, -S(O)2(R20), -C(O)R20, -C(O)N(R20)2, =O=NO(R20), -CN, -NHCN, C1-6 alkyl and 5- to 12-membered heterocycles, where the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*; and where each R1* is independently selected from halogen and C1-6 alkyl. In some cases, R1 is Petition 870250100147, dated 10 / 31 / 2025, p. 153 / 437 148 / 431 selected from hydrogen,

[00188] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 8- to 10-membered heterocycle. In some cases, the heterocycle is bicyclic. Petition 870250100147, dated 10 / 31 / 2025, p. 154 / 437 149 / 431 In some cases, the heterocycle contains at least one nitrogen atom. In some cases, the heterocycle contains at least two nitrogen atoms. In some cases, N each of which is optionally substituted. In some cases, one or more optional substituents of R1 are independently selected from halogen. , oxo, THE R20-S. , n θ ' e heteroaryl of 5 to 9 members, where the 5 to 9 member heteroaryl is substituted with at least one R1*, where R1* is selected from halogen and C1-6 alkyl. In some cases, one or more optional substituents of R1 are independently selected from In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 155 / 437 150 / 431

[00189] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 8- to 9-membered bridged heterocycle. In some cases, the heterocycle , each of which is optionally substituted. In some cases, one or more substituents of R1 are selected from halogen, C1-6 alkyl, -N(R20)2, and C1-6 aminoalkyl. In some cases, R1 is selected from and

[00190] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted 8-membered bridged heterocycle, where the heterocycle contains heteroatoms selected from nitrogen. In some cases, one or more substituents of R1 are selected from C1-6 alkyl, -N(R20)2, and C1-6 aminoalkyl. In some cases, the The heterocycle of R1 is selected from --------- and -------- , each of which is optionally Petition 870250100147, dated 10 / 31 / 2025, p. 156 / 437 151 / 431 replaced. In some cases, R1 is selected from -Ά and -2. In some cases, R1 It is — . In some cases, R1 is

[00191] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a 12 to 15 membered heterocycle optionally substituted. optionally substituted members. optionally substituted members. optionally substituted members. In some cases, R1 In some cases, R1 In some cases, R1 In some cases, R1 is a heterocycle with 12, 13, 14, or 15 optionally substituted members. In some cases, the heterocycle of R1 is tricyclic. In some cases, the R1 heterocycle contains a fused heterocycle. In some cases, the R1 heterocycle contains a spiral heterocycle. In some cases, the R1 heterocycle contains both a fused and a spiral heterocycle. In some cases, the R1 heterocycle is an unsaturated heterocycle. In some cases, the R1 heterocycle is a non-aromatic heterocycle. In some cases, the R1 heterocycle contains at least one double bond. In some cases, the R1 heterocycle contains at least two double bonds. In some cases, the R1 heterocycle contains at least two heteroatoms. In some cases, the R1 heterocycle contains at least three heteroatoms. In some cases, the R1 heterocycle contains at least four heteroatoms. In some cases, the R1 heterocycle contains at least five heteroatoms. In some cases, the R1 heterocycle contains at least 6 heteroatoms. In some cases, the R1 heterocycle contains at least 7 heteroatoms. In some cases, the heteroatoms are selected from oxygen, nitrogen, and sulfur. In some cases, the R1 heterocycle contains at least 3, 4, or 5 nitrogen atoms and at least 1 sulfur atom. In some cases, the R1 heterocycle contains at least 3, 4, or 5 nitrogen atoms and at least 1 oxygen atom. In some cases, the R1 heterocycle contains at least 3, 4, or 5 nitrogen atoms. In some cases, the R1 heterocycle contains at least 3, 4, or 5 nitrogen atoms and no other heteroatoms. In some cases, the heteroatoms are selected from nitrogen and sulfur. In some cases, the heteroatoms are selected from nitrogen and oxygen. In some Petition 870250100147, dated 10 / 31 / 2025, page 157 / 437 152 / 431 In these cases, R1 is selected from , each of which is optionally replaced with one or more substituents. In some cases, R1 is selected from , each of which is optionally replaced with one or more substituents. In some cases, the one or more optional substituents of R1 are independently selected from halogen, -OH, -NHCN, -S(O)2(R2O), -S(O)2N(R2O)2, Petition 870250100147, dated 10 / 31 / 2025, p. 158 / 437 153 / 431 -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, =NH, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, -NHCN, S(O)2(R2O), -S(O)2N(R2O)2, -S(O)N(R2O)2, -S(O)R2O(=NR2O), -C(O)N(R2O)2, C(O)NHOR2O, -N(R2O)2, -C(O)R2O, -NO2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of R1 are independently selected from halogen, -OH, C1-6 alkyl, and -C(O)N(R2O)2. In some cases, R1 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 159 / 437 154 / 431 and

[00192] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a heterocycle of 12 to 15 (P f \ V_A w) members optionally substituted. In some cases, R1 is -J-, where the Ring W is an optionally substituted heterocycle, and Ring P is an optionally substituted carbocycle or optionally substituted heterocycle, where Ring P forms a spiral cycle with Ring W. In some cases, Ring W is an optionally substituted fused heterocycle. In some cases, Ring P and Ring W combine to form a heterocycle containing at least 12 and at most 15 atoms. In some cases, Ring P and Ring W together have at least 12 and at most 15 atoms. In some cases, Ring W is a fused 10-membered heterocycle. Of / N optionally substituted. In some cases, R1 is -J— , where Ring P is an optionally substituted carbocycle or optionally substituted heterocycle. In In some cases, R1 is In some cases, the P-ring is an optionally substituted carbocycle. In some cases, the P-ring is an optionally substituted heterocycle. In some cases, the P-ring forms an optionally substituted C3-C6 carbocycle or an optionally substituted 4- to 6-membered heterocycle. In some cases, Petition 870250100147, dated 10 / 31 / 2025, p. 160 / 437 155 / 431 The P-ring forms an optionally substituted C3 carbocycle. In some cases, the P-ring forms an optionally substituted C4 carbocycle. In some cases, the P-ring forms an optionally substituted C5 carbocycle. In some cases, the P-ring forms an optionally substituted 4-membered heterocycle. In some cases, the P-ring forms an optionally substituted 5-membered heterocycle. In some cases, the P-ring forms an optionally substituted 5-membered heterocycle. In some cases, the P-ring contains at least 1, 2, or 3 heteroatoms. In some cases, the heteroatoms are selected from oxygen, nitrogen, and sulfur. In some cases, the P-ring contains 1 sulfur atom. In some cases, the P-ring contains 1 nitrogen atom. In some cases, the P-ring contains 1 oxygen atom.In some cases, one or more optional substituents of Ring P are independently selected from halogen, -OH, -NHCN, =O, =NR2O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, and C2-6 alkynyl. In some cases, one or more optional substituents of Ring P are independently selected from halogen, -OH, =O, =NH, -CN, and C1-6 alkyl. In some cases, one or more optional substituents of Ring W are independently selected from halogen, -OH, -NHCN, -S(O)2(R2O), S(O)2N(R2O)2, -S(O)N(R2O)2, -S(O)R2O(=NR2O), -C(O)N(R2O)2, -C(O)NHOR2O, -N(R2O)2, C(O)R2O, -NO2, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C16 haloalkyl, C1-6 alkyl and C2-6 alkynyl. In some cases, one or more optional substituents of Ring W are independently selected from halogen, -S(O)2(R20), S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, C(O)R20 and C1-6 alkyl.In some cases, one or more optional substituents for Ring W are independently selected from -C(O)R20. In some cases, Ring P is substituted. In some cases, Ring W is substituted.

[00193] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is selected from an optionally substituted saturated 6- to 7-membered heterocycle. In some cases, R1 is selected from an optionally substituted saturated 6-membered heterocycle. In some cases, R1 is selected from —L», which is optionally substituted. In some cases, one or more optional substituents are independently selected from halogen, -CN, -NHCN, C1-6 cyanoalkyl, and C1-6 alkyl. In some cases, one or more optional substituents are independently selected from -CN, -NHCN, C1-6 cyanoalkyl, and C1-6 Petition 870250100147, dated 10 / 31 / 2025, p. 161 / 437 156 / 431 alkyl. In some cases, one or more optional substituents are independently selected from -CN, -NHCN, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, one or more optional substituents are independently selected from -NHCN and C1-6 alkyl. In some cases, R1 is selected from —I—, which is replaced with one or more substituents selected from -NHCN and C1-6 alkyl. In some cases, R1 is selected from

[00194] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), R1 is a bridging heterocycle. In some cases, R1 is selected from a 7- to 10-membered bridging heterocycle. In some cases, R1 is selected from an 8-membered bridging heterocycle. In some cases, the bridging heterocycle of R1 contains at most 1 nitrogen atom. In some cases, the bridging heterocycle of R1 contains at most 2 nitrogen atoms. In some cases, the bridging heterocycle of R1 contains at least 2 nitrogen atoms. In some In some cases, R1 is selected from , which is optionally replaced. In some cases, R1é

[00195] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the optional substituents of R1 are independently selected from one or more halogens, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. In some cases, the optional substituents of R1 are independently selected from one or more halogens, B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), Petition 870250100147, dated 10 / 31 / 2025, p. 162 / 437 157 / 431 NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, N(R20)2, -C(O)R20, -C(O)20, -ROC(O)20 -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl C2-6 alkyne.

[00196] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the optional substituents of R1 are independently selected from one or more of halogens, -B(OR20)2, -OH, -O-C1-6 alkyl, -SR20, -N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl. In some cases, the optional substituents of R1 are independently selected from one or more halogens, -B(OR20)2, -OH, -SR20, -N(R20)2, -NO2, =NO(R20), C1-6 alkoxyalkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, the optional substituents of R1 are independently selected from one or more halogens, -OH, -NH2, and C1-6 alkoxy. In some cases, the optional substituents of R1 are independently selected from one or more halogens, -OH, and C1-6 alkoxy.In some cases, the optional substituents of R1 are independently selected from one or more halogens and -OH. In some cases, the optional substituents of R1 are independently selected from one or more -OH. In some cases, the optional substituents of R1 are independently selected from one or more C1-6 alkyl, C16 hydroxyalkyl, and -OH. In some cases, the optional substituents of R1 are independently selected from one or more C1-6 hydroxyalkyl and -OH. In some cases, R1 is substituted with at least one substituent independently selected from C1-6 hydroxyalkyl and -OH. In some cases, R1 is substituted with at least one substituent independently selected from -OH.

[00197] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the heterocycle of R1 is substituted with one or more substituents. In some cases, the substituents of R1 are independently selected from one or more halogens, -B(OR20)2, -OH, -O-C1-6 alkyl, -SR20, -N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, the substituents of R1 are independently selected from one or more halogens, B(OR2O)2, -OH, -SR2O, -N(R2O)2, -NO2, =NO(R2O), C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, and C1-6 alkyl. In some cases, the substituents of R1 are Petition 870250100147, dated 10 / 31 / 2025, p. 163 / 437 158 / 431 independently selected from one or more halogens, -OH, -NH2 and C1-6 alkoxy. In some cases, the substituents of R1 are independently selected from one or more halogens, -OH and C1-6 alkoxy. In some cases, the optional substituents of R1 are independently selected from one or more halogens and -OH.

[00198] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the heterocycle of R1 is replaced with one or more substituents. In some cases, the R1 heterocycle is substituted with one or more selected halogen substituents, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkoxyalkyl, C2-6 alkenyl and C2-6 alkynyl; and optionally further substituted with one or more independently selected substituents from C1-6 alkoxyalkyl, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.In some cases, the substituents of R1 are each selected from one or more halogens, -OR20, -SR20, N(R20)2, -NHCN, -NO2, =O, -CN, C1-6 fluoroalkyl and C2-6 alkynyl; and optionally further substituted with one or more substituents independently selected from -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl and C2-6 alkenyl. In some cases, the substituents of R1 are each selected from one or more halogens, -OR20, -N(R20)2, -NHCN, =O, -CN and C2-6 alkynyl; and optionally further substituted with one or more independently selected substituents of -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl. In some cases, the substituents of R1 are each selected from one or more halogens, -OH, -NHCN, =O, -CN and C2-6 alkynyl; and optionally further substituted with one or more independently selected C1-6 alkyl substituents.In some cases, the substituents of R1 are each selected from one or more halogens, NH2, -OH, and =O.

[00199] In some embodiments, for a compound or salt of Formula (I), R100 is _R1CO different from Y-R2. In some cases, --1-- is different from Y-R2.

[00200] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is selected from Cl-C4 alkylene. Petition 870250100147, dated 10 / 31 / 2025, p. 164 / 437 159 / 431 In some cases, L is selected from C1-C2 alkylene. In some cases, L is selected from C1-C2 alkylene.

[00201] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is selected from unsubstituted Cl-C4 alkylene. In some cases, L is selected from unsubstituted Cl-C2 alkylene. In some cases, L is selected from unsubstituted Cl alkylene. In some cases, L is selected from methylene and ethylene. In some cases, L is methylene.

[00202] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from optionally substituted -L-heterocycle, optionally substituted -L-heteroaryl, optionally substituted -L-aryl, -LN(R5)2, and -LO-R5. In some cases, R2 is selected from optionally substituted 5- to 12-membered -L-heterocycle, optionally substituted 5- to 12-membered -L-heteroaryl, optionally substituted -L-C6-C12aryl, -LN(R5)2, and -LO-R5. In some cases, R2 is selected from optionally substituted -L-heterocycle, optionally substituted -L-heteroaryl, and -LN(R5)2. In some cases, R2 is selected from optionally substituted 5- to 12-membered -L-heterocycle, optionally substituted 5- to 12-membered -L-heteroaryl, and -LN(R5)2. In some cases, R2 is selected from optionally substituted -L-heterocycle and -LN(R5)2.In some cases, R2 is selected from optionally substituted 5- to 12-membered -L-heterocycles and -LN(R5)2. In some cases, R2 is selected from optionally substituted 5- to 12-membered -L-heterocycles. In some cases, R2 is selected from optionally substituted saturated 5- to 12-membered -L-heterocycles. In some cases, R2 is selected from optionally substituted L-heterocycles. In some cases, the heterocycle is selected from pyrrolidine, hexahydro-1H-pyrrolizine, pyrazolidine, imidazolidine, tetrahydrofuran, piperidine, piperazine, morpholine, azocane, and azonane. In some cases, the heterocycle is selected from cyclic sulfonamides. In some cases, the heterocycle is selected from pyrrolidine, hexahydro-1H-pyrrolizine, pyrazolidine, imidazolidine, piperidine, piperazine, azocane, and azonane. In some cases, the heteroaryl is selected from pyrrole, pyrazole, furan, thiophene, oxazole, isoxazole, isothiazole, thiazole, pyridine, pyrazine, and triazine.In some cases, the heteroaryl or heterocycle contains at most 1 nitrogen atom. In some cases, Petition 870250100147, dated 10 / 31 / 2025, p. 165 / 437 160 / 431 The heteroaryl or heterocycle contains at least 1 nitrogen atom. In some cases, the heteroaryl or heterocycle contains 1 nitrogen atom.

[00203] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is selected from C1-C4 alkylene. In some cases, L is selected from an unsubstituted C1-C4 alkylene. In some cases, L is selected from an unsubstituted C1 alkylene. In some cases, two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and the 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl. In some cases, two substituents on the same carbon atom of L combine to form a C3-C6 carbocycle or heterocycle with 3 to 8 members.In some cases, two substituents on the same carbon atom of L combine to form a C3-C6 carbocycle.

[00204] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is selected from C1-C4 alkylene. In some cases, L is selected from unsubstituted C1-C4 alkylene. In some cases, each L is independently selected from an optionally substituted C1-C4 alkylene; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl.In some cases, the optional substituents of L are selected from Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3-C6 carbocycle and 3- to 8-membered heterocycle are optionally substituted with one or more substituents selected from halogen and C1-6 haloalkyl. In some cases, L is selected from , , O , ,FF , ^X^F'^f''^. Petition 870250100147, dated 10 / 31 / 2025, p. 166 / 437 161 / 431 In some cases, L is selected from In some cases, each L is independently selected from a substituted Cl-C4 alkylene where two substituents on the same carbon atom of L combine to form a 3- to 5-membered C3-C6 carbocycle or heterocycle. In some cases, each L is independently selected from a substituted C2-C3 alkylene where two substituents on the same carbon atom of L combine to form a 4-membered C3 carbocycle or heterocycle, where the C3 carbocycle is optionally substituted with one or more selected halogen substituents. In some cases, each L is independently selected from ,independently In some cases, each L is In some cases, each L is independently selected from In some cases, each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected halogen and C1-C4 alkyl substituents. In some cases, L is selected from

[00205] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each L is independently selected from an unsubstituted Cl-C4 alkylene. In some cases, L is selected from and . In some cases, L is selected from .

[00206] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from heterocycle, ClC6 alkyl, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -L-heteroaryl, -L-cycloalkyl, -L-C1 ... 162 / 431 N(R20)2, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-C1-C6 haloalkyl, -L-OR20, -LNR20C(O)-ari1, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), L-OC(O)N(R20)2 and -LC(=O)OCi-C6 alkyl, where the heterocycle, the heterocyclic part of L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -L-NR20C(O)-aryl, the aryl part of -LNR20C(O)-aryl, the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally replaced with one or more R7.

[00207] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from heterocycle, L-heterocycle, -L-aryl, -L-heteroaryl and -LN(R20)2, wherein the heterocycle, the heterocyclic part of -L-heterocycle, are each optionally replaced with one or more R6 and wherein the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally replaced with one or more R7.

[00208] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -L-heteroaryl, -L-cycloalkyl, -LNHC(=NH)NH2, -LC(O)N(R20)2, -L-C1-C6 haloalkyl, -L-NR20C(O)-aryl, -L-COOH, -LNR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OC1-C6 alkyl, where the heterocycle, the heterocyclic moiety of -L-heterocycle and the cycloalkyl moiety of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl moiety of -L-NR20C(O)-aryl, the aryl moiety of -L-aryl and the heteroaryl moiety of -L-heteroaryl are each optionally substituted with one or more R7;and where the heterocycle, the heterocyclic moiety of the -L-heterocycle and the heteroaryl moiety of the -L-heteroaryl each contains at least one heteroatom selected from nitrogen, oxygen, silicon and sulfur.

[00209] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is an L-heterocycle, where the heterocyclic part is optionally substituted. In some cases, R2 is an L-heterocycle, where the heterocyclic part is a bicyclic heterocycle. In some cases, R2 is an L-heterocycle, where the heterocyclic part is a monocyclic heterocycle. In some cases, R2 is an L-heterocycle, where the heterocyclic part is a saturated heterocycle. In some cases, R2 is selected Petition 870250100147, dated 10 / 31 / 2025, p. 168 / 437 163 / 431 of a 5- to 10-membered -L-heterocycle. In some cases, R2 is selected from a 5- to 10-membered -(C1C2 alkylene)-heterocycle. In some cases, R2 is selected from a 5- to 8-membered -L-heterocycle. In some cases, R2 is selected from a saturated 5- to 8-membered -L-heterocycle. In some cases, R2 is a 5-membered -L-heterocycle. In some cases, R2 is an 8-membered -L-heterocycle. In some cases, the heterocycle contains at least 1 nitrogen atom. In some cases, the heterocycle contains at most 1 nitrogen atom. In some cases, the heterocycle contains 1 nitrogen atom. In some cases, the bicyclic heterocycle contains at least 1 nitrogen atom. In some cases, the heterocycle contains a silicon atom. In some cases, the bicyclic heterocycle contains at most 1 nitrogen atom. In some cases, the bicyclic heterocycle contains 1 nitrogen atom. In some cases, Y-R2 is selected from where the heterocyclic part is optionally replaced. In some cases, Y-R2 is selected from , where the heterocyclic moiety is optionally substituted. In some cases, the heterocyclic moiety is optionally substituted with one or more substituents selected from halogen, hydroxy, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, C1-C3 alkoxy, -CN, and Cl-C3 aminoalkyl. In some cases, the heterocyclic moiety is optionally substituted with one or more substituents selected from halogen, hydroxy, -CN, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, C1-C3 alkoxy, and Q-C3 aminoalkyl. In some cases, the heterocyclic moiety is optionally substituted with one or more substituents selected from C1-C3 alkyl and halogen. In some cases, Y-R2 is selected from In some cases, Y-R2 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 169 / 437 164 / 431 In some cases, Y-R2 is selected from In some cases, Y-R2 is

[00210] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from optionally substituted -L-heterocycle. In some cases, the heterocycle is a monocyclic heterocycle. In some cases, the heterocycle contains only 1 nitrogen atom. In some cases, the heterocycle contains only 1 nitrogen atom and no other heteroatoms. In some cases, Y-R2 is selected from HN-- / , which is optionally replaced with one or more R6. In some cases, each R6 is independently selected from halogen, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, (C1-C3 alkoxy)Cl-C3 alkyl, and C1-6 alkyl-N(R20)2. In some cases, Y-R2 is selected from

[00211] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from optionally substituted -L-heterocycle. In some cases, the heterocycle is a bicyclic heterocycle. In some cases, the heterocycle is a monocyclic heterocycle. In some cases, the heterocycle contains only 1 nitrogen atom. In some cases, the heterocycle contains only 1 nitrogen atom and no other heteroatoms. In some cases, Y-R2 is Petition 870250100147, dated 10 / 31 / 2025, p. 170 / 437 165 / 431 selected from where the heterocyclic part is optionally replaced. In some cases, Y-R2 is selected from HN-_ / and , where the heterocyclic part is optionally replaced. In some cases, YR2 is selected from HN-— / , where the heterocyclic part is optionally replaced. In some cases, Y-R2 is selected from , where the heterocyclic part is optionally substituted. In some cases, the heterocycle is optionally substituted with one or more substituents selected from halogen, hydroxyl, Cl-C3 alkyl, -N(R5)S(O)2(R5), -OC(O)N(R5)2, oxo, =CH2, =NO-Cl-C3 alkyl, CH2OC(O)heterocycle, -CH2heterocycle, -CH2OC(O)N(R5)2 and -O-Cl-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy. In some cases, Y-R2 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 171 / 437 166 / 431 In some cases, Y-R2 is selected from I I. ' -0. In some cases, Y-R2 is selected from , ,

[00212] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula Petition 870250100147, dated 10 / 31 / 2025, p. 172 / 437 167 / 431 (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is -L-heteroaryl, where the heteroaryl part is optionally replaced with one or more R7. In some cases, the heteroaryl contains at least one nitrogen atom. In some cases, the heteroaryl contains two nitrogen atoms. In some cases, the heteroaryl is HNN, which is optionally |N substituted. In some cases, the heteroaryl is HN-A, which is optionally substituted. In some cases, the heteroaryl is HNN, which is optionally substituted. In some cases, Y-R2 is selected from , where the heteroaryl part is optionally replaced with one or more R7s. In some cases, each R7 is independently selected from Cl-C4 alkyl, halogen, and Cl-C4 haloalkyl. In some R2 is selected from cases, Y-R2 is selected from In some cases, Y-

[00213] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is -L-aryl, optionally replaced with one or more R7. In some cases, where Y-R2 is selected from , where the heterocyclic part is optionally replaced with one or more R7. In some cases, Y-R2 is selected from

[00214] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is -LN(R20)2. In some cases, Petition 870250100147, dated 10 / 31 / 2025, p. 173 / 437 168 / 431

[00215] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is a heterocycle, optionally cx substituted with one or more R6. In some cases, the heterocycle of R6 is NH, on which is optionally replaced. In some cases, the heterocycle of R6eN, Em In some cases, Y-R2 is N.

[00216] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from , where the heterocyclic moiety is optionally substituted, where one or more optional substituents are selected from halogen, hydroxyl, Q-C3 alkyl, N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-C1-C3 alkyl, -CH2OC(O)heterocycle, CH2heterocycle, -CH2OC(O)N(R5)2, -(CH2)O-1-O-heterocycle and -OG-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl and where the heterocycle of -(CH2)O-1-O-heterocycle is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR2O and -OR2O. In some cases, one or more optional substituents are selected from: Petition 870250100147, dated 10 / 31 / 2025, p. 174 / 437 169 / 431

[00217] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 175 / 437 170 / 431 In some cases, Y-R2 is selected from where the heterocyclic part is optionally replaced with one or more R6s. In some cases, each R6 is selected from -(CH2)o-1-O-heterocycle and -(CH2)o-1-O-heterocycle, where the heterocycles of -(CH2)o-1-O-heterocycle and (CH2)o-1-S-heterocycle are each optionally replaced with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20. In some cases, each R6 is selected from -CH2-S-heterocycle and -CH2-O-heterocycle, where the heterocycles of -CH2-O-heterocycle and -CH2-S-heterocycle are each optionally replaced with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20. In some cases, each R20 is selected independently of hydrogen; and C1-6 alkyl, each of which is optionally substituted with one or more independently selected halogen substituents.In some cases, each R20 is independently selected from C1-6 alkyl groups, each of which is optionally substituted with one or more independently selected halogen substituents. In some cases, the heterocycle contains one or two nitrogen atoms. In some cases, the heterocycle is a heteroaryl. In some cases, the heterocycle is selected from: Petition 870250100147, dated 10 / 31 / 2025, p. 176 / 437 171 / 431 In some cases, each R6 is selected from -CH2-heterocycles and -CH2-O-heterocycles, where the heterocycles of -CH2-O-heterocycles and -CH2-S-heterocycles are each optionally substituted with one or two substituents. OCF3selected CF3de, N'N, F Petition 870250100147, dated 10 / 31 / 2025, p. 177 / 437 172 / 431 selected from (preferably ), where the heterocyclic moiety is optionally substituted with one or more R6 substituents. In some cases, R6 is selected from -CH2O-C1-C6 alkyl, where the alkyl of -CH2O-C1-C6 alkyl is optionally substituted with one or more substituents selected from halogen and C3- C6 carbon cycle, is selected In some cases, Y-R2de

[00218] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from heterocycle, L-heterocycle, wherein the heterocycle and the heterocyclic part of -L-heterocycle are each optionally substituted with one or more R6; -L-aryl and -L-heteroaryl, wherein the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally substituted with one or more Petition 870250100147, dated 10 / 31 / 2025, p. 178 / 437 173 / 431 R7; and -LN(R20)2. In some cases, the heterocycle of R2 is selected from , where the heterocycle of R2 is optionally replaced with one or more R6; where the aryl and heteroaryl of R2 is selected from where the aril and heteroaryl are each optionally replaced with one or more R7; and In some cases, the heterocycle of R2 is selected from , where the heterocycle is optionally replaced with one or more R6; where the aryl and heteroaryl of R2 is selected from , where the aryl and heteroaryl are each optionally replaced with one or more R7; and In some cases, each R6 is independently selected from halogen, hydroxyl, Q-C3 alkyl, Q-C3 haloalkyl, -N(R5)S(O)2(R5), OC(O)N(R5)2, =CH2, oxo, =NO-C1-C3 alkyl, -CH2OC(O)heterocycle, -CH2heterocycle, CH2OC(O)N(R5)2 and -O-Cl-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl; and where each R7 is selected from Cl-C3 alkyl, halogen and Cl-C3 haloalkyl. In some cases, the heterocycle Petition 870250100147, dated 10 / 31 / 2025, p. 179 / 437 174 / 431 of R2, the aryl and heteroaryl of R2 and -N(R20)2 of R2 is selected from In some In these cases, Y-R2 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 180 / 437 175 / 431 and ° °, where the heterocycle and the heterocyclic part of the -L-heterocycle are each optionally replaced with one or more R6; HNN, where the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally replaced with one or more R7; and In some cases, Y-R2 is selected from Petition 870250100147, dated 10 / 31 / 2025, p. 181 / 437 176 / 431 Petition 870250100147, dated 10 / 31 / 2025, p. 182 / 437 177 / 431 In some cases, Y-R2 is selected. F and F

[00219] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of hydroxy, Cl-C4 hydroxyalkyl, and Cl-C4 alkyl. In some cases, L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected substituents of Cl-C4 alkyl. In some cases, L is selected from C1-C4 alkylene. In some cases, L is selected from C1-C2 alkylene. In some cases, L is . In some cases, L is .

[00220] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula Petition 870250100147, dated 10 / 31 / 2025, p. 183 / 437 178 / 431 (IG), Formula (IH), Formula (II), or Formula (IJ), each L is independently selected from an optionally substituted Cl-C4 alkylene; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle, where the C3-C6 carbocycle is optionally substituted with one or more substituents selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl. In some cases, the optional substituents of L are selected from Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3-C6 carbocycle and 3- to 8-membered heterocycle are optionally substituted with one or more substituents selected from halogen and C1-6 haloalkyl.

[00221] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each L is independently selected from a substituted Cl-C4 alkylene, where two substituents on the same carbon atom of L join to form a C3-C6 carbocycle. In some cases, the C3-C6 carbocycle is optionally substituted with one or more substituents selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl.

[00222] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each L is independently selected from a substituted Cl-C4 alkylene and two substituents on the same carbon atom of L join to form a C3-C6 carbocycle. In some cases, each L is independently selected from a substituted C3 alkylene and where two substituents on the same carbon atom of L join to form the C3 carbocycle. In some cases, each L is independently selected from .

[00223] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from -L-heterocycle, where the heterocyclic part of -L-heterocycle is optionally replaced with one or more R6. In some cases, the heterocycle is a saturated heterocycle. In some cases, the heterocycle contains at least one nitrogen atom and at least one atom of Petition 870250100147, dated 10 / 31 / 2025, p. 184 / 437 179 / 431 sulfur. In some cases, the heterocycle contains at least one nitrogen atom. In some cases, the heterocycle contains at least one sulfur atom.

[00224] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), R2 is selected from , HN-- / and '—' , where the heterocyclic part is optionally replaced with one or more R6.

[00225] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from where the heterocyclic part is optionally replaced with one or more R6.

[00226] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from , where the heterocyclic part is optionally replaced with one or more R6.

[00227] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from more R6. , where the heterocyclic part is optionally replaced with an or

[00228] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula Petition 870250100147, dated 10 / 31 / 2025, p. 185 / 437 180 / 431 (IG), Formula (IH), Formula (II), or Formula (IJ), R2 is selected from saturated -L-heterocycle, where the saturated heterocyclic part of saturated -L-heterocycle is optionally replaced with one or more R6 and contains a nitrogen atom and a sulfur atom. In some cases, Y-R2 is selected from , where the heterocyclic part is optionally replaced with one or more R6. In some zO —\ cases, Y-R2 is selected from HNS,7O HN < / HN-ese S , onde a parte heterocíclica é opcionalmente substituída com um ou mais substituintes selecionados de C1-C3 alkyl and oxo. In some cases, Y-R2 is selected from 0 In some cases, Y-R2 is selected from

[00229] Algumas made, for a compound or from Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each R6 is independently selected from halogênio, -OH, Cl-C3 hidroxialquil, Cl-C3 alquil, Cl-C3 haloalquil, C1-C3 alkoxy, -CN, Cl-C3 aminoalquil, -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, NHC(O)phenylSO2F, pyrazolyl substitute com C1-C3 alcohol, -N(R5)2, (C1-C3 alcohol)Cl-C3 alcohol-, (C1-C3 alcohol)C(=O), oxo, (C1-C3 haloalcohol)C(=O)-, -SO2F, (C1-C3 alcohol)Cl-C3 alcohol, -CH2OC(O)N(R5)2, -CH2NHC(O)OC1-C6 alcohol, -CH2NHC(O)N(R5)2, CH2NHC(O)C1-C6 alcohol, -CH2(pyrazolyl), -CH2NHSO2C1-C6 alcohol, CH2OC(O)heterocycle, -OC(O)N(R5)2, -OC(O)NH(C1-C3 alcohol)O(Cl-C3 alcohol), OC(O)NH(C1-C3 alquil)O(Cl-C3 alquil)phenyl(C1-C3 alquil)N(CH3)2, -OC(O)NH(C1-C3 alquil)O(Cl-C3 alquil)phenyl, -OC(O)heterocycle and -CH2heterocycle,where the phenyl groups of NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(C1-C3 alkyl)phenyl are each optionally substituted with -C(O)H and OH, and where the heterocycle of -CH2heterocyclyl is optionally substituted with oxo. Petition 870250100147, dated 10 / 31 / 2025, p. 186 / 437 181 / 431

[00230] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each R6 is independently selected from halogen, -OH, Cl-C3 hydroxyalkyl, G-C3 alkyl, G-C3 haloalkyl, C1-C3 alkoxy, -CN, and Cl-C3 aminoalkyl.

[00231] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), each R6 is independently selected from halogen, -OH, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 aminoalkyl, ClC3 haloalkyl, C1-C3 alkoxy, -N(R5)2, and oxo. In some cases, each R6 is independently selected from -OH, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 aminoalkyl, C1-C3 alkoxy, and N(R5)2. In some cases, each R6 is independently selected from Cl-C3 alkyl, C1C3 alkoxy, and -N(R5)2.In some cases, each R6 is independently selected from halogen, hydroxyl, Cl-C3 alkyl, Cl-C3 haloalkyl, -N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-C1-C3 alkyl, -CH2OC(O)heterocycle, -CH2heterocycle, -CH2OC(O)N(R5)2 and -OCl-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl; and where each R7 is selected from Cl-C3 alkyl, halogen and Cl-C3 haloalkyl.

[00232] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R6 is selected from halogen, OH, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, C1-C3 alkoxy, -CN, and Cl-C3 aminoalkyl. In some cases, R6 is selected from halogen and Cl-C3 alkyl. In some cases, R6 is halogen. In some cases, R6 is Cl-C3 alkyl. In some cases, R6 is selected from halogen and Cl-C3 alkyl. In some cases, R6 is selected from methyl and fluorine.

[00233] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), R2 is selected from / N, Petition 870250100147, dated 10 / 31 / 2025, p. 187 / 437 182 / 431

[00234] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), Y-R2 is selected from

[00235] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), Y-R2 is selected from

[00236] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), Y-R2 is

[00237] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), L is selected from unsubstituted C1-C4 alkylene.

[00238] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), Y-R2 is selected from , where the heterocyclic part is optionally replaced with one or more R6.

[00239] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R6 and R2 are independently selected in each occurrence of halogen, hydroxy, G-C3 hydroxyalkyl, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, cyano and C1-C3 aminoalkyl. Petition 870250100147, dated 10 / 31 / 2025, pp. 188 / 437 183 / 431

[00240] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or Formula (IJ), R6 of R2 is independently selected in each occurrence of C1-C3 alkyl and halogen.

[00241] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), or (IJ), Y-R2 is selected from and

[00242] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (IG), the heterocycle of R1 is substituted with at least one halogen. In some cases, the heterocycle of R1 is substituted with at least one substituent selected from -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, S(O)R20(=NR20), -C(O)N(R20)2 and -C(O)NHOR20. In some cases, the heterocycle of R1 is substituted with at least one C1-6 alkyl-N(R20)2.

[00243] In some embodiments, Formula (I) is represented by Formula (IC*).

[00244] In one aspect, the present disclosure provides a compound of Formula (IC*): Formula (IC*), or a pharmaceutically acceptable salt thereof where: R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11e where optionally two R11e on the same atom of R1A join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; Petition 870250100147, dated 10 / 31 / 2025, p. 189 / 437 184 / 431 R1bé selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, 4- to 6-membered heterocycle, wherein the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle, where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(=NR20)N(R20)2, C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =o, =N(R20), =NO(R20), -CN, -NHCN, Ci-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where the C3-C12 carbocycle and heterocycle of 5 to 12 members are each optionally independently replaced with one or more R1 *; each R1* is independently halogen selected, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20S), -S(O)R20(=NR20S), -) C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)(CRO20),(20)R20, -OC -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, Ci-6 alkyl-N(R20)2, Ci-6 aminoalkyl, Ci-6 alkoxy, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, C-6-halo alkenyl, C26 alkynyl and C3–C12 carbocycle; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Ci-C6 haloalkyl, L-NR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OCi-Có alkyl, wherein the heterocycle, the heterocyclic part of -L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6e where the aryl part of -LNR20C(O)-aryl, the -L-aryl aril and -L-heteroaryl heteroaryl are each optionally replaced with one or more R7s; Each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected halogen, hydroxyl, substituents. Petition 870250100147, dated 10 / 31 / 2025, p. 190 / 437 185 / 431 C1-6 alkoxy, C1-C4 hydroxyalkyl, C1-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R2O)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; Each R5 is independently selected from hydrogen and C1-C6 alkyl; each R6é independently selected from halogen, hydroxy, Cl-C3 hydroxyalkyl, ClC3 alkyl, oxo, G-C3 haloalkyl, G-C3 alkyl-N3, C1-C3 alkoxy, cyano, =CH2, =NO-ClC3 alkyl, Cl-C3, amino alkyl (O -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, -NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, tert-butyldimethylsilyloxyCH2-, N(R5)2, (C1-C3 alkoxy)Cl-C3 alkyl-, (C1-C3), (Cl-C3), o(O) (C1-C3 haloalkyl)C(=O)-, -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, -CH2OC(O)NCF3(R5), -CH2OCl-C6 alkyl,-CH2OC(O)N(R5)2, -CH2NHC(O)OC1-C6 alkyl, -CH CH2NHC(O)C1-C6 alkyl, -CH2(pyrazolyl), -CH2NHSO2C1-C6 alkyl, CH2OC(O)heterocycle, -OC(O)N(R5)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl), alkyl)O(Cl-C3 alkyl)phenyl(C1-C3 alkyl)N(CH3)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl)phenyl, -OC(O)heterocycle, -O-Cl-C3 alkyl, -O-Cl-C6, C haloalkyl, C1-6 alkyl-N(R20)2, -SF5, -C1-C3 alkyl-N3, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20),-NR20S(O)2R20, -(CH2)o1S-heterocycle, -(CH2)o-1-O-heterocycle, -(CH2)o-1-O-phenyl and -CH2heterocycle, wherein the phenyl of -NHC(O)phenyl and -OC(O)NH(C1-C3 alkyl)(Cl-C3 alkyl)phenyl are optionally substituted with one or more substituents selected from -C(O)H and OH, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy; where the -CH2O-G-C6 alkyl group is optionally replaced with one or more selected halogen and C3-C6 carbocycle substituents; Petition 870250100147, dated 10 / 31 / 2025, p. 191 / 437 186 / 431 where the -CH2 heterocycle is optionally replaced with oxo; and where the phenyl group of -(CH2)0-1-O-phenyl is optionally replaced with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, SF5, C1-6 alkyl-OR20, -OR20; where the heterocycles of -(CH2)0-1-O-heterocycle and -(CH2)0-1-S-heterocycle are each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and OR20; each Q is selected from a connection and O; Each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C16 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and heterocycle 5 to 12 members; Each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo; Each R11 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, Petition 870250100147, dated 10 / 31 / 2025, p. 192 / 437 187 / 431 C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NR20(C=NH)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where The C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, N(R21)2, -SR21, -C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)(R21)2 and oxo; each R11ae independently selected halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)20, R20(R20) -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -OC(O)R20, -OC(O)N(R20)2, -OC(O)R20, -OC(O)N(R20)2, -OC(O)R20, -OC(O)N(O)20, -R20, -NO, =NO, N C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

[00245] In some embodiments, for a compound or salt of Formula (I) or Formula (IC*), R1a is selected from C1-3 alkyl, C3-C9 carbocycle and 4- to 8-membered heterocycle, each of which is optionally substituted with one or more R11e where optionally two R11e on the same R1A atom join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; Petition 870250100147, dated 10 / 31 / 2025, pp. 193 / 437 188 / 431 R1bé is selected from hydrogen, C1-3 alkyl, C3-C5 carbocycle, 4- to 6-membered heterocycle, wherein the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally replaced with one or more R10; or R1 and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 9-membered heterocycle, where the 5- to 9-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -N(R20)C(O)R20, -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C16 alkyl-N(R20)2, C16 aminoalkyl, C16 alkoxy, C16 hydroxyalkyl, C16 cyanoalkyl, C16 haloalkyl, C16 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C6 carbocycle and 5- to 7-membered heterocycle, where C3-C6 carbocycle and 5- to 7-membered heterocycle are each optionally replaced independently with one or more R1*;each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -C(O)N(R20)2, C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-C6 carbocycle; B is selected from a 7- to 9-membered heterocycle, wherein the 7- to 9-membered heterocycle is optionally substituted with one or more substituents independently selected from -CN, -NH2 and C1-6 alkyl; Y is -O-; R2 is selected from -L-heterocycle and -LN(CH3)2, where the heterocyclic part of -L-heterocycle is optionally replaced with one or more R6; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected Cl-C4 alkyl substituents; and where optionally two substituents on the same carbon atom of L join to form a C3-C4 carbocycle or 4-membered heterocycle, where the C3-C4 carbocycle and 4-membered heterocycle are each optionally substituted with one or more independently selected halogen substituents; each R6 is independently selected from halogen, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, oxo, Cl-C3 haloalkyl, =CH2, (C1-C3 alkoxy)Cl-C3 alkyl- and -CH2-O-heterocycle, Petition 870250100147, dated 10 / 31 / 2025, pp. 194 / 437 189 / 431 where the -CH2-O-heterocycle is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20; Each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C6 carbocycle and 5- to 7-membered heterocycle, where the carbocycle The C3-C6 and 5- to 7-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-5 alkyl, -C1-5 haloalkyl, -O-C1-5 alkyl, oxo; Each R11 is independently selected from halogen, -B(OR20)2, OR20, -SR20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -NO2, =O, =NO(R20) C3-C6 carbocycle and the 5- to 9-membered heterocycle are each optionally substituted with one or more independently selected substituents of halogen, -OH, -CN, -NO2, -N(R21)2, -SR21, -C(O)N(R21)2, C1-5 alkyl, -C1-5 haloalkyl, -O-C1-5 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)(R21)2 and oxo; each R11a is independently selected from halogen, -B(OR20)2, OR20, -SR20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl.

[00246] In some embodiments, for a compound or salt of Formula (I) or Formula (IC*), is represented by NH2,NH2 Petition 870250100147, dated 10 / 31 / 2025, pp. 195 / 437 190 / 431 Petition 870250100147, dated 10 / 31 / 2025, pp. 196 / 437 191 / 431 F F-\ ΓτΑ Z 7^ / S- , ( B / Ί —Z is represented by Z s. / fby —Z is represented by 'NZJ ( by is represented by NH2 F zQ selected from: '—' , Z, / ^O^rA. L / f\ZA / / N / Y ' Ο^ΑΝ \ ) Ao'-Z / y Z-^ 1 N—z / F ' / HN— / F In some cases5 Zn^ Z—Sn . In some cases5 Sn . In some cases5 Y-R2 is ^ / Cl=3 A / \ΓΎ / °xO > ^0 a / --7 A / NIZN NZ O \___ / 5 5 HO hnAJ n— / 5 5 HO . _F ΛζΟ\ AoV> HN— / / N— / 5 5 5 1 0 ο / ΧΧχ Ά n HN— / A 1 5 5 . In some cases5 Y-R2 is: Petition 870250100147, dated 10 / 31 / 2025, page 197 / 437 192 / 431 In some cases, Y-R2 is: In some cases, Y-R2 In some cases, Y-R2 is: In these cases, Y-R2 is: In some cases, Y-R2 is: In some In some cases, Y-R2 is: In some cases, Y-R2 In some cases, Y-R2 is: In some cases, Y-R2 is: In some cases, Y-R2 is: In some cases, Y-R2 is: In some cases, Y-R2 is: In some cases, Y-R2é: In some cases, Y-R2 is: In some cases, Y-R2é: In some cases, Y-R2 is: In some cases, Y-R2é: In some cases, Y-R2 is: In some cases, Petition 870250100147, dated 10 / 31 / 2025, pp. 198 / 437 193 / 431 is selected from Petition 870250100147, dated 10 / 31 / 2025, page 199 / 437 194 / 431 In some cases, In some cases, In some cases, HO It's .J™. In some Petition 870250100147, dated 10 / 31 / 2025, pp. 200 / 437 195 / 431 cases, cases, in some cases, OH / R1B N R1AN. In some cases, In some cases, Rw HO Oh. In some In some cases, In some cases, In some cases, In In some cases, rW In some cases, In some cases, In some cases, In some cases, In some cases, In some cases, Petition 870250100147, dated 10 / 31 / 2025, p. 201 / 437 196 / 431 Ct 1 R . In some cases, Ci r1a r1b ny I γ ™1— is -J-- rc N. Yx Y nh2 HO. / 1 N -J— . In some cases, F. Χϊχ R1 A R1B HO^ / \ ) 1 N cases, it is -L R1A ^R1b N . In some cases, —C is F\ / X Ύ1 I R4 -C . In some cases, « Cl R1A rib n IN wwL~ is -1— o N. γ^ nh2 1A R1B n γΥ ~~L~ is . In some cases, \ih2 R1AxR1b N . In some cases, C— is Cl Petition 870250100147, dated 10 / 31 / 2025, p. 202 / 437 197 / 431 In some ​In some cases, cases, . . In some cases, R1AxR1bN In some cases, s—N NH2 R1A / R1bN. In some cases, B In some cases, In some cases, In some cases, N II r1axr1b N In some cases, —J—· is —L- . In some cases, In some cases, It is —L. In some cases, In some cases, Petition 870250100147, dated 10 / 31 / 2025, page 203 / 437 198 / 431 In some cases, N In some cases, In some cases, In some cases, R1A in some cases, In some cases, N In some cases, p1 A p1 B NC N / I NC N In some cases, it is -L R1A / R1bN In some cases, --1- is In some cases, In some cases, In some cases, In some cases, In some cases, In some cases, In some cases, Petition 870250100147, dated 10 / 31 / 2025, page 204 / 437 199 / 431 In some cases, —it is -J-. In some cases, —I— is —I—. N |^1 A11 N h2n. X-, IN V In some cases, ~~1~~ is -J-.

[00247] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), where the compound is not a Michael acceptor.

[00248] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt does not include an electrophilic substituent.

[00249] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt does not include an electrophilic radical.

[00250] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt does not include an electrophilic radical.

[00251] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt does not form a covalent bond with any of the KRAS G12D mutants and / or other G12 mutants.

[00252] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt does not form a covalent bond with any of the KRAS G12D mutants and / or other G12 mutants. Petition 870250100147, dated 10 / 31 / 2025, pp. 205 / 437 200 / 431

[00253] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt is not a covalent modifier of KRAS G12D and / or other G12 mutants.

[00254] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt is a covalent modifier of KRAS G12D and / or other G12 mutants.

[00255] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt is capable of reacting with a cysteine.

[00256] In some embodiments, for a compound or salt of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), Formula (IG), Formula (IH), Formula (II), Formula (IJ), the compound or salt is not a covalent inhibitor for KRAS G12D and / or other G12 mutants.

[00257] Included in this disclosure are salts, particularly pharmaceutically acceptable salts, of the compounds described herein. The compounds of the present invention, which have sufficiently acidic, sufficiently basic, or both functional groups, can react with any of a number of inorganic bases and inorganic and organic acids to form a salt. Alternatively, compounds that are inherently charged, such as those with a quaternary nitrogen, can form a salt with an appropriate counter ion, for example, a halide such as bromide, chloride, or fluoride, particularly bromine.

[00258] Chemical entities containing carbon-carbon double bonds or carbon-nitrogen double bonds can exist in the Z- or E- form (or cis- or trans- form). In addition, some chemical entities can exist in various tautomeric forms. Unless otherwise specified, the compounds described here include all Z-, E-, and tautomeric forms.

[00259] A “tautomer” refers to a molecule where a proton exchange from one atom of a molecule to another atom of the same molecule is possible. The compounds presented here, in certain embodiments, exist as tautomers. Under circumstances where tautomerization is possible, there will be a chemical equilibrium of Petition 870250100147, dated 10 / 31 / 2025, pp. 206 / 437 201 / 431 tautomers. The exact ratio of tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include: H THE HH THE N THE OH NH2 NH N y:nNN H X- NςI'M N H HN NN* H N HN- OH NN

[00260] The compounds described herein, in some embodiments, are used in different enriched isotopic forms, for example, enriched in the content of 2H, 3H, nC, 13C and / or 14C. In one particular embodiment, the compound is deuterated in at least one position. Such deuterated forms can be obtained by the procedure described in US Patents 5,846,514 and 6,334,997. As described in US Patents 5,846,514 and 6,334,997, deuteration can increase metabolic stability and / or efficacy, thereby increasing the duration of action of drugs.

[00261] Unless otherwise indicated, the compounds described herein include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds exhibiting the present structures except for the substitution of a hydrogen by a deuterium or tritium or the substitution of a carbon by carbon enriched in 13C or 14C, are within the scope of this disclosure.

[00262] The compounds in this disclosure may optionally contain unnatural proportions of atomic isotopes in one or more atoms constituting such compounds. For example, compounds may be labeled with isotopes such as, for example, deuterium (2H), tritium (3H), iodine-125 (125I) or carbon-14 (14C). Isotopic substitutions with 2H, 11C, 13C, 14C, 15C, 12N, 13N, 15N, 16N, 16O, 17O, 14F, 15F, 16F, 17F, 18F, 33S, 34S, 35S, 36S, 35Cl, 37Cl, 79Br, 81Br and 125I are all contemplated. All isotopic variations Petition 870250100147, dated 10 / 31 / 2025, pp. 207 / 437 202 / 431 of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[00263] In certain embodiments, the compounds described herein have some or all of the 1H atoms substituted with 2H atoms. The synthesis methods for deuterium-containing compounds are well known in the art and include, by way of non-limiting example only, the following synthesis methods.

[00264] Deuterium-substituted compounds are synthesized using various methods such as those described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[00265] Deuterated starting materials are readily available and are subjected to the synthesis methods described herein in order to provide the synthesis of deuterium-containing compounds. Large numbers of deuterium-containing reagents and building blocks are commercially available from chemical suppliers such as Aldrich Chemical Co.

[00266] The compounds of the present invention also include crystalline and amorphous forms of these compounds, pharmaceutically acceptable salts and active metabolites of these compounds exhibiting the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrates), conformational polymorphs and amorphous forms of the compounds, as well as mixtures thereof.

[00267] The compounds described herein may, in some cases, exist as diastereomers, enantiomers or other stereoisomeric forms. Where the absolute stoichiometry is not specified, the compounds presented herein include all diastereomeric, enantiomeric and epimeric forms, as well as appropriate mixtures thereof. The separation of the stereoisomers may be carried out by chromatography or by the formation of diastereomers and separation by recrystallization or chromatography, or any combination thereof. (Jean Jacques, Andre Collet, Samuel H.)Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley and Sons, Inc., 1981, incorporated here by reference for dissemination purposes). Stereoisomers can also be obtained by stereoselective synthesis. Petition 870250100147, dated 10 / 31 / 2025, pp. 208 / 437 203 / 431

[00268] The methods and compositions described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs). The compounds described herein may be in the form of pharmaceutically acceptable salts. As well as, in some embodiments, active metabolites of these compounds exhibiting the same type of activity are included within the scope of this disclosure. In addition, the compounds described herein may exist in non-solvated forms as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. The solvated forms of the compounds presented herein are also considered to be described herein.

[00269] In certain embodiments, compounds or salts of compounds may be prodrugs, for example, where a hydroxyl group in the parent compound is present as an ester or a carbonate or carboxylic acid present in the parent compound is presented as an ester. The term “prodrug” encompasses compounds that, under physiological conditions, are converted into pharmaceutical agents of the present disclosure. One method for obtaining a prodrug involves one or more selected radicals which are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal such as specific target cells in the host animal. For example, esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids and esters of phosphoric acids) are preferred prodrugs of this disclosure.

[00270] The prodrug forms of the compounds described herein, where the prodrug is metabolized in vivo to produce a compound as presented herein, are included within the scope of the claims. In some cases, some of the compounds described herein may be a prodrug for another derivative or active compound.

[00271] Prodrugs are frequently used because, in some situations, they can be more easily administered than the parent drug. For example, they may be bioavailable by oral administration while the parent drug is not. Prodrugs can help increase the cellular permeability of a compound compared to the parent drug. The prodrug may also exhibit greater solubility in pharmaceutical compositions compared to the parent drug. Prodrugs can be designed as reversible drug derivatives, for use as modifiers in order to increase drug transport to specific tissues or to increase drug resistance within a cell. Petition 870250100147, dated 10 / 31 / 2025, pp. 209 / 437 204 / 431

[00272] In some embodiments, the design of a prodrug increases the lipophilicity of the pharmaceutical agent. In some embodiments, the design of a prodrug increases the effective solubility in water. See, for example, Fedorak et al., Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol, 106: 405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J. Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988); Sinkula et al., J. Pharm. Sci., 64:181-210 (1975); T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series; and Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, all incorporated herein for this disclosure). According to another embodiment, the present disclosure provides methods for producing the compounds defined above.The compounds can be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials.

[00273] Transformations and synthetic chemistry methodologies useful in the synthesis of the compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 2nd ed. (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995). Pharmaceutical Formulations

[00274] Compositions comprising a therapeutically effective amount of any compound or salt of any of the Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (IC*), Formula (ID), Formula (IE), Formula (IF), or Formula (IG) (also referred to herein as “a pharmaceutical agent”) are provided herein in certain embodiments.

[00275] Pharmaceutical compositions may be formulated using one or more physiologically acceptable vehicles, including excipients and auxiliaries, which facilitate the processing of the pharmaceutical agent into preparations that are used pharmaceutically. An appropriate formulation is dependent on the chosen route of administration. A summary of pharmaceutical compositions is found, for example, in Remington: The Science and Practice of Pharmacy, 19th Ed. (Easton, Pa., Mack Publishing Company, 1995); Hoover, John E., Remington, Mack Pharmaceutical Sciences Petição 870250100147, de 31 / 10 / 2025, pág. 210 / 437 205 / 431 Publishing Co., Easton, Pennsilvania 1975; Liberman, H.A. e Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; e Pharmaceutical Dosage Forms and Drug Delivery Systems, 17aEd. (Lippincott Williams & Wilkins, 1999).

[00276] The compositions and methods of the present disclosure can be used to treat an individual in need of such treatment. In certain embodiments, the individual is a mammal such as a human or a non-human mammal. When administered to an animal, such as a human, the composition or pharmaceutical agent is preferably administered as a pharmaceutical composition comprising, for example, a pharmaceutical agent and a pharmaceutically acceptable vehicle or excipient. Pharmaceutically acceptable vehicles are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline solution or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters.In a preferred embodiment, when such pharmaceutical compositions are for administration in humans, particularly by invasive routes of administration, for example, routes such as injection or implant, which bypass transport or diffusion across an epithelial barrier, the aqueous solution is pyrogen-free or substantially pyrogen-free. Excipients may be chosen, for example, to effect a delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition may be in unit dosage form such as a tablet, capsule, granule, lyophilized powder for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition may also be present in a transdermal application system, for example, a dermal patch. The composition may also be present in a solution suitable for topical administration such as eye drops.

[00277] A pharmaceutically acceptable excipient may contain physiologically acceptable agents that act, for example, to stabilize, increase the solubility, or enhance the absorption of a compound such as a pharmaceutical agent. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose, or dextrans; antioxidants such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins; or other stabilizers or excipients. The choice of a pharmaceutically acceptable excipient, including a physiologically acceptable agent, depends, for example, on the route of administration. Petition 870250100147, dated 10 / 31 / 2025, page 211 / 437 206 / 431 Administration of the composition. The pharmaceutical preparation or composition may be a self-emulsifying drug delivery system or a micro-emulsifying drug delivery system. The pharmaceutical composition (preparation) may also be a liposome or other polymeric matrix, which may incorporate, for example, a compound of the invention. Liposomes, for example, which comprise phospholipids or other lipids, are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively simple to obtain and administer.

[00278] A pharmaceutical composition (preparation) may be administered to an individual by any of a number of routes of administration including, for example, oral, for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules, including sprinkle-type capsules and gelatin capsules, boluses, powders, granules, pastes for application to the tongue; absorption through the oral mucosa, for example, sublingual; anal, rectal or vaginal, for example, as a pessary, cream or foam; parenteral, including intramuscular, intravenous, subcutaneous or intrathecal as, for example, a sterile solution or suspension; nasal; intraperitoneal; subcutaneous; transdermal, for example, as a patch applied to the skin; and topical, for example, as a cream, ointment or spray applied to the skin, or as an eye drop. The compound may be formulated for inhalation. In certain embodiments, a compound may simply be dissolved or suspended in sterile water.

[00279] A pharmaceutical composition may be a sterile aqueous or non-aqueous solution, suspension or sterile emulsion, for example, a microemulsion. The excipients described herein are examples and by no means limiting. An effective amount or therapeutically effective quantity refers to an amount of one or more pharmaceutical agents administered to an individual, either as a single dose or as part of a series of doses, that is effective in producing a desired therapeutic effect.

[00280] Individuals can be generically monitored for therapeutic effectiveness using assays and methods appropriate to the condition being treated, assays which are familiar to those skilled in the art and are described herein. The pharmacokinetics of a pharmaceutical agent or one or more metabolites thereof, administered to an individual, can be monitored by determining the level of the pharmaceutical agent or metabolite in a biological fluid, for example, in blood, blood fraction, for example, serum and / or urine and / or other biological sample or biological tissue of the individual. Any method practiced in the art and described herein for detecting the agent Petition 870250100147, dated 10 / 31 / 2025, p. 212 / 437 207 / 431 can be used to measure the level of the pharmaceutical agent or metabolite during the course of treatment.

[00281] The dose of a pharmaceutical agent described herein for the treatment of a disease or disorder may depend on the individual's condition, i.e., stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, weight, and other factors apparent to a medical professional. Pharmaceutical compositions may be administered in a manner appropriate to the disease being treated as determined by a medical professional. In addition to the factors described herein and related above for the use of the pharmaceutical agent for the treatment of a disease or disorder, the appropriate duration and frequency of administration of the pharmaceutical agent may also be determined or adjusted by such factors as the patient's condition, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.The ideal doses of an agent can generally be determined using experimental models and / or clinical trials. The ideal dose may depend on the individual's body mass, weight, or blood volume. Using the minimum dose sufficient to provide effective therapy is usually preferred. The design and execution of preclinical and clinical studies for a pharmaceutical agent, including when administered for prophylaxis, described herein are within the competence of a person skilled in the relevant art. When two or more pharmaceutical agents are administered for the treatment of a disease or disorder, the ideal dose of each pharmaceutical agent may be different, such as less than when any agent is administered separately as a single-agent therapy. In certain particular embodiments, two pharmaceutical agents in combination may act synergistically or additively, and each agent may be used in a smaller amount than if administered separately.The amount of a pharmaceutical agent that can be administered per day may be, for example, between about 0.01 mg / kg and 100 mg / kg, or between about 0.1 and 1 mg / kg, between about 1 and 10 mg / kg, between about 10-50 mg / kg, or between about 50-100 mg / kg of body weight. In other embodiments, the amount of a pharmaceutical agent that can be administered per day is between about 0.01 mg / kg and 1000 mg / kg, between about 100-500 mg / kg, or between about 500-1000 mg / kg of body weight. The ideal dose per day or over the course of treatment may differ for the disease or disorder being treated and may also vary with the route of administration and therapeutic regimen. Petition 870250100147, dated 10 / 31 / 2025, page 213 / 437 208 / 431

[00282] Pharmaceutical compositions comprising a pharmaceutical agent may be formulated in a manner appropriate for the method of application by using techniques routinely practiced in the technical field. The composition may be in the form of a solid, for example, tablet, capsule, semi-solid, for example, gel, liquid or gas, for example, aerosol. In other embodiments, the pharmaceutical composition is administered as a bolus infusion.

[00283] Pharmaceutically acceptable excipients are well known in the pharmaceutical art and described, for example, in Rowe et al., Handbook of Pharmaceutical Excipients: A Comprehensive Guide to Uses, Properties and Safety, 5th Ed., 2006 and in Remington: The Science and Practice of Pharmacy (Gennaro, 2U Ed. Mack Pub. Co., Easton, PA (2005)). Exemplary pharmaceutically acceptable excipients include sterile saline solution and phosphate-buffered saline solution at physiological pH. Preservatives, stabilizers, colorants, buffers and the like may be provided in the pharmaceutical composition. In addition, antioxidants and suspending agents may be used. In general, the type of excipient is selected based on the route of administration as well as the chemical composition of the active ingredient(s). Alternatively, the compositions described herein may be formulated as a lyophilized powder.A composition described herein may be lyophilized or otherwise formulated as a lyophilized product by using one or more excipient solutions suitable for solubilizing and / or diluting the pharmaceutical agent(s) of the composition for administration. In other embodiments, the pharmaceutical agent may be encapsulated within liposomes by using technology known and practiced in the art. In certain particular embodiments, a pharmaceutical agent is not formulated within liposomes for application to a stent that is used for the treatment of highly, though not totally, occluded arteries. Pharmaceutical compositions may be formulated for any method of administration described herein and in the art.

[00284] A pharmaceutical composition, for example, for oral administration or for injection, infusion, subcutaneous application, intramuscular application, intraperitoneal application or other method, may be in the form of a liquid.A liquid pharmaceutical composition may include, for example, one or more of the following: a sterile diluent such as water, saline solution, preferably physiological saline solution, Aneler's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspension medium, polyethylene glycols, glycerin, propylene glycol or other solvents; agents. Petition 870250100147, dated 10 / 31 / 2025, pp. 214 / 437 209 / 431 antibacterials; antioxidants; chelating agents; buffers and tonicity adjusting agents such as sodium chloride or dextrose. A parenteral composition may be contained in ampoules, disposable syringes or multi-dose vials made of glass or plastic. The use of physiological saline solution is preferred and an injectable pharmaceutical composition is preferably sterile. In another embodiment, for the treatment of an ophthalmic condition or disease, a liquid pharmaceutical composition may be applied to the eye in the form of eye drops. A liquid pharmaceutical composition may be administered orally.

[00285] For oral formulations, at least one of the pharmaceutical agents described herein may be used separately or in combination with appropriate additives to make tablets, powders, granules or capsules and, if desired, with diluents, buffering agents, humectants, preservatives, coloring agents and flavoring agents. The pharmaceutical agents may be formulated with a buffering agent to provide protection of the co...

Claims

CLAIMS 1. Compound characterized by having Formula (I): Formula (I), or a pharmaceutically acceptable salt thereof wherein: piB R1A R1C r1D no' sx R100 is selected from , and ; R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4 to 12 membered heterocycle, each of which is optionally substituted with one or more R11 and wherein optionally two R11 on the same atom of R1A join to form a C3-C6 carbocycle or 3 to 8 membered heterocycle, wherein the C3-C6 carbocycle and the 3 to 8 membered heterocycle are each optionally substituted with one or more R11A; R1b is selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, 4- to 6-membered heterocycle, where the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally substituted with one or more R10; or R1a and R1b join with the atom to which they are attached to form R1, where R1 is a 5- to 15-membered heterocycle.where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(=NR20)N(R20)2, C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =o, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally independently substituted with one or more R1 *; Petition 870250082397, dated 12 / 09 / 2025, p. 11 / 141 2 / 119 each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2,-S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6hydroxyalkyl, C1-6 cyanoalkyl, C1-6haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl and C3-C12 carbocycle; R1C is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R12 and where optionally two R12 on the same atom of R1C join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and the 3- to 8-membered heterocycle are each optionally substituted with one or more R12A; R1d is selected from hydrogen, C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle,each of which is optionally replaced with one or more R13 and where optionally two R13 on the same R1D atom join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally replaced with one or more R13A; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Cl-C6 haloalkyl, L-NR20C(O)-aryl, -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OCl-C6 alkyl, wherein the heterocycle, the heterocyclic part of -L-heterocycle and the cycloalkyl part of -L-cycloalkyl are each optionally substituted with one or more R6 is where the aryl part of -L-NR20C(O)aryl,The aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally substituted with one or more R7; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more substituents independently selected from halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or heterocycle of 3 to 8 members,where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl; each R4 is independently selected from halogen, -NO2, -NH2, -NH(C1-6 alkyl), N(C1-6 alkyl)2, =O, =S, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl; n is selected from 0, 1, 2, 3 and 4; m is selected from 1 and 2; each R5 is independently selected from hydrogen and C1-C6 alkyl; each R6 is independently selected from halogen, hydroxy, Cl-C3 hydroxyalkyl, ClC3 alkyl, oxo, Cl-C3 haloalkyl, C1-C3 alkoxy, cyano, =CH2, =NO-Ci-C3 alkyl, Cl-C3 aminoalkyl, -N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, tert-butyldimethylsilyloxyCH2-, N(R5)2, (C1-C3 alkoxy)Cl-C3 alkyl-,(C1-C3 alkyl)C(=O), oxo, (C1-C3 haloalkyl)C(=O)-, -SO2F, (C1-C3 alkoxy)Cl-C3 alkoxy, -CH2OC(O)NCF3(R5), -CH -CH2NHC(O)N(R5)2, CH2NHC(O)C1-C6 alkyl, -CH2(pyrazol), -CH2NHSO2C1-C6 alkyl, CH2OC(O)heterocycle, -OC(O)N(R5)2, -OC(O)NH(C1-C3 alkyl-Cl), OC(O)NH(Ci-C3 alkyl)O(Cl-C3 alkyl)phenyl(C1-C3 alkyl)N(CH3)2, -OC(O)NH(Ci-C3 alkyl)O(Cl-C3 alkyl)phenyl, -OC(O)heterocycle, -O-Cl-C3, alkyl-CO C1-C3 alkyl-O-Cl-C6 haloalkyl, C1-6 alkyl-N(R20)2, -SF5, -C1-C3 alkyl-N3, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)2N(R20)2, -S(O)R20, -(O -(CH2)o1S-heterocycle, -(CH2)o-1-O-heterocycle, -(CH2)o-1-O-phenyl and -CH2heterocycle, where the phenyl of -NHC(O)phenyl and -OC(O)NH(Ci-C3 alkyl)(Cl-C3 alkyl) are commonly substituted or commonly substituted selected -C(O)H and OH, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with selected heterocycle substituents,oxo and hydroxy; wherein the alkyl of -CH2O-G-C6 alkyl is optionally substituted with one or more substituents selected from halogen and C3-C6 carbocycle; wherein the heterocycle of -CH2heterocycle is optionally substituted with oxo; Petition 870250082397, dated 12 / 09 / 2025, p. 13 / 141 4 / 119 wherein the phenyl of -(CH2)oiO-phenyl is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, SF5, C1-6 alkyl-OR20, -OR20; and where the heterocycles of -(CH2)0-1-O-heterocycle and -(CH2)0-1-S-heterocycle are each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and OR20; each Q is selected from a connection and O; each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; R8 is selected from a 5- to 12-membered heterocycle,wherein the 5- to 12-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -OR20, -SR20, S(O)2(R20) -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)N(R20) -OC(O)R20, -OC(O)N(R20)2, -C(O)NR20-OR20, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyano, alkyl alkyl, C1-6, halo C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; R9 is selected from hydrogen, halogen, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 alkylN(R20)2, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyano, Cyl-Cyl, halo alkyl, C2-6 alkenyl, C2-6 alkynyl and Ca-Co carbocycle, wherein the Ca-Co carbocycle is optionally substituted with one or more halides, -CN, -NO2, N(R20)2, -OR20, -SR20, C1-6 alkyl-N,(R20)2C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; or R8 and R9 combine with the atoms to which they are attached to form B, where B is selected from a 7- to 15-membered heterocycle and C7-C15 carbocycle, where the 7- to 15-membered heterocycle and the C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, Petition 870250082397, of 12 / 09 / 2025, p. 14 / 141 5 / 119 OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C16 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,C3-C12 5- to 12-membered carbocycle and heterocycle; each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-O alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo; Each R11, R12, and R13 is independently selected from halogen, -B(OR20)2, -OR20, SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20),-NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -ROO(20) -OC(O)N(R20)2, -NR20(C=NH)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyl, C1-6, alkyl halo, C1-6 C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and heterocycle of 5 to 12 members, wherein the C3-C12 carbocycle and heterocycle of 5 to 12 members are each optionally substituted with one or more selected substituents, independently of -OH, -CN, -NO2, N(R21)2, -SR21, -C(O)N(R21)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)(OR21)2, and -OP(O)2; each R11a, R12a and R13A is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR2020), -NR20(20) C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20,-OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; each R20 is selected independently of hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and heterocycle of 3 to 12 members, each of which is optionally substituted with one or more substituents independently. Petition 870250082397, dated 12 / 09 / 2025, p. 15 / 141 6 / 119 selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and heterocycle of 3 to 12 members; and each R21 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and heterocycle of 3 to 12 members, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6 alkyl)2,C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

2. Compound or salt according to claim 1, characterized in that R1^ „R1B _R1C NO R100 is selected from —I— and -J·— .

3. Compound or salt according to claim 1, characterized in that R1^ R1B N R100 is -L .

4. Compound or salt according to any one of claims 1 to 3, characterized in that Formula (I) is represented by R1^ / R1B N N'^N xX ^R2 NY R8 4 (R )n Formula (IA), or a pharmaceutically acceptable salt thereof.

5. Compound or salt according to any one of claims 1 to 3, characterized in that Formula (I) is represented by R1^ ^R1B N N'^N ^R2 / NNY R9 πθ (R4)n π' 1 ζτ üá R Formula (IB), or a pharmaceutically acceptable salt thereof. Petition 870250082397, dated 12 / 09 / 2025, p. 16 / 141 7 / 119 6. Compound or salt according to any one of claims 1 to 3, characterized in that Formula (I) is represented by Formula (IC), or a pharmaceutically acceptable salt thereof.

7. Compound or salt according to claim 1 to 6, characterized in that each R9 is selected from hydrogen, halogen, -CN, -N(R20)2, -OR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C3-C6cycloalkyl, wherein the C3-C6cycloalkyl is optionally substituted with one or more halogens, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C16 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.

8. Compound or salt according to claim 7, characterized in that each R9 is selected from hydrogen, -CN, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C3-C6 cycloalkyl, wherein the C3-C6 cycloalkyl is optionally substituted with one or more halogens, -CN, -NO2, -N(R20)2, -OR20, -SR20, C1-6 aminoalkyl, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.

9. Compound or salt according to claim 8, characterized in that each R9 is selected from hydrogen, halogen, C1-6 alkyl and C3-C6 cycloalkyl.

10. Compound or salt according to claim 9, characterized in that each R9 is selected from hydrogen, fluorine, methyl and cyclopropyl.

11. Compound or salt according to any one of claims 1 to 10, characterized in that R8 is selected from an optionally substituted 5- to 6-membered heteroaryl.

12. Compound or salt according to any one of claims 1 to 11, characterized in that R8 is selected from an optionally substituted 5-membered heteroaryl. Petition 870250082397, dated 12 / 09 / 2025, p. 17 / 141 8 / 119 13. Compound or salt according to any one of claims 1 to 12, characterized in that the heteroaryl of R8 has at least one sulfur atom.

14. Compound or salt according to any one of claims 1 to 10, characterized in that the heteroaryl of R8 is , which is optionally substituted.

15. Compound or salt according to any one of claims 1 to 14, characterized in that one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN.

16. Compound or salt according to any one of claims 1 to 15, -CF3 NC characterized in that R8 is selected from H2N I NC—I s R^s h2n ,CHF2 NC—| R^S NC—| R^S NC—IR^S NC—| R^S h2n h2n h2n h2n 17. Compound or salt according to any one of claims 1 to 10, characterized in that R8 is selected from a 6 to 9 membered heteroaryl optionally substituted.

18. Compound or salt according to claim 17, characterized in that R8 is selected from , and , each of which is optionally substituted.

19. Compound or salt according to claims 17 or 18, characterized in that one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN.

20. Compound or salt according to any one of claims 17 to 19, characterized in that one or more optional substituents of R8 are independently selected from halogen, C2-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN. Petition 870250082397, dated 12 / 09 / 2025, page 18 / 141 9 / 119 21. Compound or salt according to claim 20, characterized in that one or more optional substituents of R8 are independently selected from halogen, C1-6 haloalkyl, -N(R20)2 and -CN.

22. Compound or salt according to any one of claims 17 to 21, characterized in that R8 is selected from NH2, N Cl —s V^z—NH V^z—NH , and .

23. Compound or salt according to any one of claims 1 to 10, characterized in that R8 is selected from an optionally substituted 9-membered heteroaryl.

24. Compound or salt according to claim 23, characterized in that the heteroaryl group of R8 has at least one sulfur atom.

25. Compound or salt according to claims 23 or 24, characterized in that the heteroaryl group of R8 is bicyclic.

26. Compound or salt according to any one of claims 23 to 25, characterized in that R8 is ^^Z, which is optionally substituted.

27. Compound or salt according to claim 26, characterized in that one or more optional substituents of R8 are independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, -N(R20)2 and -CN.

28. Compound or salt according to any of claims 24 to 27, characterized in that R8 is Petition 870250082397, dated 12 / 09 / 2025, page 19 / 141 10 / 119 29. Compound or salt according to any one of claims 1 to 10, characterized in that R8 is selected from an optionally substituted 5- to 12-membered unsaturated heterocycle.

30. Compound or salt according to claim 29, characterized in that R8 is selected from an optionally substituted 9-membered unsaturated heterocycle.

31. Compound or salt according to any one of claims 29 to 30, characterized in that the heterocycle of R8 is a bicyclic heterocycle.

32. Compound or salt according to any one of claims 29 to 31, characterized in that the R8 heterocycle has at least one sulfur atom.

33. Compound or salt according to any one of claims 29 to 32, characterized in that the heterocycle of R8 is , which is optionally substituted.

34. Compound or salt according to claim 33, characterized in that one or more optional substituents of R8 are independently selected from halogens, -N(R20)2 and -CN.

35. Compound or salt according to claim 34, characterized by the fact that N / --NH2 that R8 is .

36. Compound or salt according to any one of claims 1 to 35, characterized in that B is selected from an optionally substituted 8- to 15-membered fused heterocycle and an optionally substituted C8-C15 fused carbocycle.

37. Compound or salt according to claims 1 or 36, characterized in that B is an optionally substituted fused heterocycle of 8 to 15 members, wherein B contains at least one heteroatom selected from nitrogen, sulfur, and selenium.

38. Compound or salt according to claims 1 or 36, characterized in that B is an optionally substituted cast C8-C15 carbocycle. Petition 870250082397, dated 12 / 09 / 2025, p. 20 / 141 11 / 119 39. Compound or salt according to any one of claims 36 to 38, characterized in that for B, the optionally substituted 8- to 15-membered fused heterocycle and the optionally substituted C8-C15 fused carbocycle are each independently bicyclic or tricyclic.

40. Compound or salt according to any one of claims 36 to 39, characterized in that the heterocycle or carbocycle of B is bicyclic.

41. Compound or salt according to any one of claims 36 to 39, characterized in that the heterocycle or carbocycle of B is tricyclic.

42. Compound or salt according to any one of claims 36 to 41, characterized in that for B, the optionally substituted 8- to 15-membered fused heterocycle and the optionally substituted C8-C15 fused carbocycle are selected from , and S·- / , each of which is optionally substituted with one or more substituents.

43. Compound or salt according to claim 42, characterized in that for B, the optionally substituted 8- to 15-membered fused heterocycle and the optionally substituted C8-C15 fused carbocycle are selected, each of which is optionally substituted with one or more substituents.

44. Compound or salt according to any one of claims 36 to 43, characterized in that for B, the one or more optional substituents of the heterocycle and carbocycle are each independently selected from oxo, -NH2, halogen and C1-C3 alkyl.

45. Compound or salt according to any one of claims 36 to 44, characterized in that for B, the optionally substituted 8- to 15-membered fused heterocycle and the optionally substituted C8-C15 fused carbocycle are selected from H0 NH2.

46. ​​Compound or salt according to any one of claims 1 to 3 or 6, characterized in that R8 and R9 combine with the atoms to which they are attached to form B.

47. Compound or salt according to claims 1, 6 or 46, characterized in that B contains at least one heteroatom selected from nitrogen, oxygen, sulfur and selenium.

48. Compound or salt according to claim 46 or 47, characterized in that B is selected from an optionally substituted 8- to 15-membered heterocycle and an optionally substituted C8-C15 carbocycle.

49. Compound or salt according to claim 46 or 47, characterized in that B is selected from an optionally substituted 8- to 15-membered fused heterocycle and an optionally substituted C8-C15 fused carbocycle.

50. Compound or salt according to claim 46 or 47, characterized in that B is an optionally substituted fused heterocycle of 8 to 15 members.

51. Compound or salt according to claim 46 or 47, characterized in that B is an optionally substituted unsaturated fused carbocycle C8-C15.

52. Compound or salt according to any one of claims 46 to 51, characterized in that for B, the heterocycle and carbocycle are each independently bicyclic or tricyclic.

53. Compound or salt according to claim 52, characterized in that for B, the heterocycle and carbocycle are each independently bicyclic.

54. Compound or salt according to claim 52, characterized in that for B, the heterocycle and carbocycle are each independently tricyclic. Petition 870250082397, dated 12 / 09 / 2025, p. 22 / 141 13 / 119 55. Compound or salt according to any of claims 46 to 54, characterized in that B is selected from , and substituents, each of which is optionally substituted with one or more 56. Compound or salt according to claim 55 characterized in that HN, each of which is optionally substituted with one or more substituents.

57. Compound or salt according to claim 56, characterized in that B is selected from HN, each of which is optionally substituted with one or more substituents.

58. Compound or salt according to any one of claims 46 to 57, characterized in that for B, one or more optional substituents are independently selected from oxo, -NH2, halogen, C1-C3 alkyl. Petition 870250082397, dated 12 / 09 / 2025, p. 23 / 141 14 / 119 59. Compound or salt according to claim 58, characterized in that B is selected from 60. Compound or salt according to any of claims 46 to 57, characterized in that for B, one or more optional substituents of the heterocycle and carbocycle are independently selected in each occurrence of halogen, C1-C3 alkyl, -B(OR20)2, -OR20, -C(O)N(R20)2, -N(R20)2, =O, -CN, -NHCN, C16 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

61. Compound or salt according to claim 59, characterized in that for B, one or more optional substituents of the heterocycle and carbocycle are independently selected in each occurrence of halogen, oxo, -NH2, C1-C3 alkyl, -B(OH)2, -OH, -O-Cl-C3 haloalkyl, -C(O)NH2, -NH2, =O, -CN, C1-6 alkoxy, C1-6 hydroxyalkyl and C2-6 alkynyl.

62. Compound or salt according to claims 60 or 61, characterized by the fact that B is selected from NH2, NH2, NH2, ^ / , Petition 870250082397, dated 12 / 09 / 2025, p. 24 / 141 15 / 119 O ™ρ H0 \ —ϊ 2 \ I ο / Χ~\—Iθ\ \ V \ AJ ι> / \ VJ \ #CN ΓΊ s \ ~?ν C=# HN—#= / e NH2 , , , e.

63. Compound or salt according to any one of claims 1 or 46 to 54, characterized in that B is an optionally substituted 7- to 12-membered fused heterocycle.

64. Compound or salt according to claims 1 or 63, characterized in that B is an optionally substituted 7- to 11-membered fused heterocycle.

65. Compound or salt according to claims 63 or 64, characterized in that B is an optionally substituted 8- to 10-membered fused heterocycle. Petition 870250082397, dated 12 / 09 / 2025, p. 25 / 141 16 / 119 66. Compound or salt according to claim 65, characterized in that B is an optionally substituted 8- to 9-membered fused heterocycle.

67. Compound or salt according to any one of claims 63 to 66, characterized in that the heterocycle is an unsaturated heterocycle.

68. Compound or salt according to any one of claims 63 to 67, characterized in that B has at least one sulfur atom.

69. Compound or salt according to any one of claims 63 to 68, characterized in that B has at least one sulfur atom and at least one nitrogen atom.

70. Compound or salt according to any one of claims 63 to 69, characterized in that B has at least one sulfur atom and at least one oxygen atom.

71. Compound or salt according to any one of claims 63 to 70, characterized in that B has two sulfur atoms.

72. Compound or salt according to any one of claims 63 to 71, characterized in that B is selected from which it is optionally substituted.

73. Compound or salt according to claim 72, characterized in that B is selected from optionally substituted. , each of which is Petition 870250082397, dated 12 / 09 / 2025, page 26 / 141 17 / 119 74. Compound or salt according to claim 73, characterized in that od Uv cv cv 7 V# V# NN that B is selected from s , s— , s—' , s~^ , s—' , s~^ and , each of which is optionally substituted.

75. Compound or salt according to any of claims 63 to 74, characterized in that one or more optional substituents of B are independently selected in each occurrence from halogen, oxo, -NH2, C1-C3 alkyl, -B(OH)2, -OH, -O-Cl-C3 haloalkyl, -C(O)NH2, -NH2, =O, -CN, C1-6 alkoxy, C1-6 hydroxyalkyl and C2-6 alkynyl.

76. Compound or salt according to claim 75, characterized in that one or more optional substituents of B are independently selected in each occurrence of halogen, C1-C3 alkyl, -NH2 and -CN.

77. Compound or salt according to any of claims 63 to 76, characterized in that B is selected from NH2, NH2, Petition 870250082397, dated 12 / 09 / 2025, p. 27 / 141 18 / 119 nh2 p nh2, and 78. Compound or salt according to any one of claims 46 to 54, characterized in that B is selected from an optionally substituted 7- to 12-membered fused heterocycle and C9-10 is optionally substituted fused carbocycle.

79. Compound or salt according to claim 78, characterized in that the heterocycle of B has at least one sulfur atom.

80. Compound or salt according to claim 78 or 79, characterized in that the heterocycle of B has one or two sulfur atoms.

81. Compound or salt according to claim 80, characterized in that the heterocycle of B has at least one nitrogen atom.

82. Compound or salt according to any one of claims 77 to 80, characterized in that B is selected from each of which is optionally substituted.

83. Compound or salt according to any one of claims 78 to 82, characterized in that one or more optional substituents of B are independently selected in each occurrence of halogen, C1-C3 alkyl, B(OR20)2, -OR20, -C(O)N(R20)2, -N(R20)2, =O, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl. Petition 870250082397, dated 12 / 09 / 2025, page 28 / 141 19 / 119 84. Compound or salt according to claim 83, characterized in that one or more optional substituents of B are independently selected at each occurrence of halogen, C1-C3 alkyl, -OH, -NH2, =O and -CN.

85. Compound or salt according to claim 84, characterized in that B is selected from HO NH2 86. Compound or salt according to any one of claims 78 to 81, characterized in that B is selected from an optionally substituted fused heterocycle of 8 to 10 members featuring at least one sulfur atom.

87. Compound or salt according to claim 86, characterized in that B is selected from each of which is optionally substituted.

88. Compound or salt according to claims 86 or 87, characterized in that one or more optional substituents of B are independently selected in each occurrence of halogen, C1-C3 alkyl, -OR20, -C(O)N(R20)2, N(R20)2, =O, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

89. Compound or salt according to claim 88, characterized in that one or more optional substituents of B are independently selected at each occurrence of halogen, C1-C3 alkyl, -NH2 and -CN. Petition 870250082397, dated 12 / 09 / 2025, p. 29 / 141 20 / 119 90. Compound or salt according to any one of claims 86 to 89, characterized in that B is substituted.

91. Compound or salt according to any one of claims 86 to 90, characterized in that B is substituted with at least one -NH2.

92. Compound or salt according to any one of claims 86 to 91, 93. Compound or salt according to any one of claims 86 to 91, characterized in that B is substituted with at least one -NH2 and at least one -CN.

94. Compound or salt according to claim 92, characterized in that B is selected from NH2 and 95. Compound or salt according to claims 1 or 6, characterized by the fact that 96. Compound or salt according to claims 1 or 6, characterized in that 97. Compound or salt according to any one of claims 1 to 96, characterized in that n is selected from 0 and 1. Petition 870250082397, dated 12 / 09 / 2025, page 30 / 141 21 / 119 98. Compound or salt according to any one of claims 1 to 97, characterized in that n is 1.

99. Compound or salt according to any one of claims 1 to 98, characterized in that each R4 is independently selected from halogen, NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, =O, -CN, C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C1-6 haloalkyl.

100. Compound or salt according to claim 99, characterized in that each R4 is independently selected from =O.

101. Compound or salt according to any one of claims 1 to 96, characterized in that n is 0.

102. Compound or salt according to any one of claims 1 to 101, characterized in that Y is -O-.

103. Compound or salt according to any one of claims 1 to 102, characterized in that L is selected from C1-C4 alkylene.

104. Compound or salt according to claim 103, characterized in that L is selected from unsubstituted C1-C4 alkylene.

105. Compound or salt according to any one of claims 1 to 102, characterized in that each L is independently selected from an optionally substituted Cl-C4 alkylene; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3-C6 carbocycle and the 3- to 8-membered heterocycle are each optionally substituted with one or more substituents selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl.

106. Compound or salt according to claim 105, characterized in that the optional substituents of L are selected from Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle where the C3-C6 carbocycle and the 3- to 8-membered heterocycle are optionally substituted with one or more substituents selected from halogen and C1-6 haloalkyl. Petition 870250082397, dated 12 / 09 / 2025, p. 31 / 141 22 / 119 107. Compound or salt according to any one of claims 105 to 106, characterized in that L is selected from 108. Compound or salt according to claim 107, characterized in that L is selected from 109. Compound or salt according to claim 105 or 106, characterized in that each L is independently selected from a Cl-C4 substituted alkylene and where two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or heterocycle of 3 to 5 members.

110. Compound or salt according to claim 109, characterized in that each L is independently selected from a substituted C2-3 alkylene and where two substituents on the same carbon atom of L join to form a C3 carbocycle or 4-membered heterocycle, where the C3 carbocycle is optionally substituted with one or more halogen substituents selected from other compounds.

111. Compound or salt according to claims 109 or 110, characterized in that each L is independently selected from FF, , , and ^OÒ.

112. Compound or salt according to claim 111, characterized in that each L is independently selected from FF, , and 113. Compound or salt according to claim 112, characterized in that each L is independently selected from Petition 870250082397, dated 12 / 09 / 2025, page 32 / 141 23 / 119 114. Compound or salt according to claims 109 or 110, characterized in that each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more independently selected halogen and Cl-C4 alkyl substituents.

115. Compound or salt according to claim 114, characterized in that L is selected from 116. Compound or salt according to claim 114, characterized in that each L is independently selected from an unsubstituted Cl-C4 alkylene.

117. Compound or salt according to claim 116, characterized in that L is selected from 118. Compound or salt according to claim 117, characterized in that L is selected from .

119. Compound or salt according to any of claims 1 to 118, characterized in that R2 is selected from heterocycle, -L-heterocycle, -L-aryl, L-heteroaryl and -LN(R20)2, wherein the heterocycle, the heterocyclic part of -L-heterocycle, are each optionally substituted with one or more R6 and wherein the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally substituted with one or more R7.

120. Compound or salt according to claim 119, characterized in that R2 is an -L-heterocycle, wherein the heterocyclic part of R2 is an optionally substituted heterocycle.

121. Compound or salt according to claim 119 or 120, characterized in that R2 is an -L-heterocycle, optionally substituted with one or more R6 and wherein the heterocyclic part of the -L-heterocycle has at least one heteroatom selected from nitrogen, oxygen, silicon and sulfur.

122. Compound or salt according to any one of claims 1 to 121, characterized in that Y-R2 is selected from HN—' and where the heterocyclic part is optionally replaced with one or more R6.

123. Compound or salt according to any of claims 119 to 122, characterized in that the heterocyclic moiety of R2 is a heterocycle optionally substituted with one or more substituents selected from halogen, hydroxyl, -CN, C1-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, C1-C3 alkoxy and Cl-C3 aminoalkyl.

124. Compound or salt according to claim 123, characterized in that the heterocyclic moiety of R2 is a heterocycle optionally substituted with one or more substituents selected from C1-C3 alkyl and halogen.

125. Compound or salt according to any one of claims 1 to 124, characterized in that Y-R2 is selected from 126. Compound or salt according to any one of claims 119 to 122, characterized in that R6 of R2 is independently selected in each occurrence from halogen, hydroxy, Cl-C3 hydroxyalkyl, Cl-C3 alkyl, Cl-C3 haloalkyl, C1C3 alkoxy, cyano and Cl-C3 aminoalkyl.

127. Compound or salt according to claim 124, characterized in that R6 of R2 is independently selected in each occurrence of C1-C3 alkyl and halogen.

128. Compound or salt according to claim 127, characterized in that Y-R2 is selected from 129. Compound or salt according to any of claims 1 to 121, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 34 / 141 25 / 119 where the heterocyclic part is optionally replaced with one or more R6.

130. Compound or salt according to claim 129, characterized in that Y-R2 is selected from O 131. Compound or salt according to any one of claims 1 to 121, characterized in that Y-R2 is selected where the heterocycle is optionally substituted.

132. Compound or salt according to claim 131, characterized in that the heterocycle is optionally substituted with one or more substituents selected from halogen, hydroxyl, Cl-C3 alkyl, -N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-ClC3 alkyl, -CH2OC(O)heterocycle, -CH2heterocycle, -CH2OC(O)N(R5)2 and -O-Cl-C3 alkyl, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl.

133. Compound or salt according to any one of claims 1 to 6 or 131 to 132, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 35 / 141 26 / 119 134. Compound or salt according to any of claims 1 to 121, characterized in that Y-R2 is selected from , where the heterocyclic moiety is optionally substituted, where one or more optional substituents are selected from halogen, hydroxyl, Cl-C3 alkyl, -N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-Cl-C3 alkyl, -CH2OC(O)heterocycle, -CH2heterocycle, CH2OC(O)N(R5)2, -(CH2)0-1-O-heterocycle and -O-Cl-C3 alkyl, where the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxyl and where the heterocycle of -(CH2)0-1-O-heterocycle is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and OR20.

135. Compound or salt according to claim 134, characterized in that one or more optional substituents are selected from: ,OH Petition 870250082397, dated 12 / 09 / 2025, page 36 / 141 27 / 119 136. Compound or salt according to claims 134 or 135, characterized in that Y-R2 is selected from 137. Compound or salt according to claim 119, characterized in that R2 is -L-heteroaryl, wherein the heteroaryl moiety is optionally replaced with one or more R7s.

138. Compound or salt according to claim 137, characterized in that each R7 is independently selected from halogen and Cl-C4 haloalkyl; Petition 870250082397, dated 12 / 09 / 2025, p. 37 / 141 28 / 119 139. Compound or salt according to claim 138, characterized in that Y-R2 is selected from with 140. that R2 141. Compound or salt according to claim 119, characterized in that it is -L-aryl, optionally substituted with one or more R7. Compound or salt according to claim 140, characterized in that Y-R2 is selected from optionally substituted with one or more R7, where the phenyl part is 142. Compound or salt according to claim 141, characterized in that Y-R2 is selected from 143.

144. Compound or salt according to claim 119, characterized in that it is -L-heteroaryl, optionally substituted with one or more R7. Compound or salt according to claim 143, characterized in that Y-R2 is selected from hn~ne, where the heteroaryl part is optionally substituted with one or more R7.

145. Compound or salt according to claims 143 or 144, characterized in that Y-R2 is selected from 146. that R2 147. Compound or salt according to claim 119, characterized in that it is -LN(R20)2. Compound or salt according to claim 146, characterized in that Y-R2 is selected from N ,, . Petition 870250082397, dated 12 / 09 / 2025, p. 38 / 141 29 / 119 148. Compound or salt according to claim 119, characterized in that R2 is a heterocycle optionally substituted with one or more R6.

149. Compound or salt according to claim 148, characterized in that Y-R2 is 150. Compound or salt according to claims 1 to 6 or 126, characterized in that Y-R2 is 151. Compound or salt according to any one of claims 1 to 119, characterized in that R2 is selected from heterocycle, -L-heterocycle, wherein the heterocycle and the heterocyclic part of -L-heterocycle are each optionally substituted with one or more R6; -L-aryl and -L-heteroaryl, wherein the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally substituted with one or more R7; and -LN(R20)2.

152. Compound or salt according to claim 151, characterized in that the heterocycle of R2 is selected from where the heterocycle of R2 is optionally replaced with one or more R6; wherein the aryl and heteroaryl of R2 are selected from [O XX n~nh , , / N oon~nh e hnN , wherein the aryl and heteroaryl are each optionally replaced with one or more R7; and 153. Compound or salt according to claim 152, characterized in that the heterocycle of R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 39 / 141 30 / 119 where the heterocycle is optionally replaced with one or more R6; where the aryl and heteroaryl of R2 are selected from II Kl' and πH N, where the aryl and heteroaryl are each optionally replaced with one or more R7; and 154. Compound or salt according to any of claims 151 to 153, characterized in that each R6 is independently selected from halogen, hydroxy, Cl-C3 alkyl, Cl-C3 haloalkyl, -N(R5)S(O)2(R5), -OC(O)N(R5)2, =CH2, oxo, =NO-Cl-C3 alkyl, -CH2OC(O)heterocycle, -CH2heterocycle, -CH2OC(O)N(R5)2 and -O-ClC3 alkyl, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy; and wherein each R7 is selected from Cl-C3 alkyl, halogen and Cl-C3 haloalkyl.

155. Compound or salt according to any one of claims 151 to 154, characterized in that the heterocycle of R2, the aryl and heteroaryl of R2 and -N(R20)2 of R2 are selected from Petition 870250082397, dated 12 / 09 / 2025, page 40 / 141 31 / 119 156. Compound or salt according to any of claims 1 to 118, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 41 / 141 32 / 119 HNVo HN;s / O e 0 0, where the heterocycle and the heterocyclic part of -L-heterocycle are each optionally substituted with one or more R6; A-'Vv Avqy A / γ\, N-nh , n'NH and HN-n , where the aryl of -L-aryl and the heteroaryl of L-heteroaryl are each optionally substituted with one or more R7; and 157. Compound or salt according to any of claims 1 to 118, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 42 / 141 33 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 43 / 141 34 / 119 158. Compound or salt according to any one of claims 1 to 118, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 44 / 141 35 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 45 / 141 36 / 119 159. Compound or salt according to any one of claims 1 to 118, characterized in that Y-R2 is selected from FF, F 160. Compound or salt according to any one of claims 1 to 118, characterized in that Y is -O- and R2 is selected from 5-membered L-heteroaryl, where L is selected from an optionally substituted C1-C4 alkylene and where the heteroaryl is optionally substituted with one or more R7, where each R7 is preferably selected from halogen, C1-C4 alkyl and C1-C4 haloalkyl.

161. Compound or salt according to any one of claims 160, characterized in that Y-R2 is selected from 162. Compound or salt according to any one of claims 1 to 118, characterized in that Y-R2 is selected from , where the heterocycle and the heterocyclic part of -L-heterocycle are each optionally replaced with one or more R6; Petition 870250082397, dated 12 / 09 / 2025, p. 47 / 141 38 / 119 zoe hn'N , where the aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally replaced with one or more R7; and 163. Compound or salt according to claims 1 to 118 or 162, characterized in that each R6 is independently selected from halogen, hydroxy, Cl-C3 alkyl, Cl-C3 haloalkyl, oxo, C1-C3 alkoxy, G-C3 hydroxyalkyl, (C1-C3 alkoxy)Cl-C3 alkyl, =CH2, -OC(O)N(R5)2, =NO-C1-C3 alkyl, -N(R5)S(O)2(R5), -CH2OC(O)N(R5)2, CH2OC(O)heterocycle, -(CH2)O-1S-heterocycle, -(CH2)O-1-O-heterocycle and -OG-C3 alkyl, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy and wherein the heterocycle of -(CH2)0-1-O-heterocycle and -(CH2)0-1-S-heterocycle are each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20.

164. Compound or salt according to claim 163, characterized in that each R6 is independently selected from Petition 870250082397, dated 12 / 09 / 2025, p. 48 / 141 39 / 119 165. Compound or salt according to any one of claims 1 to 118 or 163 to 164, characterized in that Y-R2 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 49 / 141 40 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 50 / 141 41 / 119 166. Compound or salt according to any one of claims 1 to 165, characterized in that R1B is hydrogen.

167. Compound or salt according to any one of claims 1 to 165, characterized in that R1B is selected from an optionally substituted C1-6 alkyl.

168. Compound or salt according to any one of claims 1 to 165, characterized in that R1B is methyl.

169. Compound or salt according to any one of claims 1 to 165, characterized in that R1B is selected from an optionally substituted C3-C6 carbocycle.

170. Compound or salt according to any one of claims 1 to 169, characterized in that R1A is selected from an optionally substituted C1-6 alkyl.

171. Compound or salt according to claim 170, characterized in that R11 is -N(R20)2. Petition 870250082397, dated 12 / 09 / 2025, p. 51 / 141 42 / 119 172. Compound or salt according to claim 171, characterized in that R1a is selected from HO and 173. Compound or salt according to any one of claims 1 to 172, characterized in that R1A is a C4-C6 carbocycle, where the C4-C6 carbocycle is optionally replaced with one or more R11s.

174. Compound or salt according to claim 173, characterized in that each R11 is selected from -N(R20)2 and where each R20 is selected from hydrogen and optionally substituted C16 alkyl.

175. Compound or salt according to claim 174, characterized in that NH2 _.NH2 A where R1a is selected from ' , ' , ' and ' 176. Compound or salt according to any one of claims 1 to 175, characterized in that R1A is selected from a 4- to 12-membered heterocycle, wherein the 4- to 12-membered heterocycle is optionally replaced with one or more R11s.

177. Compound or salt according to any one of claims 1 to 169 or 176, pNH characterized in that R1A is selected from ' / nh and V each of which is optionally substituted with one or more R11 and where each R11 is independently selected from -OH, C1-6 aminoalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, -C(O)R20, C3-C12 carbocycle and 5- to 12-membered heterocycle, where the C3-C12 carbocycle and the 5- to 12-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl and oxo. Petition 870250082397, dated 12 / 09 / 2025, p. 52 / 141 43 / 119 178. Compound or salt according to claims 176 or 177, characterized in that each R11 is selected from halogen, -OH, -N(R20)2, -C(O)R20, -C(O)N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.

179. Compound or salt according to claim 178, characterized in that R1a is selected from 180. Compound or salt according to any of claims 1 to 169, characterized in that R1A is selected from an optionally substituted C1-6 alkyl and where optionally two R11s on the same atom of R1A join to form an optionally substituted C3-C6 carbocycle.

181. Compound or salt according to claim 180, characterized in that R11 is -CN and where two R11s on the same R1A atom join to form an unsubstituted C3 carbocycle. Petition 870250082397, dated 12 / 09 / 2025, p. 53 / 141 44 / 119 182. Compound or salt according to claim 181, characterized in that R1a is selected from ' and '.

183. Compound or salt according to claim 182, characterized in that / \^-=N that R1a is selected from '.

184. Compound or salt according to any one of claims 1 to 3 or 7 to 165, characterized in that R100 is selected from, and 185. Compound or salt according to any one of claims 1 to 183, characterized in that R1B is selected from hydrogen, optionally substituted C1-6 alkyl and optionally substituted C3-C6 carbocycle.

186. Compound or salt according to any one of claims 1 to 185, characterized in that R1B is selected from hydrogen, C1-6 alkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl and C3-C6 carbocycle.

187. Compound or salt according to any one of claims 1 to 186, characterized in that R1B is selected from hydrogen, methyl, ethyl, C2 hydroxyalkyl and cyclopropyl.

188. Compound or salt according to any one of claims 1 to 187, characterized in that R1B is hydrogen.

189. Compound or salt according to any one of claims 1 to 188, characterized in that R1B is selected from an optionally substituted C1-6 alkyl.

190. Compound or salt according to any of claims 1 to 189, characterized in that R1B is selected from methyl and ethyl. Petition 870250082397, dated 12 / 09 / 2025, pp. 54 / 141 45 / 119 191. Compound or salt according to any one of claims 1 to 190, characterized in that R1B is methyl.

192. Compound or salt according to any one of claims 1 to 190, characterized in that R1B is selected from an optionally substituted C3-C6 carbocycle.

193. Compound or salt according to claim 192, characterized in that R1b is 194. Compound or salt according to claims 1 to 165, characterized in that R1B is selected from hydrogen, C1-6 alkyl, C3 carbocycle, 4- to 5-membered heterocycle, wherein the C1-6 alkyl, C3 carbocycle and 4- to 5-membered heterocycle are each optionally substituted with one or more R10, wherein each R10 is independently selected from halogen, -OR20, -C(O)N(R20)2, -N(R20)2, -C(O)OR20, =O, -CN, C2-6 alkenyl, C1-6 haloalkyl, C3-C6 carbocycle and 4-membered heterocycle.

195. Compound or salt according to claim 193, characterized in that R1b is selected from * , 196. Compound or salt according to any one of claims 1 to 195, characterized in that R1A is selected from a C1-3 alkyl, C3 carbocycle and 5- to 6-membered heterocycle, each of which is optionally substituted with one or more R11 and where optionally two R11 on the same atom of R1A join to form a C3 carbocycle.

197. Compound or salt according to any of claims 1 to 196, characterized in that R11 is selected from halogen, -OR20, -N(R20)2, C(O)N(R20)2, -CN, =O, -NH(C=NH)NH2, C2-6 alkenyl, C3-C6 carbocycle, and heterocycle of Petition 870250082397, dated 12 / 09 / 2025, p. 55 / 141 46 / 119 5 to 6 members, wherein the 5 to 6 membered heterocycle and C3-C6 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -SR21, -P(O)(R21)2, -OH, -CN, -N(R21)2, -C(O)N(R21)2, C1-10 alkyl and -C1-10 haloalkyl; and wherein optionally two R11 on the same R1A atom join to form a C3 carbocycle.

198. Compound or salt according to any of claims 1 to 197, characterized in that each R21 is independently selected from hydrogen; and C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more independently selected substituents from halogen, oxo, C3-6 carbocycle and 3- to 6-membered heterocycle.

199. Compound or salt according to any of claims 1 to 198, characterized in that R1A is Petition 870250082397, dated 12 / 09 / 2025, p. 56 / 141 47 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 57 / 141 48 / 119 200. Compound or salt according to any one of claims 1 to 169 or 185 to 199, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 58 / 141 49 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 59 / 141 50 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 60 / 141 51 / 119 201. Compound or salt according to any one of claims 1 to 169 or 185 to 200, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 61 / 141 52 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 62 / 141 53 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 63 / 141 54 / 119 202. Compound or salt according to any of claims 1 to 183, characterized in that R1B is selected from C1-6 alkyl and 4- to 5-membered heterocycle, wherein the C1-6 alkyl and 4- to 5-membered heterocycle are each optionally substituted with one or more R10, wherein each R10 is independently selected from halogen, -OR20, -C(O)N(R20)2, -N(R20)2, -C(O)OR20, =O, -CN, C2-6 alkenyl, C1-6 haloalkyl, C3-C6 carbocycle and 4-membered heterocycle.

203. Compound or salt according to claim 202, characterized in that 204. Compound or salt according to claims 1 to 165 or 202 to 203, R1XB XR1A RN characterized in that R100 or N is preferably N Petition 870250082397, dated 12 / 09 / 2025, p. 64 / 141 55 / 119 205. Compound or salt according to claims 1 to 165 or 202 to 204, characterized in that R100 or —1— is selected from VV Ί J\n I JrCN 206. Compound or salt according to any one of claims 1 to 169 or 185 to 195, characterized in that R1A is selected from an optionally substituted C1-6 alkyl.

207. Compound or salt according to claim 206, characterized in that R1a is selected from an optionally substituted C1-3 alkyl and where optionally two R11s on the same atom of R1A join to form a C3 carbocycle.

208. Compound or salt according to claim 207, characterized in that R1a is selected from an optionally substituted C1-2 alkyl. Petition 870250082397, dated 12 / 09 / 2025, p. 65 / 141 56 / 119 209. Compound or salt according to any one of claims 206 to 208, characterized in that R1A is selected from 210. Compound or salt according to any one of claims 206 to 209, R11 characterized in that R1A is selected from 211. Compound or salt according to any one of claims 206 to 210, R11 characterized in that R1A is selected from 212. Compound or salt according to any one of claims 206 to 211, characterized in that R11 is selected from an optionally substituted 5- to 12-membered heterocycle.

213. Compound or salt according to any one of claims 206 to 212, characterized in that R11 is selected from an optionally substituted 5- to 8-membered heterocycle.

214. Compound or salt according to any one of claims 206 to 196, characterized in that R11 is selected from an optionally substituted 5- to 6-membered heterocycle.

215. Compound or salt according to any one of claims 206 to 213, characterized in that R11 is selected from an optionally substituted 5- to 6-membered heteroaryl.

216. Compound or salt according to any one of claims 206 to 214, characterized in that R11 is selected from CN INH, each of which is optionally substituted. Petition 870250082397, dated 12 / 09 / 2025, p. 66 / 141 57 / 119 217. Compound or salt according to any one of claims 206 to 216, characterized in that R11 is selected from and , each of which is optionally substituted.

218. Compound or salt according to any one of claims 206 to 217, characterized in that R11 is selected from , each of which is optionally substituted.

219. Compound or salt according to any one of claims 206 to 218, characterized in that one or more optional substituents are independently selected from halogen, -OH, -CN, -N(R21)2, C1-10 alkyl and -C1-10 haloalkyl.

220. Compound or salt according to any of claims 206 to 219, characterized in that each R21 is independently selected from hydrogen; and C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more independently selected substituents from halogen, oxo, C3-6 carbocycle and 3- to 6-membered heterocycle.

221. Compound or salt according to any of claims 206 to 220, characterized in that one or more optional substituents of R11 are selected from halogen, C1-6 haloalkyl, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, and C1-10 alkyl.

222. Compound or salt according to any one of claims 206 to 221, characterized in that one or more optional substituents of R11 are selected from -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2 and C1-10 alkyl.

223. Compound or salt according to any of claims 206 to 222, characterized in that one or more optional substituents of R11 are selected from -NH2 and C1-10 alkyl. Petition 870250082397, dated 12 / 09 / 2025, p. 67 / 141 58 / 119 224. Compound or salt characterized by the fact that it is a selected -NH2.

225. A compound or salt according to any one of claims 206 to 223, or more optional substituents of R11, is any one of claims 206 to 224, characterized in that R11 is selected from 226. Compound or salt according to any one of claims 206 to 225, characterized in that R1A is selected from 227. Compound or salt according to any one of claims 206 to 226, characterized in that R1A is selected from 228. Compound or salt according to any one of claims 1 to 165 or 206 to 214, characterized in that R1A is Petition 870250082397, dated 12 / 09 / 2025, p. 68 / 141 59 / 119 229. Compound or salt according to any one of claims 1 to 165 or 185 to 195, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 69 / 141 60 / 119 230. Compound or salt according to any one of claims 1 to 165 or 185 to 195, characterized in that R100 or is selected from 231. Compound or salt according to any one of claims 1 to 165 or 185 to 195, characterized in that R100 or --1- is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 70 / 141 61 / 119 232. Compound or salt according to claim 231, characterized in that <BXR1A N que R100 ou —1— 233. Compound or salt according to claim 232, characterized in that R100 or —L— is selected from 234. Compound or salt according to any one of claims 206 to 215, characterized in that R11 is selected from, S—N o—N HN—NS—N / =N / =N / ^N / / \\ ' \ ' \ Z i .N HN. Rç NH , , , and , each of which is optionally substituted.

235. A compound or salt according to any one of claims 206 to 215 or selected from 234, characterized in that R11, each of which is optionally substituted.

236. Compound or salt according to any one of claims 206 to 215 or 234 to 235, characterized in that one or more optional substituents are independently selected from halogen, oxo, -OH, -OCH3, -CN, -N(R21)2, C(O)N(R21)2, -P(O)(R21)2, -SCH3, C1-10 alkyl and -C1-whaloalkyl.

237. Compound or salt according to any of claims 206 to 215 or 234 to 236, characterized in that one or more optional substituents of R11 are selected from halogen, oxo, -OH, -OCH3, C1-6 haloalkyl, -NH2, -SCH3, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, and C1-6 alkyl.

238. Compound or salt according to any one of claims 206 to 215 or 234 to 237, characterized in that R11 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 72 / 141 63 / 119 239. Compound or salt according to any one of claims 1 to 165 or 185 to 195, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 73 / 141 64 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 74 / 141 65 / 119 240. Compound or salt according to any one of claims 1 to 165 or 185 to 195, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 75 / 141 66 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 76 / 141 67 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 77 / 141 68 / 119 241. Compound or salt according to any one of claims 1 to 165, characterized in that R1A and R1B combine with the atoms to which they are attached to form R1, and R1 is selected from an optionally substituted 5- to 12-membered heterocycle.

242. Compound or salt according to claim 241, characterized in that R1 is selected from a 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, -OH, -N(R2O)2, -NO2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl.

243. Compound or salt according to claim 242, characterized in that R1 is selected from a 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, -OH, -N(R20)2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl and C1-6 haloalkyl.

244. Compound or salt according to claims 241 or 243, characterized in that each R20 is selected from hydrogen and C1-3 alkyl.

245. Compound or salt according to any of claims 241 or 244, characterized in that each R20 is selected from hydrogen and C1 alkyl.

246. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is unsaturated.

247. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is saturated.

248. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is bridged.

249. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is a spiro heterocycle.

250. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is a fused heterocycle.

251. Compound or salt according to any one of claims 241 or 244, characterized in that the 5- to 12-membered heterocycle of R1 is not aromatic. Petition 870250082397, dated 12 / 09 / 2025, pp. 78 / 141 69 / 119 252. Compound or salt according to any one of claims 241 or 251, characterized in that R1 is selected from each of which is optionally substituted.

253. Compound or salt according to claim 252, characterized in that one or more optional substituents are each independently selected from halogen, -OH, -N(R2O)2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, =O, -CN, C1-6 hydroxyalkyl and C1-6 haloalkyl.

254. Compound or salt according to claims 252 or 253, characterized in that R1 is selected from , each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -N(R2O)2, -NO2, C1-6 aminoalkyl, C16 alkoxy, =O, -CN, C1-6 hydroxyalkyl and C1-6 haloalkyl.

255. Compound or salt according to claim 254, characterized in that N that R1 is selected from —'— , —।— and 256. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from a 6- to 8-membered heterocycle, which is optionally substituted.

257. Compound or salt according to claim 256, characterized in that R1 is selected from a saturated 7-membered heterocycle, an 8-membered bridging heterocycle, and an unsaturated 6- to 7-membered heterocycle, each of which is optionally substituted.

258. Compound or salt according to claim 257, characterized in that R1 is selected from , each of which is optionally substituted.

259. Compound or salt according to claim 258, characterized in that one or more optional substituents are independently selected from OH, -CN, oxo, C1-6 cyanoalkyl. Petition 870250082397, dated 12 / 09 / 2025, pp. 80 / 141 71 / 119 260. Compound or salt according to claims 258 or 259, characterized in that R1 is selected from N 261. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from an optionally substituted 6- to 7-membered heterocycle.

262. Compound or salt according to claim 261, characterized in that the 6- to 7-membered heterocycle contains only 1 nitrogen atom and wherein the 6- to 7-membered heterocycle is optionally substituted.

263. Compound or salt according to claim 262, characterized in that R1 is selected from an optionally substituted unsaturated 6-membered heterocycle.

264. Compound or salt according to any one of claims 261 to 263, characterized in that R1 is selected from an optionally substituted 7-membered unsaturated heterocycle.

265. Compound or salt according to any one of claims 261 to 264, characterized in that R1 is selected from , -J— and , any one of which is optionally substituted. Petition 870250082397, dated 12 / 09 / 2025, p. 81 / 141 72 / 119 266. Compound or salt according to any of the claims in 265, characterized in that R1 is selected from -4-, —, and -L, any of which is optionally substituted.

267. Compound or salt according to any one of claims 261 to 266, characterized in that one or more optional substituents of R1 are each independently selected from halogen, -OR20, -N(R20)2, =O, -CN, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 alkyl, -NHCN and C2-6 alkynyl.

268. Compound or salt according to any one of claims 261 to 267, characterized in that each is optionally substituted with one or more substituents independently selected from halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl.

269. Compound or salt according to any one of claims 261 to 268, characterized in that one or more optional substituents of R1 are each independently selected from halogen.

270. Compound or salt according to any of claims 261 to 269, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 82 / 141 73 / 119 271. Compound or salt according to any one of claims 256 to 257, characterized in that R1 is selected from , each is optionally substituted with one or more substituents independently selected from halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl.

272. Compound or salt according to claim 271, characterized in that R1 is selected from , where each is optionally substituted with one or more substituents independently selected from halogen, -OH, -NH2, -NO2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl.

273. Compound or salt according to claim 272, characterized in that R1 is selected from , where each is optionally substituted with one or more independently selected halogen and C1-6 haloalkyl substituents.

274. Compound or salt according to claim 273, characterized in that R1 275. is selected from , , Compound or salt according to any of claims 256, characterized in that R1 is selected from —I— , which is optionally substituted with one or more independently selected halogen, -OH, -NH2, -NO2, C1-6 cyanoalkyl, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl and C1-6 alkyl substituents. Petition 870250082397, dated 12 / 09 / 2025, p. 83 / 141 74 / 119 276. Compound or salt according to claim 275, characterized in that R1 is selected from , which is optionally substituted with one or more independently selected halogen and C1-6 cyanoalkyl substituents.

277. Compound or salt according to claim 276, characterized in that R1 278. Composto ou sal de accordo com qualquer uma das reivindicações 1 a 165, O characterized by the fact that R1 is selected from Petition 870250082397, de 12 / 09 / 2025, pág. 84 / 141 75 / 119 H Οχ ΝΠ2 ΝΗ2 fF Á σ- ο'Α ο ι:) N N N N N 5 5 5 5 55 OH H° A < OH 0H nu0H Λ°η Λ,οη χη ,ψ 5 5 5 5 5 OH OH 1 HO 1 HO ηι1 HO ΗΟ Λ % IX17) τι N N N N N 5 5 5 5 τ ΙI ΑΑ^0Η Α~ΝΆ ^Α ^Α 5 5 5 5 OH OH OH OH J\ Α, Α / θΠ χΑ / F ΗΟ / ^,OH ΗΟ, ^Α ^Α ^Α ^Α 5 5 5 5 5 N OH OH I OH α.....X 0' Λ cJx / 1 1 1 I 1 η 5 5 5 5 5 Λ Ν OH 1 1 OH oi Ax A ô ^A ^A ^A ^A v 5 5 5 5 N II σN^ cA^ AA CA Λ N N N N N 5 5 5 5 HO HOx iA—H rV°H ^A ^A 5 5 N A' θH on0H 1 F Ix ?$ 5 5 5 FX^FF HO^ / x. HO^ / \ ^A 5 5 5 d ζχΑΝ XF LA / OH L ) F N N 5 5 χχ^°H v\ / 0H I\Γ N 5 5 OH H^NγO A / OH A / OH A ^A 5 5 Αη2 CV2 ο ™L ο 5 5 Ο O^N x N N 5 5 5 Petition 870250082397, de 12 / 09 / 2025, pág. 85 / 141 76 / 119 Petition 870250082397, de 12 / 09 / 2025, pág. 86 / 141 77 / 119 Petition 870250082397, de 12 / 09 / 2025, pág. 87 / 141 78 / 119 Petition 870250082397, de 12 / 09 / 2025, pág.88 / 141 79 / 119 Petition 870250082397, dated 12 / 09 / 2025, pp. 89 / 141 80 / 119.

279. Compound or salt according to claim 241, characterized in that R1 is selected from an optionally substituted 6- to 7-membered heterocycle.

280. Compound or salt according to claim 279, characterized in that the 6- to 7-membered heterocycle contains only 1 nitrogen atom and optionally one or more additional heteroatoms selected from oxygen and sulfur.

281. Compound or salt according to claim 279 or 280, characterized in that one or more optional additional heteroatoms are selected from sulfur.

282. Compound or salt according to any one of claims 279 to 281, characterized in that the 6- to 7-membered heterocycle contains only 1 nitrogen atom and no other additional heteroatoms.

283. Compound or salt according to any one of claims 279 to 282, characterized in that the 6- to 7-membered heterocycle is a non-aromatic 6- to 7-membered heterocycle.

284. Compound or salt according to any one of claims 279 to 283, characterized in that the 6- to 7-membered heterocycle of R1 is linked to the respective Formula through only 1 nitrogen atom. Petition 870250082397, dated 12 / 09 / 2025, pp. 90 / 141 81 / 119 285. Compound or salt according to any one of claims 279 to 283, characterized in that R1 is selected from and , each of which is optionally substituted.

286. Compound or salt according to any one of claims 279 to 285, characterized in that one or more optional substituents of R1 are each independently selected from halogen, -OH, -CN, C1-6 cyanoalkyl, -NHCN, C1-6 alkyl, oxo and C2-6 alkynyl.

287. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from an optionally substituted 6- to 10-membered heterocycle.

288. Compound or salt according to claim 287, characterized in that R1 is selected from , , —L and —L- , each of which is optionally substituted.

289. Compound or salt according to claim 288, characterized in that one or more optional substituents are independently selected from halogen, =O, -OH, -C(O)N(R2O)2, C2-6 alkynyl, -NHCN, -CN, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl and C1-6 alkyl.

290. Compound or salt according to claims 288 or 289, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 91 / 141 82 / 119 291. Compound or salt according to claim 241, characterized in that R1 is selected from a 7- to 11-membered spiral heterocycle.

292. Compound or salt according to claim 291, characterized in that R1 is selected from a 10-membered spiral heterocycle.

293. Compound or salt according to claims 291 or 292, characterized in that the spiro heterocycle has at least 3 nitrogen atoms.

294. Compound or salt according to claim 291, characterized in that H N-^ that R1 is selected from -1- and —I— , each of which is optionally substituted.

295. Compound or salt according to claim 294, characterized in that H that R1 is selected from —J— and —I— , each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -N(R2O)2, -NO2, =O, -CN, -NHCN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. Petition 870250082397, dated 12 / 09 / 2025, p. 92 / 141 83 / 119 296. Compound or salt according to claim 295, characterized in that R1 is selected from —ue 297. Compound or salt according to claim 296, characterized in that R1 is selected from 298. Compound or salt according to claim 241, characterized in that R1 is selected from an optionally substituted 9- to 11-membered unsaturated heterocycle.

299. Compound or salt according to claim 298, characterized in that R1 is selected from an optionally substituted 10-membered unsaturated heterocycle.

300. Compound or salt according to claims 298 or 299, characterized in that R1 is optionally substituted.

301. Compound or salt according to claim 300, characterized in that R1 is , which is optionally substituted with one or more substituents selected from halogen, -OH, -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl.

302. Compound or salt according to claim 301, characterized in that R1 is selected from —I— and —I— and Petition 870250082397, dated 12 / 09 / 2025, p. 93 / 141 84 / 119 -1- , each of which is additionally optionally substituted with one or more substituents selected from halogen, -OH, -N(R20)2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl.

303. Compound or salt according to any of claims 298 to 302, characterized in that one or more optional substituents of R1 are independently selected from halogen, -OH, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -C(O)N(R20)2, -C(O)NHOR20, -N(R20)2, -C(O)R20, -NO2, =O, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl and C2-6 alkynyl.

304. Compound or salt according to claims 302 or 303, characterized in that R1 is selected from and --------- , each of which is optionally substituted. Petition 870250082397, dated 12 / 09 / 2025, pp. 94 / 141 85 / 119 305. Compound or salt according to claim 304, characterized in that R1 is selected from 306. Compound or salt according to claim 300, characterized in that one or more optional substituents of R1 are independently selected from halogen, -OH, -N(R2O)2, =O, -CN, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, -C(O)N(R2O)2, C1-6 alkyl and C2-6 alkynyl. Petition 870250082397, dated 12 / 09 / 2025, pp. 95 / 141 86 / 119 307. Compound or salt according to claim 306, characterized in that one or more optional substituents of R1 are independently selected from halogen and -C(O)N(R20)2.

308. Compound or salt according to claim 307, characterized in that R1 is selected from — and -------- .

309. Compound or salt according to claim 308, characterized in that R1 is .

310. Compound or salt according to claim 308, characterized in that O what R1 is -4- .

311. Compound or salt according to claim 300, characterized in that one or more optional substituents of R1 are independently selected from halogen, C1-6 alkyl, C1-6 alkyl-N(R20)2, -C(O)NR20OR20, -C(O)N(R20)2 and -C(O)R20.

312. Compound or salt according to claim 311, characterized in that one or more optional substituents of R1 are selected from chlorine, Petition 870250082397, dated 12 / 09 / 2025, pp. 96 / 141 87 / 119 313. Compound or salt according to claim 312, characterized in that R1 is selected from and 314. Compound or salt according to claim 300, characterized in that one or more optional substituents of R1 are independently selected from halogen, -N(R20)2, -CN, C1-6 alkyl, C1-6 cyanoalkyl, C1-6 alkyl-N(R20)2, C1-6 alkyl-SO2. Petition 870250082397, dated 12 / 09 / 2025, p. 97 / 141 88 / 119 C1-6 alkyl, C2-6 alkenyl, -C(O)NR20OR20, -C(O)N(R20)2, -C(O)R20 and 5 to 10 membered heterocycle, wherein the 5 to 10 membered heterocycle is optionally independently substituted with one or more R1*, wherein each R1* is independently selected from halogen, -OR20 and C1-6 alkyl.

315. Compound or salt according to claim 314, characterized in that one or more optional substituents of R1 are selected from chlorine, -NH2, -CN, C1 alkyl, C2 alkenyl, 316. Compound or salt according to claim 315, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 98 / 141 89 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 99 / 141 90 / 119 317. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from an optionally substituted 6- to 11-membered heterocycle (for example, a 6-, 7-, 8-, 9-, 10- and 11-membered heterocycle).

318. Compound or salt according to claim 317, characterized in that one or more optional substituents of R1 are selected from halogen, -OR20, C(O)N(R20)2, -C(O)R20, -S(O)2R20, =O, -C1-6 alkyl (=NR20OR20), =NO(R20), -CN, NHCN, C1-6 alkyl and 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*; and wherein each R1* is independently selected from halogen and C1-6 alkyl. Petition 870250082397, dated 12 / 09 / 2025, pp. 100 / 141 91 / 119 319. Compound or salt according to claims 317 or 318, characterized by Petition 870250082397, dated 12 / 09 / 2025, pp. 101 / 141 92 / 119 320. Compound or salt according to claims 318 or 319, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 102 / 141 93 / 119 321. Compound or salt according to any of claims 317 or 318, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 103 / 141 94 / 119 322. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 104 / 141 95 / 119, each of which is optionally substituted.

323. Compound or salt according to claim 322, characterized in that one or more optional substituents of R1 are selected from -OH, =NO(R20), -NHCN and C1-6 alkyl.

324. Compound or salt according to claims 322 or 323, characterized in that R1 is selected from hydrogen, and 325. Compound or salt according to any one of claims 241 to 251, characterized in that R1 is selected from a 7- to 10-membered heterocycle optionally substituted. Petition 870250082397, dated 12 / 09 / 2025, pp. 105 / 141 96 / 119 326. Compound or salt according to claim 325, characterized in that R1 is selected from hydrogen, each of which is optionally substituted.

327. Compound or salt according to claim 326, characterized in that one or more optional substituents of R1 are independently selected from halogen, -NH2, -S(O)2(R20), -C(O)R20, -C(O)N(R20)2, =O,=NO(R20), -CN, -NHCN, C16 alkyl and 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle is optionally independently substituted with one or more R1*; and wherein each R1* is independently selected from halogen and C1-6 alkyl.

328. Compound or salt according to any of claims 325 to 327, characterized in that R1 is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 106 / 141 97 / 119 O 329. Compound or salt according to claim 241, characterized in that R1 is selected from an optionally substituted 8- to 10-membered heterocycle.

330. Compound or salt according to claim 329, characterized in that the heterocycle is bicyclic.

331. Compound or salt according to claims 329 or 330, characterized in that the heterocycle has at least two nitrogen atoms.

332. Compound or salt according to any one of claims 329 to 331, characterized in that HN NH each of which is optionally substituted.

333. Compound or salt according to any of claims 329 to 332, characterized in that one or more optional substituents of R1 are independently selected from halogen, oxo, Petition 870250082397, 12 / 09 / 2025, p. 107 / 141 98 / 119 O r20-s. , ιι y θ ' and 5 to 9 membered heteroaryl, wherein the 5 to 9 membered heteroaryl is substituted with at least one R1*, wherein R1* is selected from halogen and C1-6 alkyl.

334. Compound or salt according to any one of claims 329 to 333, characterized in that one or more optional substituents of R1 are , oxo, independently selected from chlorine, 335. Compound or salt according to any of claims 329 to 334, characterized in that it presents Petition 870250082397, dated 12 / 09 / 2025, pp. 108 / 141 99 / 119 336. Compound or salt according to any one of claims 1 or 7 to 165, R1A ^R1b .R1C NO characterized in that R100 is selected from —।— and —X , where R1A is selected from C1-6 alkyl, where the C1-6 alkyl is optionally substituted with one or more R11 and where optionally two R11 on the same atom of R1A join to form a C3C6 carbocycle, where the C3-C6 carbocycle is optionally substituted with one or more R11A; or R1a and R1b join with the atom to which they are attached to form R1, where R1 is an optionally substituted 6 to 10 membered heterocycle; R1B is selected from hydrogen and C1-6 alkyl; and R1C is selected from C1-6 alkyl, where C1-6 alkyl is optionally replaced with one or more R12 and where optionally two R12 on the same R1C atom join to form a C3-C6 carbocycle, where C3-C6 carbocycle is optionally replaced with one or more R12A.

337. Compound or salt according to claim 336, characterized in that R14 / N where R100 is selected from: —X , where R1A is selected from C1-6 alkyl, where the C1-6 alkyl is optionally substituted with one or more R11 and where optionally two R11 on the same R1A atom join to form an unsubstituted C3 carbocycle; X— , where R1C is selected from C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more R12 and where optionally two R12 on the same R1C atom join to form an unsubstituted C3 carbocycle; and —।— , where R1A and R1B combine with the atom to which they are attached to form R1, where R1 is selected from -i-, _!_ , _L , , _1_ , each of which is optionally substituted.

338. Compound or salt according to claims 336 or 337, characterized in that: each R11 is selected from -CN and optionally two R11s on the same atom of R1A join to form an unsubstituted C3 carbocycle; each R12 is selected from -CN and optionally two R12s on the same atom of R1C join to form an unsubstituted C3 carbocycle; and one or more substituents of R1 are independently selected from halogen, OR20, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(R20)2.

339. Compound or salt according to claim 338, characterized in that: R11 is selected from R12 is selected from CN or one or more substituents of R1 are independently selected from halogen, -OH, -CN, oxo, C1-6 alkyl, C1-6 hydroxyalkyl and -C(O)N(CH3)2.

340. Compound or salt according to claim 339, characterized in that OH OH that R100 is selected from 341. Compound or salt according to claim 241, characterized in that R1 is selected from a substituted 6- to 7-membered heterocycle, wherein the 6- to 7-membered heterocycle is substituted with at least one -NHCN and optionally further substituted with one or more C1-6 alkyl groups.

342. Compound or salt according to claim 341, characterized in that R1 is selected from -3— and —1— .

343. Compound or salt according to claim 241, characterized in that R1 is selected from an optionally substituted 8- to 9-membered bridge heterocycle.

344. Compound or salt according to claim 342, characterized in that the heterocycle of R1 is selected from , , each of which is optionally substituted.

345. Compound or salt according to claims 342 or 343, characterized in that one or more substituents of R1 are selected from halogen, C1-6 alkyl, N(R20)2 and C1-6 aminoalkyl.

346. Compound or salt according to any one of claims 342 to 345, characterized in that R1 is selected from 347. Compound or salt according to claim 241, characterized in that R1 is selected from an optionally substituted 8-membered bridging heterocycle, wherein the heterocycle contains selected nitrogen heteroatoms.

348. Compound or salt according to claim 346, characterized in that the heterocycle of R1 is selected from —I— and —I—, each of which is optionally substituted. Petition 870250082397, dated 12 / 09 / 2025, pp. 111 / 141 102 / 119 349. Compound or salt according to claim 347, characterized in that one or more substituents of R1 are selected from C1-6 alkyl, -N(R20)2 and C1-6 aminoalkyl.

350. Compound or salt according to claims 347 or 348, characterized by the fact that R1 is selected from -t- and —I— (preferably --1-- ).

351. Compound or salt according to any of claims 1 to 169, characterized in that R100 or is selected from Petition 870250082397, dated 12 / 09 / 2025, p. 112 / 141 103 / 119 Petition 870250082397, dated 12 / 09 / 2025, p. 113 / 141 104 / 119 352. Compound or salt according to any one of claims 1 to 2 or 7 to 165, characterized in that R100 is 353. Compound or salt according to claim 352, characterized in that Formula (I) is represented by Formula (ID), or a pharmaceutically acceptable salt thereof.

354. Compound or salt according to claim 352, characterized in that Formula (I) is represented by Formula (IE), or a pharmaceutically acceptable salt thereof.

355. Compound or salt according to claim 352, characterized in that Formula (I) is represented by Petition 870250082397, dated 12 / 09 / 2025, pp. 114 / 141 105 / 119 Formula (IF), or a pharmaceutically acceptable salt thereof.

356. Compound or salt according to any one of claims 352 to 355, characterized in that R1C is selected from an optionally substituted C1-6 alkyl.

357. Compound or salt according to any one of claims 352 to 356, characterized in that R1C is selected from an optionally substituted C1-6 alkyl and where optionally two R12s on the same atom of R1C join to form an optionally substituted C3-C6 carbocycle.

358. Compound or salt according to claim 358, characterized in that R12 is selected from -OH and -CN and wherein two R12 on the same R1C atom join to form an unsubstituted C3 carbocycle.

359. Compound or salt according to any one of claims 352 to 355, ZV°H characterized in that R1C is selected from ' , ' and .

360. Compound or salt according to any one of claims 352 to 355, ho^A \^n / R1CT οό <y caracterizado pelo fato de que —1— é selecionado de —L- , —Le Petição 870250082397, de 12 / 09 / 2025, pág. 115 / 141 106 / 119 361. Compound or salt according to any one of claims 352 to 355, characterized in that R1C is selected from an optionally substituted 5- to 6-membered heterocycle.

362. Compound or salt according to claim 361, characterized in that R1C is selected from an optionally substituted 5-membered heterocycle having at least one oxygen atom.

363. Compound or salt according to any one of claims 361 to 362, characterized in that R1C is selected from , which is optionally substituted.

364. Compound or salt according to claim 363, characterized in that each R12 is selected from halogen, -OR20, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl and C1-6 alkyl.

365. Compound or salt according to claim 364, characterized in that each R12 is selected from -OH.

366. Compound or salt according to any one of claims 361 to 365, characterized in that R1C is H0.

367. Compound or salt according to claim 1, characterized in that l^0 R100 is HO -L.

368. Compound or salt according to claims 1 to 2 or 7 to 165, characterized by the fact that R100 is .

369. Compound or salt according to claim 368, characterized in that Formula (I) is represented by Petition 870250082397, dated 12 / 09 / 2025, pp. 116 / 141 107 / 119 Formula (IJ), or a pharmaceutically acceptable salt thereof.

370. Compound or salt according to claim 368, characterized in that Formula (I) is represented by Formula (IH), or a pharmaceutically acceptable salt thereof.

371. Compound or salt according to claim 368, characterized in that Formula (I) is represented by Formula (II), or a pharmaceutically acceptable salt thereof.

372. Compound or salt according to any one of claims 1 or 368 to 371, characterized in that R1D is selected from an optionally substituted C1-6 alkyl.

373. Compound or salt according to any one of claims 368 to 372, characterized in that R1D is selected from an optionally substituted C1-6 alkyl and where optionally two R13s on the same atom of R1D join to form an optionally substituted C3-C6 carbocycle. Petition 870250082397, dated 12 / 09 / 2025, pp. 117 / 141 108 / 119 374. Compound or salt according to claim 373, characterized in that R13 is selected from -OH and -CN and where two R13 on the same R1d atom join to form an unsubstituted C3 carbocycle.

375. Compound characterized in that it has the Formula (IC*): Formula (IC*), or a pharmaceutically acceptable salt thereof characterized in that: R1a is selected from C1-6 alkyl, C3-C12 carbocycle and 4- to 12-membered heterocycle, each of which is optionally substituted with one or more R11 and where optionally two R11 on the same atom of R1a join to form the C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11a; R1b is selected from hydrogen, C1-6 alkyl, C3-C6 carbocycle, 4- to 6-membered heterocycle, characterized in that the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally substituted with one or more R10; or R1a and R1b combine with the atom to which they are attached to form R1, where R1 is a heterocycle of 5 to 15 members,where the 5- to 15-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -S(O)2(R20), -S(O)2N(R20)2, S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -C(O)N(R20)2, -C(=NR20)N(R20)2, C1-6 alkyl(=NR20OR20), -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =o, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, where C3-C12 carbocycle and 5- to 12-membered heterocycle are each optionally independently substituted with one or more R1 *; Petition 870250082397, dated 12 / 09 / 2025, p. 118 / 141 109 / 119 each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2,-S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, N(O)R20,C(O)20 -N(R20)2, -C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6, amino alcohol, C1-6 C1-6hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C26 alkynyl and C3-C12 carbocycle; Y is -O-; R2 is selected from heterocycle, -L-heterocycle, -LN(R20)2, -L-OR20, -L-aryl, -Lheteroaryl, -L-cycloalkyl, -L-NHC(=NH)NH2, -LC(O)N(R20)2, -L-Cl-C6, -L-Cl -L-COOH, -L-NR20S(O)2(R20), -LS(O)2N(R20)2, -LN(R20)C(O)(OR20), -L-OC(O)N(R20)2 and -LC(=O)OCl-C6 alkyl, where the heterocycle, apart from the heterocyclic heterocyclic -L-heterocyclic moiety -L-cycloalkyl are each optionally substituted with one or more R6 and where the aryl moiety of -L-NR20C(O)aryl,The aryl of -L-aryl and the heteroaryl of -L-heteroaryl are each optionally substituted with one or more R7; each L is independently selected from a Cl-C4 alkylene optionally substituted with one or more substituents independently selected from halogen, hydroxy, C1-6 alkoxy, Cl-C4 hydroxyalkyl, Cl-C4 alkyl, C3-C6 carbocycle and 3- to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO2, =O, =S, -CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and where optionally two substituents on the same carbon atom of L join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more independently selected halogen substituents, -OH, -NO2, =O, =S, -CN,C1–6 alkylN(R20)2, C1–6 aminoalkyl, C1–6 alkoxy, C1–6 hydroxyalkyl, and C1–6 haloalkyl; each R5 is independently selected from hydrogen and C1–C6 alkyl; each R6 is independently selected from halogen, hydroxy, Cl-C3 hydroxyalkyl, ClC3 alkyl, oxo, Cl-C3 haloalkyl, Cl-C3 alkyl-N3, C1-C3 alkoxy, cyano, =CH2, =NO-ClC3 alkyl, Cl-C3, amino alkyl -N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, -NHC(O)phenyl, -NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, tert-butyldimethylsilyloxyCH2-, Petição 8702500823, pp. 2025 / 920. 119 / 141 110 / 119 N(R5)2, (C1-C3 alkoxy)Ci-C3 alkyl-, (C1-C3 alkyl)C(=O), oxo, (C1-C3 haloalkyl)C(=O)-, -SO2F, (C1-C3 alkoxy)Cl-Cl-C3(N),C -CH2OCl-C6 alkyl,-CH2OC(O)N(R5)2, -CH2NHC(O)OCi-C6 alkyl, -CH2NHC(O)N(R5)2, CH2NHC(O)Ci-C6 alkyl, -CH2(pyrazolyl), -CH2NHSO2C1-C6 alkyl, heterocyclic C -OC(O)N(R5)2, -OC(O)NH(C1-C3 alkyl)O(Cl-C3 alkyl), OC(O)NH(Ci-C3 alkyl)O(Cl-C3 alkyl)phenyl(C1-C3 alkyl)N(CH3)2,-OC(O)NH(Ci-C3 alkyl)O(Cl-C3 alkyl)phenyl, -OC(O)heterocycle, -O-Cl-C3 alkyl, -O-Ci-C6 haloalkyl, C1-C3 alkyl-O-Cl-C6 haloalkyl, C1-6 alkyl-N(R20)2, -SF5, -C1-C3 alkyl-N3, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, -(CH2)o1S-heterocycle, -(CH2)0-1-O-heterocycle, -(CH2)0-1-O-phenyl and -CH2heterocycle, where phenyl of -NHC(O)phenyl and -OC(O)NH(Ci-C3 (alkyl)(Cl-C3 alkyl)phenyl are optionally substituted with one or more substituents selected from -C(O)H and OH, wherein the alkyl of -O-Cl-C3 alkyl is optionally substituted with substituents selected from heterocycles, oxo and hydroxyl; wherein the alkyl of -CH2O-Q-C6 alkyl is optionally substituted with one or more substituents selected from halogen and C3-C6 carbocycle; wherein the heterocycle of -CH2heterocycle is optionally substituted with oxo; and wherein the phenyl of -(CH2)O-1-O-phenyl is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, SF5, C1-6 alkyl-OR2O,-OR20; wherein the heterocycle of -(CH2)0-1-O-heterocycle and -(CH2)0-1-S-heterocycle are each optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and OR20; each Q is selected from a connection and O; each R7 is independently selected from halogen, hydroxy, HC(=O)-, Cl-C4 alkyl, Cl-C4 alkoxy, Cl-C4 haloalkyl, Cl-C4 hydroxyalkyl and -N(R5)2; B is selected from a 7- to 15-membered heterocycle and a C7-C15 carbocycle, where the 7- to 15-membered heterocycle and the C7-C15 carbocycle are each optionally substituted with one or more independently selected halogen substituents, -CN, -NO2, =O, -N(R20)2, -B(OR20)2, -OR20, -SR20, -S(O)2(R20), Petition 870250082397, dated 12 / 09 / 2025, p. 120 / 141 111 / 119 S(O)2N(R20)2, -NR20S(O)2R20, -C(O)N(R20)2, -C(O)NR20OR20, -N(R20)C(O)R20, N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -C(O)R20, -C(O)OR20, -OC(O)R20, OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl,C16 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle; each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5- to 12-membered heterocycle, wherein the C3-C12 carbocycle and the 5- to 12-membered heterocycle are each optionally substituted with one or more independently selected halogen substituents, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo; each R11 is independently selected from halogen,-B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)2R20, C(O)N(R20)2, -N(O)20(R20) -N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NR20(C=NH -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 and heterocyclic heterocyclic 15 members, wherein the C3-C12 carbocycle and the 5- to 12-membered heterocycle are each optionally substituted with one or more independently selected halogen substituents, -OH, -CN, -NO2, N(R21)2, -SR21, -C(O)N(R21), -Cl haloalkyl, -O-C1-10 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)(R21)2 and oxo; each R11a is independently selected from halogen, -B(OR20)2, -OR20, -SR20, S(O)2(R20), -S(O)2N(R20)2, -S(O)N(R20)2, -S(O)R20(=NR20), -NR20S(O)20, R20(R20) -N(R20)C(O)R20,-N(R20)C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; Petition 870250082397, of 09 / 12 / 2025, p. 121 / 141 112 / 119 each R20 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-10 alkyl, C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle; and each R21 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle and 3- to 12-membered heterocycle,each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -N(C1-6alkyl)2, C1-10 alkyl, -C1-10 haloalkyl, -O-C1-10 alkyl, oxo, C3-12 carbocycle and 3- to 12-membered heterocycle.

376. Compound or salt according to claim 375, characterized in that R1a is selected from C1-3 alkyl, C3-C9 carbocycle and 4- to 8-membered heterocycle, each of which is optionally substituted with one or more R11 and where optionally two R11 on the same atom of R1A join to form a C3-C6 carbocycle or 3- to 8-membered heterocycle, where the C3-C6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more R11A; R1b is selected from hydrogen, C1-3 alkyl, C3-C5 carbocycle, 4- to 6-membered heterocycle, where the C1-6 alkyl, C3-C6 carbocycle and 4- to 6-membered heterocycle are each optionally substituted with one or more R10;or R1a and R1b combine with the atom to which they are attached to form R1, where R1 is a 5- to 9-membered heterocycle, where the 5- to 9-membered heterocycle is optionally substituted with one or more independently selected halogen substituents, -B(OR20)2, -N(R20)2, -OR20, -SR20, -N(R20)C(O)R20, -N(R20)C(O)OR20, -C(O)R20, C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C16 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C6 carbocycle and 5 to 7 member heterocycle, wherein the C3-C6 carbocycle and the 5 to 7 member heterocycle are each optionally replaced independently with one or more R1*;Each R1* is independently selected from halogen, -B(OR20)2, -OR20, -SR20, -C(O)N(R20)2, C(O)NR20OR20, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =N(R20), =NO(R20), -CN, -NHCN, C1-6 alkyl Petition 870250082397, dated 12 / 09 / 2025, p. 122 / 141 113 / 119 N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-C6 carbocycle; B is selected from a 7- to 9-membered heterocycle, wherein the 7- to 9-membered heterocycle is optionally substituted with one or more substituents independently selected from -CN, -NH2 and C1-6 alkyl; Y is -O-; R2 is selected from -L-heterocycle and -LN(CH3)2, wherein the heterocyclic part of -L-heterocycle is optionally substituted with one or more R6; each L is independently selected from a C1-C4 alkylene optionally substituted with one or more substituents independently selected from C1-C4 alkyl;and where optionally two substituents on the same carbon atom of L join to form a C3-C4 carbocycle or 4-membered heterocycle, wherein the C3-C4 carbocycle and the 4-membered heterocycle are each optionally substituted with one or more independently selected halogen substituents; each R6 is independently selected from halogen, C1-C3 hydroxyalkyl, C1-C3 alkyl, oxo, C1-C3 haloalkyl, =CH2, (C1-C3 alkoxy)Cl-C3 alkyl- and -CH2-O-heterocycle, wherein the -CH2-O-heterocycle is optionally substituted with one or more substituents selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OR20 and -OR20;each R10 is independently selected from halogen, -B(OR20)2, -OR20, -SR20, C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, -C(O)R20, -C(O)OR20, OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, -NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C6 carbocycle and 5 to 7 heterocycle members, where the C3-C6 carbocycle and the 5 to 7 members are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, C1-5 alkyl, -C1-5 haloalkyl, -O-C1-5 alkyl, oxo;each R11 is independently selected from halogen, -B(OR20)2, OR20, -SR20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -NO2, =O, =NO(R20) 12 / 09 / 2025, p. 123 / 141 114 / 119 5 to 9 members, wherein the C3-C6 carbocycle and the 5 to 9 member heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO2, -N(R21)2, -SR21, -C(O)N(R21)2, C1-5 alkyl, -C1-5 haloalkyl, -O-C1-5 alkyl, S(O)2(R21), -P(O)(OR21)2, -OP(O)(OR21)2, -P(O)(R21)2 and oxo;each R11a is independently selected from halogen, -B(OR20)2, OR20, -SR20, -C(O)N(R20)2, -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)2, C(O)R20, -C(O)OR20, -OC(O)R20, -OC(O)N(R20)2, -NO2, =O, =NO(R20), -CN, NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl.; 377. Compound or salt according to claims 375 or 376, characterized in that Petition 870250082397, dated 12 / 09 / 2025, pp. 124 / 141 115 / 119 Y-R2 is selected is selected from Petition 870250082397, dated 12 / 09 / 2025, pp. 125 / 141 116 / 119 Petition 870250082397, dated 12 / 09 / 2025, pp. 126 / 141 117 / 119 378. Pharmaceutical composition characterized in that it comprises a compound or salt as defined in any one of claims 1 to 377 and a pharmaceutically acceptable excipient.

379. A method for treating a disease or disorder, characterized in that it comprises administering to an individual needing such treatment a compound or salt as defined in any one of claims 1 to 377 or the pharmaceutical composition as defined in claim 378.

380. A method for treating a disease or disorder, characterized in that it is by using a compound or salt as defined in any of claims 1 to 377 or a pharmaceutical composition as defined in claim 378.

381. Method for inhibiting KRas G12D and / or other G12 mutants, characterized in that it is by using a compound or salt as defined in any one of claims 1 to 377 or a pharmaceutical composition as defined in claim 378.

382. Method for inhibiting KRas G12D and / or other G12 alleles, characterized in that it is by using a compound or salt as defined in any of claims 1 to 377 or a pharmaceutical composition as defined in claim 378.

383. Method for inhibiting KRas G12D and / or other alleles, characterized by the fact that it is by using a compound or salt as defined in any one of claims 1 to 377 or a pharmaceutical composition as defined in claim 378.

384. Method according to claim 379, characterized in that the disease or disorder is a cancer associated with the KRas G12D mutant.

385. Method according to claim 379, characterized in that the disease or disorder is a cancer associated with the KRas G12V mutant.

386. Method according to any one of claims 377 to 385, characterized in that the disease or disorder is a cancer selected from: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchial carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);Genitourinary tract: kidney (adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testicle (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gallbladder carcinoma, ampullary carcinoma, cholangiocarcinoma;Bones: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, chordoma of malignant giant cell tumor, Petition 870250082397, dated 12 / 09 / 2025, pp. 128 / 141 119 / 119 osteochondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), neurofibroma of the spinal cord, meningioma, glioma, sarcoma);Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumoral cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematological: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles, dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma.

387. Method according to claim 386, characterized in that the disease or disorder is a cancer, wherein the cancer is non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer or pancreatic cancer; or wherein the cancer is a cancerous tumor.

388. Use of a compound as defined in any one of claims 1 to 376, characterized in that it is in the preparation of a compound that degrades a target protein by utilizing chemical modification of the compound as defined in any one of claims 1 to 376.